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     Previous studies indicated that 6%-30% of newly synthesized proteins are rapidly 
degraded by the ubiquitin-proteasome system. This has generally been assumed to occur 
post-translationally, following failure of chaperone-assisted folding mechanisms. 
However, the extent and significance of co-translational quality control remains largely 
unknown. In investigations of ISG15, an interferon-induced ubiquitin-like protein, our 
lab found that ISG15 is conjugated to a very broad spectrum of newly synthesized 
proteins. The major ligase for ISG15, Herc5, co-fractionated with polysomes, and further 
studies indicated that the processes of translation and ISGylation were closely coupled. 
Here, I employ an in vitro run-off translation system and puromycin labeling experiments 
to demonstrate that nascent polypeptides are ISGylated within active translation 
complexes, providing direct support for the co-translational mechanism for ISG15 
conjugation.     
     Approaches developed for studying co-translational ISGylation were subsequently 
used to examine co-translational ubiquitination (CTU), which we hypothesized might be 
 vii 
important in quality control of newly synthesized proteins. Consistent with this, I found 
that the pathway for degradation of newly synthesized proteins was initiated while 
proteins were being translated, with ubiquitination of actively translating nascent 
polypeptides. CTU is a conserved and robust pathway from yeast to mammals, with 5-6% 
of total nascent polypeptides being ubiquitinated in S. cerevisiae, and 12-15% in human 
cells. CTU products contained primarily K48-linked polyubiquitin chains, consistent with 
a proteasomal targeting function. Although nascent chains previously have been shown to 
be ubiquitinated within stalled and defective translation complexes (referred to here as 
CTUS), nascent chain ubiquitination also occurred within active translation complexes 
(CTUA). CTUA accounted for approximately two-thirds of total CTU (CTUT) in human 
cells and approximately half of CTUT in yeast cells. CTUA was increased in response to 
agents that induce protein misfolding, whereas CTUS was increased in response to agents 
that led to translational misreading or stalling. These results indicate that ubiquitination 
of nascent chains occurs in two contexts and define CTUA as a component of a quality 
control system that marks proteins for destruction before their synthesis is complete.  
     Finally, decreased translation fidelity is thought to lead to the accumulation of 
misfolded proteins and hasten the aging process. As CTU is a pathway for quality control 
of newly synthesized proteins, I explored whether CTU plays a protective role during the 
replicative aging process in budding yeast. Consistent with previous reports using human 
cells, I found that newly synthesized proteins are a major source of proteasome substrates 
under non-stressed conditions. Transient proteasome inhibition (using MG132) led to a 
decrease of yeast replicative life span (RLS), whereas simultaneous treatment with 
 viii 
cycloheximide, a translation inhibitor, suppressed this effect. Deletion of Ltn1, the major 
E3 ligase of the CTUS pathway, also shortened the RLS of yeast. Together, these results 
provide a preliminary set of evidence supporting the hypothesis that the quality of newly 
synthesized proteins is an important determinant of aging.   
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Chapter 1: Introduction 
 
1.1 A BRIEF OVERVIEW OF THE UBIQUITIN-PROTEASOME SYSTEM (UPS) 
When the lysosome was discovered in the 1950s, it was assumed to be the site of all 
cellular protein degradation. However, between the mid-1950s and the late 1970s, 
accumulating lines of evidence suggested that the degradation of at least certain classes 
of cellular proteins must be lysosome-independent. Firstly, half-lives vary between 
proteins, from minutes to days. The relatively non-selective lysosomal degradation 
cannot explain the selective degradation of proteins with different half-lives (Goldberg & 
St John 1976). Secondly, inhibition of lysosomal function with its inhibitors showed 
distinct effects on degradation of different proteins: the degradation of endocytosed 
proteins was largely inhibited, whereas only a limited effect was observed on the 
degradation of intracellular proteins (Knowles & Ballard 1976; Poole et al. 1977; Neff et 
al. 1979). All these findings suggested the existence of non-lysosomal protein 
degradation pathway(s).  
In 1975, Goldstein and colleagues reported that an 8.5 kD protein (now known as 
ubiquitin) found in cow thymus induced the differentiation of T lymphocytes and B 
lymphocytes (Goldstein et al. 1975). Furthermore, they found this protein was not only in 
the thymus, but also in all other tissues, as well as in all tested eukaryotes, including yeast, 
plants, and animal cells (Goldstein et al. 1975). In 1977, Ira Goldknopf and Harris Busch 
reported that histone H2A was a branched protein, with two amino termini and one 
carboxy terminus (Goldknopf & Busch 1977). In the same year, Lois Hunt and Margaret 
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Dayhoff revealed that one of the N-termini of H2A was identical to the N-terminus of 
ubiquitin, suggesting that ubiquitin could be conjugated to other proteins (Hunt & 
Dayhoff, 1977). Also in 1977, Etlinger and Goldberg developed a cell-free, non-
lysosomal, and ATP-dependent protein degradation system using rabbit reticulocytes 
(Etlinger & Goldberg 1977). Using this cell-free proteolytic system, Hershko, 
Ciechanover, and colleagues published a series of elegant papers describing a three-step 
ubiquitin conjugation cascade, which is catalyzed by E1, E2 and E3 enzymes 
(Ciehanover et al. 1978; Ciechanover et al. 1980; Hershko et al. 1980; Ciechanover et al. 
1981; Hershko et al. 1981; Haas et al. 1982; Hershko et al. 1983). However, it soon 
became clear that ubiquitin conjugation cannot fully explain the ATP requirement for 
intracellular protein degradation, as ATP is still necessary for breakdown of ubiquitinated 
proteins (Tanaka et al. 1983; Hershko et al. 1984). Several years later, two different 
groups identified a very large ATP-dependent proteolytic complex, the 26S proteasome 
(Hough et al. 1987; Waxman et al. 1987). We now know that ATP is used by the 
proteasome to unfold and translocate proteins into its internal proteolytic chamber for 
degradation (Benaroudj et al. 2003). The contribution of Aaron Ciechanover, Avram 
Hershko and Irwin Rose to the discovery of ubiquitin-proteasome system leads to the 
2004 Nobel Prize in Chemistry.          
1.1.1 Ubiquitin  
Ubiquitin is a small protein present in all eukaryotic organisms. It is highly 
conserved; there are only 3 amino acids differences out of its total 76 amino acids 
between human and yeast ubiquitin. Ubiquitin can be covalently conjugated to target 
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proteins by isopeptide bond formation between its C-terminal carboxyl group and an ε-
amino group of a lysine residue. This conjugation process, known as ubiquitination, 
requires three types of enzymes: ubiquitin activating enzymes (E1s), ubiquitin 
conjugating enzymes (E2s), and ubiquitin ligases (E3s) (Figure 1.1) (Pickart 2001; 
Passmore & Barford 2004). In human cells, there are two E1s (Uba1 and Uba6), 
approximately 60 E2s, and over 600 E3s (Rape 2009).  
Ubiquitin can be linked to a target protein as one molecule at either a single site 
(monoubiquitination) or multiple sites (multi-monoubiquitination). Its seven internal 
lysine residues (K6, K11, K27, K29, K33, K48, K63) and N-terminal amino group (M1) 
can also be linked to other ubiquitin molecules to form polyubiquitin chains 
(polyubiquitination). Different types of polyubiquitin chains are associated with different 
cellular functions, although our understanding of this remains incomplete. K48-linked 
polyubiquitin chains are the main chain type involved in proteasomal degradation, 
whereas K63-linked chains function in various non-proteolytic cellular events, including 
endocytosis, DNA repair, and immune signaling (Bennett & Harper 2008; Hayden & 
Ghosh 2008; Zeng et al. 2010). The functions of other chain types are largely unknown, 
although all of them have been demonstrated in vivo. It has been proposed that all non-
K63 chains might work as protein degradation signals, based on the observation that 
proteasome inhibition increases the level of all non-K63 chains (Xu et al. 2009; Kim et 
al. 2011b). K11 chains are suggested to function as a degradation signal in ERAD (ER-
associated degradation) and APC/C (anaphase promoting complex/cyclosome)-mediated 
cell cycle regulation (Haas & Wilkinson 2008; Jin et al. 2008; Xu et al. 2009). In 
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Drosophila, K29 chains have been reported to mediate the lysosomal degradation of 
Deltex, a positive regulator of Notch signalling (Chastagner et al. 2006). In addition, 
linear polyubiquitin chain (M1 chain) is reported to play an important role in NF-kB 
activation (Iwai & Tokunaga 2009).    
Ubiquitin is encoded by multiple genes. The yeast ubiquitin encoding genes are 
UBI1 (RPL40A), UBI2 (RPL40B), UBI3 (RPS31), and UBI4. The human ubiquitin 
encoding genes are RPS27A, UBA52, UBB, and UBC (Kimura & Tanaka 2010). All 
ubiquitin proteins are translated as inactive precursors, as fusion proteins to a ribosomal 
protein or as a linear fusion of multiple ubiquitin moieties. Prior to being conjugated to 
substrates, ubiquitin precursors must be processed by de-ubiquitinating enzymes (DUBs) 
to expose its Gly-Gly motif at the C-terminus (Passmore & Barford 2004). Ubiquitin 
expressed artificially in a pre-processed form functions normally, ruling out a maturation 
requirement for expression as fusion proteins. Another possibility is that fusion of 
ubiquitin to highly expressed ribosomal proteins allows ubiquitin to be expressed at 
similarly high levels (Kimura & Tanaka 2010). While ubiquitin could conceivably play a 
chaperone function toward the ribosomal proteins to which it is fused, this is clearly not a 
necessity as yeast strains that are engineered to lack the ubiquitin fusion proteins show no 
abnormalities (Finley et al. 1989).      
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Figure 1.1: The ubiquitin-proteasome system (UPS) 
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1.1.2 Ubiquitin activating enzymes (E1s) 
A single yeast (Uba1) and two human (Ube1, Uba6) ubiquitin E1 enzymes have 
been reported (Figure 1.1) (Jin et al. 2007; Rape 2009). Ubiquitin E1 contains three 
functional domains: an adenylation domain, a catalytic Cys domain, and a ubiquitin 
folding domain (UFD) (Schulman & Harper 2009). The adenylation domain is 
responsible for the activation of ubiquitin molecules. It simultaneously binds a ubiquitin 
molecule (Ub) and a molecule of ATP and catalyzes the formation of Ub~AMP with the 
release of pyrophosphate. The active site thiolate of the catalytic domain attacks the 
Ub~AMP to form E1~Ub. This charging of E1 with ubiquitin induces a profound 
conformational change in the E1 protein, leading to the exposure of the C-terminal 
ubiquitin fold domain (UFD), which is responsible for recruiting E2 proteins. The 
activated ubiquitin is then transferred from the active site cysteine of E1 to the active site 
cysteine of recruited E2 through a transthiolation reaction, leading to the formation of 
E2~Ub (Ye & Rape 2009).  
In addition to ubiquitin, sixteen human ubiquitin-like proteins (UBLs) have been 
reported (Schulman & Harper 2009). In general, all UBLs are structurally similar, but 
different UBLs have their own E1 activating enzymes. E1 enzymes for specific UBLs can 
be monomeric (UBA1, UBA6 and UBE1L), heterodimeric (SAE1–UBA2 and NAE1–
UBA3), or homodimeric (UBA4, UBA5 and ATG7) (Schulman & Harper 2009). UBLs 
and their E1s are believed to have originated from prokaryotic biosynthetic pathways. 
The bacterial proteins MoaD (molybdopterin-converting factor subunit 1) and ThiS 
(thiamine biosynthesis protein S), which share the UBL fold, can be activated by C-
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terminal acyl-adenylation. This reaction is catalyzed by MoeB (molybdopterin 
biosynthetic enzyme B) and ThiF (thiamine biosynthesis protein F) respectively, whose 
sequences are homologous to the domain of E1s that is responsible for UBL binding and 
adenylation. MoaD and ThiS cannot be conjugated to other proteins, rather they are 
involved in sulfur transfer reactions in the molybdopterin and thiamine biosynthesis 
pathway, respectively (Taylor et al. 1998; Lake et al. 2001; Leimkuhler et al. 2001).    
1.1.3 Ubiquitin conjugating enzymes (E2s) 
    11 yeast and around 60 human E2 enzymes have been reported (Figure 1.1) (Rape 
2009; Finley et al. 2012). All E2 enzymes share a conserved ubiquitin-conjugating 
domain (UBC domain, ~150 amino acids), containing the catalytic cysteine (Pickart 
2001). Since E2 enzymes are in the center of the ubiquitin conjugation cascade, they must 
interact with both the E1 and E3 enzymes. The interactions of the E2 with E1 and E3 
enzymes are generally mutually exclusive, because the E1 and E3 interaction regions 
overlap extensively (Eletr et al. 2005; Eletr & Kuhlman 2007). Two studies reported that 
E1 enzymes preferentially bind to free E2 enzymes, rather than ubiquitin-charged E2s 
(Bencsath et al. 2002; Huang et al. 2005). In addition to the UBC domain, some E2 
enzymes have unique N- and/or C-terminal extensions, which are believed to mediate 
speciﬁc interactions and regulations (van Wijk & Timmers 2010). Although E3 ligases 
determine substrate specificity of ubiquitin conjugation, E2 enzymes determine the 
polyubiquitin chain types in RING-E3 mediated ubiquitination (van Wijk & Timmers 
2010). For instance, yeast Ubc6 and human Ube2C/UbcH10 are responsible for the 
formation of K11 chains in ERAD and cell cycle regulation, respectively (Haas & 
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Wilkinson 2008; Jin et al. 2008). As discussed below, E2 enzymes do not determine chain 
type specificity when they function with another class of E3s, HECT E3s.             
1.1.4 Ubiquitin ligases (E3s) 
     E3 enzymes catalyze the transfer of the E2 charged ubiquitin to substrate lysine 
residues. There are two major groups of E3 ligases: RING E3s and HECT (Homologous 
to E6AP C-Terminus) E3s. The RING E3s function as scaffold proteins that bind 
activated E2 and substrate simultaneously, facilitating the transfer of ubiquitin directly 
from E2 to substrate. In the case of HECT E3 ligases, ubiquitin is transferred from the 
charged E2 to the active site cysteine of HECT E3. More recently, a third class of E3-
ligases was identified, the RBR (RING-in-between-RING) E3-ligases, which catalyze 
ubiquitin conjugation by using both RING and HECT-like mechanisms. There are 28 
HECT E3 ligases (5 in yeast), 14 RBR E3 ligases (2 in yeast), and over 600 RING E3 
ligases in humans (60-100 in yeast). This large pool of E3 ligases defines the substrate 
specificity of the ubiquitin conjugation pathway.    
RING E3 ligases 
The RING domain was first discovered in a DNA-binding protein, Ring1. Although 
the RING domain was originally thought to be involved in DNA binding, we now know 
most RING domain proteins mediate ubiquitin transfer. The first linkage between RING 
domains and ubiquitination was established by the discovery of a RING domain protein, 
Rad18, which can promote ubiquitination of histones (Bailly et al. 1997). The RING 
domain is a type of zinc finger motif containing 6-7 cysteines and 1-2 histidines arranged 
as the following order: Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-Cys-
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X2-Cys (X could be any amino acid) (Deshaies & Joazeiro 2009). Structure studies of the 
RING domain revealed that its conserved cysteines and histidines are buried inside the 
core domain and are important for stabilizing the three-dimensional structure of the 
domain through interaction with two atoms of zinc.  
The RING domain mediates the interaction with E2-conjugating enzymes, whereas 
the substrate recognition is mediated by other portions of the RING E3 ligase. For 
example, a monomeric RING E3 ligase, Cbl, recognizes tyrosine-phosphorylated target 
proteins through its phosphotyrosine-binding domain (PTB) (Joazeiro et al. 1999). The 
U-Box domain is another E2 binding domain, called a RING-like domain. Although lack 
of conserved cysteine and histidine residues and no requirement of zinc atoms for 
structural stabilization, the three-dimensional structure of the U-Box domain is still 
similar to the RING domain. Mechanistically, both RING E3s and U-box E3s act as 
scaffold proteins which bind to a ubiquitin-activated E2 enzyme and a substrate, 
promoting transfer of ubiquitin from E2 to a substrate (Deshaies & Joazeiro 2009).   
Many RING E3 ligases are multimeric protein complexes, such as the SCF complex, 
containing Skp1, Cul1, Rbx1/Roc1 and an F-box protein. Skp1 and Cul1 are the 
backbone of the SCF complex, whereas F-box proteins and Rbx1/Roc1 are responsible 
for substrate recognition and E2 recruitment, respectively. Besides F-box proteins, many 
alternative substrate binding proteins, including SOCS box, VHL box, or BTB domain-
containing proteins, could be incorporated into cullin-RING E3 ligase (CRL) complexes, 
allowing this type of E3 ligases to target a wide range of substrates (Petroski & Deshaies 
2005). 
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HECT E3 ligases 
    The first discovered HECT E3 ligase was E6AP, which is hijacked by the human 
papillomavirus (HPV) E6 protein to promote the ubiquitination and degradation of p53 
(Huibregtse et al. 1991; Scheffner et al. 1993). When purified E6AP is used for an in 
vitro ubiquitination assay, it accepts ubiquitin from E2 and forms a thioester with 
ubiquitin as an intermediate step in E6AP-dependent ubiquitination (Scheffner et al. 
1995). Sequence analysis revealed that a group of proteins containing a similar C-
terminal domain (~350 residues) as E6AP were also capable of thioester formation, 
defining a new group of ubiquitin E3 ligases, the HECT E3 ligases (Homologous to 
E6AP Carboxyl-Terminus) (Huibregtse et al. 1995).  
Structural studies have shown that the HECT domain consists of a ~250-amino-acid 
N-lobe and a ~100-amino-acid C-lobe, connected by a 4-amino-acid flexible hinge. The 
N-lobe is the site for recruitment of ubiquitin-charged E2s, and the C-lobe contains the 
active site cysteine that accepts ubiquitin from the E2 through a transthiolation reaction 
(Huang et al. 1999). Although the C-terminal domains of HECT E3s are highly 
conserved, their substrate specificity is determined by their variant N-terminal regions 
(Scheffner & Kumar 2014). The Huibregtse lab reported that the C-lobe determines the 
polyubiquitin chain type specificity among HECT E3 ligases. Kim et al. showed that 
swapping the C lobe of Rsp5, a K63-specific HECT E3, with the C lobe of E6AP, a K48-
specific HECT E3, resulted in Rsp5 preferentially catalyzing K48-linked chains 
formation (Kim & Huibregtse 2009). In addition, Kim et al. reported that a non-covalent 
ubiquitin binding site (UBS) within the N-lobe of the Rsp5 HECT domain is important 
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for ubiquitin chain elongation, with the proposed function being to localize and orient the 
distal end of the ubiquitin chain to promote the addition of the next ubiquitin molecule 
(Kim et al. 2011a).  
RBR E3 ligases 
The RBR (RING-in-between-RING) E3 ligases were first described by two different 
groups in 1999 (Morett & Bork 1999; van der Reijden et al. 1999). This class of proteins 
is characterized by the RBR signature, which consists of two RING finger domains 
(RING1 and RING2 domain), with an IBR domain (in-between RING domain) in the 
middle (Smit & Sixma 2014). RBR E3 ligases follow a two-step mechanism to mediate 
the transfer of ubiquitin molecule from the E2 to substrates. The ubiquitin transfer is 
initiated by the interaction of a ubiquitin-charged E2 with RING1 domain, similar to the 
interaction of E2s with classical RING E3-ligases. However, instead of facilitating the 
transfer of ubiquitin to substrates directly, this interaction in RBR proteins is used to 
promote the transfer of ubiquitin to the active site cysteine on RING2, to form a HECT-
like thioester intermediate prior to the transfer of ubiquitin to its target protein (Smit & 
Sixma 2014).  
This RING/HECT-hybrid mechanism was first uncovered in the study of the 
reactivity profile of UBCH7, a human E2 enzyme (Wenzel et al. 2011). UBCH7 exhibits 
broad specificity for HECT E3 ligases, but often fails to function with RING E3 ligases 
(Anan et al. 1998; Zheng et al. 2000). Wenzel and colleagues found that unlike many E2s 
that can function with RING E3s, UBCH7 lacks intrinsic E3-independent reactivity with 
lysines, explaining its preference for HECT E3s. Meanwhile, they also found that 
 12 
UBCH7 shows activity with RBR E3 ligases, including Parkin and HHAR1, and the 
successful transfer of ubiquitin requires a conserved cysteine residue in RING2 domains. 
Moreover, in vitro assays showed that HHAR1 can form a β-ME (β-mercaptoethanol) 
sensitive intermediate with ubiquitin, indicating that RBR proteins function like 
RING/HECT hybrids (Wenzel et al. 2011).  
1.1.5 Deubiquitinating enzymes (DUBs) 
Deubiquitinases are a group of proteases that can hydrolyze isopeptide bonds 
between ubiquitin and the substrate. The human genome encodes around 79 
deubiquitinases, which are classified into five families: ubiquitin C-terminal hydrolases 
(UCHs), ubiquitin-specific proteases (USPs), ovarian tumor proteases (OTUs), Josephins 
and JAB1/MPN+ metalloenzymes. Most DUBs are Cys proteases, except for 
JAB1/MPN+ family members, which are zinc metalloproteases (Komander et al. 2009).  
DUBs have three major functions in cellular pathways. First, as mentioned above, 
ubiquitins are translated as inactive precursors either fused to ribosomal proteins or as a 
linear fusion of multiple ubiquitin moieties. DUB activity is required to process these 
precursors and generate active monomeric ubiquitin molecules with exposed C-termini. 
UCH family members are believed to be the major players in processing ubiquitin 
precursors, based on their preference for linear ubiquitin fusion proteins as substrates. 
Second, DUBs are important for recycling ubiquitin and maintaining ubiquitin 
homeostasis in cells. Some DUBs are normally associated with proteasomes and 
endocytic vesicles to release ubiquitin prior to substrate degradation. Third, DUBs are 
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important regulators of protein stability. They act as antagonists of ubiquitin signaling to 
rescue mis-conjugated proteins (Komander et al. 2009).   
1.1.6 The proteasome  
The 26S proteasome is the location for the degradation of most ubiquitinated 
proteins. It consists of two multi-subunit components: the 20S core particle and the 19S 
regulatory particle. The core particle is made up of 28 subunits which are arranged into 
four seven-subunit rings (two α-subunit rings and two β-subunit rings). The four rings are 
stacked to form a hollow barrel-like structure, with two β-subunit rings in the center and 
two α-subunit rings at each end. The core particle contains six proteolytic sites which are 
all located inside the chamber. As these six proteolytic sites show relatively low 
preference for specific amino acids, together they can digest almost any amino acid 
sequence (Nussbaum et al. 1998; Kisselev et al. 1999). The entrances to the proteasome 
core particle at both ends are so narrow that folded proteins cannot pass through, 
therefore preventing the unspecific degradation of folded native cellular proteins by the 
20S particle (Lowe et al. 1995; Groll et al. 1997). 
The 19S regulatory particle is responsible for recognizing ubiquitinated proteasome 
substrates, removing ubiquitin chains, and unfolding target proteins for entering the core 
particle. These distinct functions are performed by its different subunits: Firstly, two 
intrinsic ubiquitin receptors (Rpn10 and Rpn13), together with several detachable 
ubiquitin receptors are essential for recognition of ubiquitinated proteins. Several recent 
structural studies showed that Rpn10 and Rpn13 are about 9 nm apart from each other, 
which is closely matched to the length of the K48 chain with four ubiquitin moieties. This 
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may account for why proteasome substrates need a polyubiquitin chain equal to or longer 
than four ubiquitin molecules for tight binding to the proteasome (Beck et al. 2012; da 
Fonseca et al. 2012; Lander et al. 2012). Secondly, Rpn11 is a proteasome-associated 
deubiquitinase whose function is to remove the entire polyubiquitin chain from 
proteasome substrates for recycling (Verma et al. 2002; Yao & Cohen 2002). Thirdly, the 
19S particle contains six ATPases (Rpt1-6) that form a ring-like structure and dock onto 
the core particle. They unfold the proteasome substrates and promote the translocation of 
unfolded proteins into the core particle by hydrolyzing ATPs (Hanson & Whiteheart 2005; 
Sauer & Baker 2011). With the concerted effort of these different subunits, the 19S 
particle promotes the degradation of ubiquitinated proteasome substrates by the core 
particle. 
 
1.2 ISG15: AN ANTI-VIRAL UBIQUITIN-LIKE PROTEIN  
1.2.1 Ubiquitin-like proteins 
Ubiquitin-like proteins (UBLs) are a group of proteins, whose structures resemble 
the β-grasp fold of ubiquitin (Figure 1.2). So far, seventeen ubiquitin-like proteins have 
been identified, including SUMO1-4, Nedd8, FAT10, URM1, and ISG15 (Schulman & 
Harper 2009). Similar to ubiquitin conjugation, ubiquitin-like proteins are covalently 
linked to substrate proteins through the formation of isopeptide bond between their C-
terminal glycine and a substrate amino group (normally a lysine side chain). Conjugation 
of ubiquitin-like proteins to substrates requires the E1-E2-E3 enzymatic cascade similar 
to that of ubiquitin. Meanwhile, many UBL-specific proteases have been identified, 
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which function to process UBL precursors and remove UBLs from target proteins. 
Although structurally related, very little evidence suggests that UBLs signal target 
proteins for proteasomal degradation, with the exception of FAT10, which can target its 
conjugated proteins for degradation with the assistance of NUM1L (NEDD8 ultimate 
buster-1 long) (Hipp et al. 2005; Schmidtke et al. 2009; Rani et al. 2012). In contrast, 
most of UBLs have critical regulatory roles in many cellular processes, including nuclear 
transport, translation, autophagy and antiviral pathways (van der Veen & Ploegh 2012). 
In some cases, protein conjugation activity is not necessary for certain UBLs to perform 
their particular biological functions. For example, Urm1 can function as a sulphur carrier 
in thiolation of tRNAs (Leidel et al. 2009; Noma et al. 2009). Recently, Bogunovic and 
colleagues reported that ISG15 can act as an extracellular cytokine to promote IFN-γ 
production for the control of mycobacterial disease (Bogunovic et al. 2012). They found 
that although ISG15 has no detectable signal peptide sequence, it can still be secreted by 
human neutrophils, monocytes and lymphocytes. Secreted ISG15 can act on T and 
natural killer (NK) lymphocytes to induce IFN-γ production. Interestedly, a synergistic 
effect on IFN-γ induction was observed when the cells were simultaneously treated with 
ISG15 and interleukin 12 (IL-12), another cytokine well-known to induce IFN-γ 
production. In addition, they found that inherited ISG15 deficiency is associated with 
severe mycobacterial disease in both mice and humans, providing supportive evidence of 
the essential role of ISG15 in the control of mycobacteria infection (Bogunovic et al. 
2012).  
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Figure 1.2: The structures of ubiquitin-like proteins resemble the structure of ubiquitin 
 
ISG15 (red) and NEDD8 (green) structurally resemble ubiquitin (blue). Structures are adapted  from 
(Durfee 2010) (PDB files 1Z2M, 2KO3, and 1UBQ).  
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1.2.2 ISG15 and its pathway enzymes 
 ISG15 is a 17 kD IFN-α/β-induced UBL consisting of two ubiquitin-like domains 
that are connected via a six-residue linker (Figure 1.2) (Narasimhan et al. 2005). The N-
terminal domain of ISG15 is 32% identical to ubiquitin, whereas the C-terminal domain 
is 37% identical. ISG15 was the first identified UBL (Farrell et al. 1979), only 4 years 
later than the discovery of ubiquitin. Many years passed before the enzymes for ISG15 
conjugations were identified, beginning with the ISG15 E1 enzyme (Ube1L/UBA7) in 
2001 (Yuan & Krug 2001). UbcH8/Ube2L6 and Herc5 were subsequently identified as 
the major E2 and E3 enzymes for ISG15 conjugation, respectively (Yuan & Krug 2001; 
Zhao et al. 2004; Dastur et al. 2006). Similar to ISG15, all these enzymes are IFN-α/β-
induced. Although several other IFN-induced E3 ligases have been identified by 
microarray analysis (Nakasato et al. 2006; Zou & Zhang 2006), Dastur et al. showed that 
depletion of Herc5 by siRNA eliminated nearly all ISG15 conjugated products in 
interferon treated cells, suggesting Herc5 is the major E3 ligase for ISG15 conjugation 
(Dastur et al. 2006). In addition, ISGylation could be broadly reconstituted by co-
expression of Ube1L, UbcH8, ISG15, and Herc5 in non-interferon treated cells, 
suggesting that these represent the core enzymes for ISG15 conjugation. One of the IFN-
induced E3 ligases is Herc6, the closest relative of Herc5 in human cells. Interestingly, 
human Herc6 does not support ISG15 conjugation but mouse Herc6 does support 
conjugation (Ketscher et al. 2012; Oudshoorn et al. 2012).     
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Like ubiquitin and many other UBLs, ISG15 is translated as an inactive precursor, 
so that an ISG15-specific protease is required to process its C-terminus for exposing the 
LRLRGG motif. Ubp43 was reported as a deconjugating enzyme of ISG15 (Malakhov et 
al. 2002); however it is not responsible for ISG15 precursor processing, as ISG15 
conjugation still occurred in Ubp43-/- mice (Knobeloch et al. 2005). Several non-catalytic 
functions of Ubp43 have been reported recently. For example, Ubp43 negatively 
regulates IFN signaling by binding to the IFNAR2 receptor subunit and blocking the 
interaction between JAK and the IFN receptor (Malakhova et al. 2006). In addition, 
Ubp43 was identified as an important repressor of IFN-α and drug-induced apoptosis, and 
this anti-apoptotic function is also independent of its ISG15 isopeptidase activity (Potu et 
al. 2010).          
1.2.3 Anti-viral function of ISG15 
Type 1 interferons are a component of the innate immune response. When viruses or 
bacteria infect cells, cells rapidly detect infected pathogens based on pathogen-associated 
molecular patterns (PAMPs) present on bacteria or viruses. Pattern recognition receptor 
proteins (PRRs) can recognize PAMPs and trigger the activation of multiple downstream 
signaling cascades, including interferon-regulatory factors (IRFs), leading to the 
production of type I interferon (IFN-α/β) (Mogensen 2009). IFN-α/β is then secreted in 
an autocrine and paracrine manner, and induces the expression of over a hundred 
interferon stimulated genes (ISGs), including MxA, PKR, p56, OAS1, APOBEC3G, 
many TRIM ubiquitin ligases, and the ISG15 conjugation machinery (Schoggins & Rice 
2011).  
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Expression of ISGs facilitates the establishment of an anti-viral state; however, the 
biochemical mechanism of the anti-viral effects are understood for only a handful of 
ISGs. MxA has been shown to accumulate at the ER membrane where it can recognize 
and trap viral nucleocapsid-like structures, preventing these trapped viral components 
from being used for the generation of new virus particles (Haller et al. 2007). TRIM5α is 
a retrovirus-specific restriction factor. It can interfere with the capsid uncoating process 
of the retrovirus, therefore preventing the subsequent reverse transcription and delivery of 
viral genome into the nucleus. The RING domain of TRIM5α is not absolutely required 
for retrovirus restriction (Stremlau et al. 2004). Consistent with this, proteasome 
inhibition did not significantly affect the restriction of retrovirus infection by TRIM5α 
(Stremlau et al. 2004; Sebastian & Luban 2005; Stremlau et al. 2006).  
 ISG15 has been reported to have anti-viral activity against several types of RNA 
and DNA viruses, including influenza, Sindbis, herpes, Human Immunodeficiency Virus 
(HIV), and Ebola (Lenschow et al. 2005; Okumura et al. 2006; Okumura et al. 2008; 
Hsiang et al. 2009). In most cases examined, ISG15 conjugation is essential for the 
antiviral activity, as the mice lacking the ISG15 E1 activating enzyme, Ube1L, showed 
more viral susceptibility (Giannakopoulos et al. 2009; Lai et al. 2009). It has been shown 
that unconjugated ISG15 molecules also have anti-viral activity. For example, the 
ubiquitination-induced interaction of viral Gag protein and the host’s Tsg101 protein (a 
central component of the endosomal sorting complex (ESCRT-1)) is required for the 
release of HIV virions. Free ISG15 is reported to block the release of HIV-1 virions from 
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infected tissue culture cells by inhibition of the ubiquitination of Gag and Tsg101 
proteins. Similarly, Nedd4-mediated ubiquitination of Ebola VP40 matrix protein is also 
required for the efficient release of VP40 virus-like particles (VLPs). Okumura et al. 
showed that ISG15 interacts with Nedd4 ubiquitin ligase and inhibits ubiquitination of 
VP40 to prevent efficient release of VLPs (Okumura et al. 2006; Okumura et al. 2008). 
In addition, free ISG15 is critical for the control of Chikungunya virus (CHIKV) 
infection. There is an increase in lethality in ISG15−/− mice but not UbE1L−/− mice 
following CHIKV infection. Interestingly, no differences in viral loads were observed 
between wild-type and ISG15−/− mice; however, a dramatic increase in proinflammatory 
cytokines and chemokines was observed in ISG15−/− mice, suggesting that the cytokine 
storm contributes to the lethality of ISG15−/− mice after CHIKV infection (Werneke et al. 
2011).  
Several recent studies have begun to unravel the molecular mechanism of the anti-
viral role of ISG15 conjugation. Influenza A NS1 protein (NS1A) was identified as an 
ISG15 target in virus-infected cells. Chen et al. showed that ISGylation of NS1A protein 
blocks its binding to importin-α, impairing the nuclear import of NS1A protein. 
Meanwhile, mutation of ISGylation sites of NS1A dramatically enhances viral replication 
in interferon-treated cells (Zhao et al. 2010). ISG15 modification of a certain cellular 
protein is critical for the antiviral activity. ISGylation of interferon regulatory factor-3 
(IRF-3) was found to increase its stability by antagonizing its ubiquitination. As a 
consequence, IRF-3 mediated transcription was enhanced, promoting the production of 
IFN-β (Lu et al. 2006).  
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 Consistent with the anti-viral role of ISG15, viruses have developed different 
mechanisms to antagonize ISG15 and its conjugation pathway (Zhao et al. 2013). 
Inﬂuenza B NS1 protein (NS1B) has been shown to bind ISG15 and block its conjugation 
(Yuan & Krug 2001). Similarly, Vaccinia virus protein, E3, is also able to bind ISG15 
and repress the conjugation of ISG15 (Guerra et al. 2008). Moreover, several viruses, 
including SARS Coronavirus, human Coronavirus NL63, Nairoviruses and Arteriviruses, 
encode proteases to remove ISG15 from target proteins (Frias-Staheli et al. 2007; 
Lindner et al. 2007; Clementz et al. 2010). 
1.2.4 ISG15 targets a broad range of newly synthesized proteins 
As discussed previously, the ubiquitin system contains over 600 E3 ligases to 
facilitate the transfer of ubiquitin to specific targets. Generally, E3 ligases recognize 
substrates through protein-protein interaction motifs. As a result, one E3 ligase generally 
recognizes only a small group of proteins sharing a common protein-protein interaction 
motif. Currently, more than 300 cellular proteins have been identified as ISG15 targets 
(Giannakopoulos et al. 2005; Zhao et al. 2005; Takeuchi et al. 2006). These identified 
ISG15 targets are involved in various cellular pathways, including cytoskeletal 
organization, stress responses, translation, transcription, RNA splicing, and general 
metabolism. In addition, no common primary sequence motif was identified within the 
ISG15 target proteins. Given that Herc5 is the only major E3 ligase for ISG15 
conjugation, this raises a very important question: how can a single E3 ligase recognize 
and target such a large number of substrates?  
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In addressing this question, Durfee et al. found that: 1) the range of ISG15 substrates 
extends even further and includes exogenously expressed bacterial, viral, and non-
naturally occurring proteins, 2) only newly synthesized proteins can be targeted for 
ISGylation, and 3) Herc5 co-fractionation with polysomes through interaction with the 
60S ribosomal subunit (Durfee et al. 2010). These findings suggested a co-translational 
model for ISG15 conjugation: Herc5 associates with ribosomes and stochastically 
transfers ISG15 to newly synthesized proteins, while they are being translated. This 
model implies that in the context of virally infected cells, newly translated viral proteins 
may be an important class of ISG15 substrates (Figure 1.3).  
One major issue of the anti-viral activity of ISG15 conjugation is that only a very 
small fraction of the total pool of any target protein was ISGylated and therefore, it is 
unclear how modification of a small fraction of viral protein might have a significant 
reduction on overall viral infectivity. Durfee et al proposed a dominant negative effect 
model for explaining the antiviral activity of ISGylation. This model has been tested in a 
human papillomavirus 16 (HPV16) pseudovirus system. As predicted, only a small 
fraction of HPV16 L1 capsid protein was ISGylated and incorporated into mature 
pseudovirus. However, given that each HPV pseudovirion has 360 molecules of L1 
protein, almost every pseudovirion contains multiple copies of ISGylated L1 protein. As 
a result, the overall viral infectivity was largely inhibited (Durfee et al. 2010). 
Although our previous data was consistent with the co-translational model of ISG15 
conjugation, direct evidence was still lacking. The goal of chapter 2 of my thesis is to 
rigorously test this co-translational model.  
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1.3 CELLULAR PROTEOSTASIS AND ITS LINKAGE WITH AGING  
Every human cell contains several billion protein molecules, ranging in size from 3 
kDa to 3700 kDa (Wolff et al. 2014). These proteins must fold into specific three-
dimensional conformations to obtain their functional activities. Inappropriately folded 
proteins need to be disposed of immediately and efficiently to maintain protein 
homeostasis. Deficiencies in protein folding or eliminating aberrant proteins are 
associated with many age-related diseases, such as Alzheimer’s disease, Parkinson’s 
disease, and cataracts (Balch et al. 2008; Douglas & Dillin 2010; Lopez-Otin et al. 2013). 
Understanding the mechanisms of protein folding, quality control and disposal of 
misfolded proteins is therefore crucial for therapeutic intervention in these disease states.  
Figure 1.3: Co-translational model for ISG15 conjugation. (Adapted from Durfee et al. 2010)   
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1.3.1 Challenges of protein folding in vivo 
The earliest studies of protein folding were performed in vitro, by examining the 
refolding of denatured proteins in the absence of any other component or energy source. 
These studies found that small proteins with only a single domain could fold 
spontaneously in vitro very rapidly, demonstrating that the primary amino acid sequence 
of a protein contains all the necessary information for its correct protein folding 
(Anfinsen 1973; Chan & Dill 1998). However, large and multi-domain proteins often 
failed to reach their native structures during in vitro experiments. Considering the 
average number of protein domains per human protein is 3.7, human cells must have 
ways to ensure the efficient folding of proteins (Wolff et al. 2014). 
Protein folding in the cell is believed to be more complicated and challenging than 
folding in vitro. First, the cellular environment is a very crowded environment, with the 
protein concentration up to 300-400 mg/ml, approaching the saturation point for protein 
crystallization (Asherie 2004). This crowded environment increases the tendency of non-
native, partially folded proteins to form protein aggregates (Ellis & Minton 2006). 
Second, a nascent polypeptide cannot fold into a stable native structure until the complete 
protein has been synthesized and released from ribosome (Cabrita et al. 2009; Eichmann 
et al. 2010). As protein translation is relatively slow, with an elongation rate around 5 
amino acids per second in human cell, nascent chains are therefore exposed as partially 
folded and aggregation-prone intermediates for relatively long periods of time (synthesis 
of a protein with an average length of 550 amino acids requires ~110 seconds). Generally, 
a single mRNA molecule is occupied and translated by multiple ribosomes 
 25 
simultaneously, forming a polyribosome (or polysome). In the context of polysomes, the 
local concentration of nascent polypeptides is very high, further increasing the probability 
of interactions between partially folded nascent chains on adjacent ribosomes. Moreover, 
many proteins require certain post-translational modifications, interaction with specific 
ligands or binding partners, or a specific location for proper folding (Dunker et al. 2008; 
Kim et al. 2013).  
1.3.2 Strategies to facilitate protein folding in vivo 
Due to such challenges, cells have developed several strategies to ensure efficient 
and correct protein folding in vivo. The core strategy is the development of chaperone 
systems. Molecular chaperones are defined as proteins that interact with, stabilize, or help 
other proteins to reach their functional conformation, but they are not present in the final 
structure of their client proteins (Hartl & Hayer-Hartl 2009; Kim et al. 2013). Chaperone 
proteins are often referred to as heat-shock proteins (HSPs), as certain chaperones are 
heat- or stress-induced. Cells contain several different classes of chaperones, which are 
normally classified based on their molecular weight (e.g., HSP40, HSP60, HSP70, 
HSP90, HSP100, and several small HSPs). Chaperones are highly abundant proteins in 
cells, with multiple essential functions in maintaining proteome homeostasis, including 
de novo protein folding, refolding of denatured proteins, protein trafficking, and 
promoting the degradation of misfolded proteins (Hartl et al. 2011).   
  The central role of constitutively expressed chaperones is to facilitate de novo 
protein folding. Chaperones involved in de novo folding can be further divided into two 
groups based on whether or not they interact with ribosomes (Preissler & Deuerling 
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2012). The first group includes chaperones that associate with ribosomes and bind to 
nascent chains as soon as they emerge from the ribosomal exit tunnel. These proteins 
assist the early steps of de novo folding during translation. Eukaryotic cells contain two 
ribosome-associated chaperone systems, the nascent chain-associated complex (NAC) 
and the HSP70-based triad system (Rospert et al. 2002; Kampinga & Craig 2010; Jaiswal 
et al. 2011). The second group of chaperone proteins do not interact with the ribosome, 
including cytosolic HSP70/40, HSP60/10 (chaperonins) and prefoldin (Preissler & 
Deuerling 2012). They act downstream of the ribosome-associated chaperones, 
controlling the late de novo folding steps. Binding of chaperones to nascent polypeptides 
could prevent their premature folding and keep nascent chains in a soluble and folding-
competent state. In addition, chaperonins provide an enclosed space for substrate protein 
folding. Most of chaperonin substrates are between 20 to 60 kDa and contain complex 
α/β or α+β structures (Fujiwara et al. 2010), and they are free to fold in the enclosed 
environment for approximately 10 seconds (Kerner et al. 2005; Horwich & Fenton 2009).        
 In addition to the chaperones described above, another class of chaperones in cells 
is linked to the stress response, assisting the re-folding of stress-denatured proteins 
(Albanese et al. 2006). In yeast, the stress-linked chaperones include HSP104, Sti1 and 
Ssa4. The expression of stress-linked chaperones is induced under stress conditions, 
controlled by the heat shock factors (HSFs) (Akerfelt et al. 2010). Rapid repression of 
global protein translation is observed under stress conditions, primarily due to inhibition 
of translation initiation as well as elongation pausing (Spriggs et al. 2010; Liu et al. 2013; 
Shalgi et al. 2013). These findings showed that the protein synthesis machinery can 
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control protein production by sensing the intracellular folding environment, preventing 
the production of proteins in a hostile environment and reducing the burden on chaperone 
systems under stress conditions (Holcik & Sonenberg 2005).    
 In addition to chaperone systems, cells also have several other strategies to 
facilitate correct protein folding. For example, many mRNAs are simultaneously 
translated by multiple ribosomes, forming the polyribosome structure. To avoid mis-
interactions between the nascent chains on two adjacent ribosomes, polysomes are 
organized in a pseudohelical arrangement in vivo to maximize the distance between 
nascent chains on adjacent ribosomes (Brandt et al. 2009). Denatured full length multi-
domain proteins are normally unable to refold correctly, due to non-native inter-domain 
interactions. To avoid these non-native contacts, eukaryotic cells evolved a domain-wise 
co-translational folding strategy (Netzer & Hartl 1997; Frydman et al. 1999). Relatively 
slow elongation rates (~5 amino acid per sec in eukaryotes versus ~20 amino acids per 
sec in bacteria) in concert with translational pausing at rare codons prevents later 
domains from emerging from the ribosome until the folding of the previous domain is 
completed (Zhang & Ignatova 2009). The sequential domain folding strategy may have 
allowed for the explosive evolution of complex multi-domain proteins in eukaryotes 
(Agashe et al. 2004).  
1.3.3 Strategies for clearance of misfolded proteins 
     Protein synthesis is a complicated process, with the participation of approximately 
400 proteins (Kim et al. 2013). Errors occurring in each step, including transcription, 
mRNA processing, and translation, can have large adverse effects on the stability of the 
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protein (DePristo et al. 2005; Levine et al. 2005; Ogle & Ramakrishnan 2005; Pickrell et 
al. 2010). Although the error rate of protein synthesis is kept at a relatively low level, 
huge numbers of aberrant proteins are still produced. For example, the rate of amino acid 
mis-incorporation is only one in every 5,000-10,000 amino acids, but given the average 
length of a protein is approximate 550 amino acids, this means that 5%-10% of proteins 
of average length contain at least one mis-incorporated amino acid (Wolff et al. 2014). 
As a result, a significant fraction of newly synthesized proteins never attain their 
functional state, even with the help of molecular chaperones. Consistent with this, 6%-30% 
of all newly synthesized proteins are rapidly degraded in eukaryotic cells (Schubert et al. 
2000; Vabulas & Hartl 2005; Qian et al. 2006). In addition to this continuous stream of 
misfolded proteins from newly synthesized proteins under normal conditions, a number 
of abnormal conditions can enhance the production of misfolded proteins, such as 
elevated temperature, exposure to chemicals or heavy metals, and bacteria or viral 
infections (Voisine et al. 2010).  
Given that misfolded proteins are toxic, cells have elaborate strategies to monitor 
and clear misfolded proteins. The three major parallel strategies are: 1) refolding of 
misfolded proteins with the assistance of chaperones, 2) degradation of misfolded 
proteins through UPS and autophagy systems, and 3) sequestration of misfolded proteins 
into specialized quality control compartments (Figure 1.4) (Chen et al. 2011). Each 
strategy has its own advantages and drawbacks. Protein refolding is a fast and energy-
efficient way to deal with deleterious proteins, and misfolded proteins can be recovered 
via this strategy. However, as discussed above, many multi-domain proteins are not able 
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to correctly refold due to non-native inter-domain interactions (Netzer & Hartl 1997). 
Degradation is a permanent way to clear misfolded proteins. Sequestration is a way to 
mitigate the burden on quality control systems when they are overloaded with misfolded 
proteins (Kaganovich et al. 2008), but inclusions are difficult to clear and some normal 
proteins may also be sequestrated due to the relatively low specificity of this process 
(Olzscha et al. 2011). 
   
 
 
 
 
 
 
 
Degradation of misfolded proteins via proteolytic pathways     
     Eukaryotic cells have two proteolytic pathways: the ubiquitin-proteasome (UPS) 
system and the autophagy/lysosome system. Most of the soluble misfolded and damaged 
proteins are degraded by the UPS, the major degradation pathway in eukaryotes, which 
Figure 1.4: Three major strategies to clear misfolded proteins. (Adapted from Chen et al. 2011) 
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corresponds to 80%-90% of total intracellular protein degradation (Goll et al. 2008). 
Recognition of misfolded proteins by ubiquitin E3 ligases may need the assistance of 
chaperones. For example, CHIP (carboxy-terminal HSP70 interacting protein) E3 ligase 
interacts with HSP70 and targets HSP70-bound misfolded proteins for proteasomal 
degradation (Arndt et al. 2007). Ubiquitination of misfolded endoplasmic reticulum (ER) 
proteins also requires the participation of chaperones. Two ubiquitin E3 ligases, Hrd1 and 
Doa10, are anchored to the ER membrane and mediate ubiquitination of misfolded ER 
proteins in a HSP70-dependent manner (Hirsch et al. 2009). Degradation of ubiquitinated 
proteins may also require other factors, such as p97/Cdc48-Ufd1-Npl4 complex and its 
cofactors. P97/Cdc48 is an AAA ATPase (ATPases associated with diverse 
cellular activities) with intrinsic ubiquitin binding affinity (Jentsch & Rumpf 2007). 
Cdc48/p97 is believed to function as a ‘segregase’ to extract ubiquitinated protein from 
its original complex by using the energy from ATP hydrolysis (Ye 2006), ensuring the 
specific degradation of ubiquitinated substrates but not their normal interaction partners.   
     Protein aggregates are too big to be degraded by the proteasome; therefore most 
protein aggregates are disposed of by the autophagy pathway. Autophagy is a relatively 
unspecific degradation pathway that is used to clear the unnecessary or dysfunctional 
cellular components or organelles, such as malfunctioned mitochondria and deficient 
ribosomes. This is done by engulfing the substrates and ultimately delivering the 
substrates to the lysosome (Klionsky et al. 2011; Murrow & Debnath 2013). At least 
three different forms of autophagy have been described: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) (Lee et al. 2012; Murrow & 
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Debnath 2013). Unlike the other two forms of autophagy, CMA is a relatively specific 
pathway, which requires an HSC70-containing complex for substrate selection and 
delivery into the lysosome (Arias & Cuervo 2011). Several studies revealed functional 
interactions between UPS and autophagy pathways. For instance, when the UPS function 
was blocked, autophagy was induced as a compensatory degradation pathway (Pandey et 
al. 2007). Similarly, inhibition of the autophagy pathway resulted in accumulation of 
proteasomal substrates in the cell (Komatsu et al. 2005).  
Sequestration of misfolded proteins to quality control compartments 
 Sequestration of misfolded proteins into inclusions was initially thought as a 
backup strategy to manage toxic materials when quality control failed, as inclusions were 
often formed when chaperones and proteolytic systems were overwhelmed (Chen et al. 
2011). A growing amount of evidence reveals that sequestration of misfolded proteins 
also occurs in healthy cells under normal growth conditions, suggesting a physiological 
feature of protein quality control (Escusa-Toret et al. 2013). Misfolded proteins are sorted 
into different spatial compartments based on their solubility and properties. Soluble 
ubiquitinated misfolded proteins are sequestrated into the Q-body and juxtanuclear 
quality control compartment (JUNQ). In contrast, insoluble amyloid aggregates are sorted 
into the insoluble protein deposit (IPOD) compartment that is next to the vacuole 
(Kaganovich et al. 2008; Sontag et al. 2014). Sorting of misfolded proteins with different 
properties to specific compartments is believed to enhance the efficiency of protein 
quality control. JUNQ co-localizes with high level of chaperones and proteasomes, 
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suggesting that the protein refolding and degradation are highly promoted in this 
compartment. IPOD is associated with autophagy-related protein Atg8, which may 
facilitate degradation of the sequestered insoluble aggregates by lysosomes (Kaganovich 
et al. 2008). Sequestration of misfolded proteins is also thought to be important for 
rejuvenation of daughter cells. During asymmetric cell division, sequestered misfolded 
and damaged proteins were all inherited by the mother cell, giving the daughter cell clean 
components as well as full replicative potential (Aguilaniu et al. 2003; Ouellet & Barral 
2012).     
1.3.4 Classic model for quality control of newly synthesized proteins 
 In the 1970's, many studies of protein degradation in pre-labelled mammalian cells 
revealed that a large fraction of newly synthesized proteins (6% - 30%) was removed at a 
very fast rate within the first hour of chase, followed by a slower subsequent rate, with an 
obvious discontinuity between the two rates (Poole & Wibo 1973; Bradley et al. 1976; 
Goldberg & St John 1976). This was initially attributed to the fact that cells contain two 
classes of proteins: short-lived and long-lived proteins (Poole & Wibo 1973). However, a 
subsequent study found that electrophoretic separation of samples from short pulse 
treatments, with and without a substantial (1hour) chase, had no obvious alteration in 
their protein profiles, suggesting that the two different degradation rates most likely 
represent degradation rates of folding failure or success, respectively, rather than two 
subsets of proteins with different half-lives (Wheatley et al. 1980). In 2000, Schubert et 
al. reported that rapid degradation of such a large fraction of newly synthesized proteins 
depends on proteasome activity (Schubert et al. 2000). Since polypeptides normally 
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cannot complete folding until they are fully synthesized and released from ribosomes, 
this rapid degradation has generally been assumed to occur post-translationally, 
following, for example, failure of chaperone-assisted folding mechanisms (Figure. 1.5) 
(Hartl et al. 2011).  
 
 
 
 
 
 
 
 
 
Figure 1.5: Classic post-translational model for quality control of newly synthesized 
proteins 
 
In this classic model, quality control of newly synthesized proteins was generally assumed to start 
post-translationally, after polypeptides have been released from the ribosome. If they failed to 
fold into their native state even with the help of chaperones, ubiquitin E3 ligases will be recruited 
to target chaperone-bound misfolded proteins for proteasomal degradation. The protein 
aggregates are degraded by autophagy. 
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      New evidence suggests that protein synthesis may be highly coupled with 
ubiquitination and degradation. Two studies observed co-translational ubiquitination of 
the cystic fibrosis transmembrane conductance regulator (CFTR), a very large protein 
prone to misfolding, and the secretory protein ApoB (Apolipoprotein B100) upon in vitro 
translation using rabbit reticulocyte lysates (Sato et al. 1998; Zhou et al. 1998). In 
addition, proteasomes were found to associate with the translation machinery (Sha et al. 
2009). Furthermore, an elegant study using the ubiquitin sandwich technique showed that 
an engineered protein bearing an amino-terminal (N-end) degradation signal could be 
degraded co-translationally in S. cerevisiae (Turner & Varshavsky 2000). However, the 
extent, specificity, and significance of co-translational protein quality control remained 
largely elusive. The major goal of the Chapter 3 of my thesis is to address these questions.     
1.3.5 Aging is linked to a gradual loss of cellular proteostasis 
Aging is defined as the time-dependent functional decline of living organisms, 
presenting as a progressive loss of physiological integrity and increase in vulnerability to 
death. The underlying cause of aging was believed to be the accumulation of cellular 
damage (Lopez-Otin et al. 2013). Aging has attracted curiosity throughout the history of 
humankind. The new era of aging research began 30 years ago following the isolation of 
the first long-lived mutant strain of C. elegans (Klass 1983). Since then, the aging 
research has accelerated rapidly. Last year, Lopez-Otin and colleagues enumerated nine 
hallmarks of aging (Figure1.6), according to the following criteria: 1) hallmarks should 
be presented during normal aging; 2) experimental aggravation of any hallmark should 
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accelerate aging; 3) experimental relief of any hallmark should retard the normal aging 
process (Lopez-Otin et al. 2013). 
 
 
 
   
  Figure 1.6: The hallmarks of aging. 
 
Nine hallmarks of aging have been proposed by Lopez-Otin et al: genomic instability, telomere 
attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial 
dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. 
They are classified into three groups: primary hallmarks, antagonistic hallmarks, and integrative 
hallmarks.  
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Loss of proteostasis has been proposed as a hallmark of aging. Onset of many age-
related diseases is connected to the accumulation of damaged proteins and/or protein 
aggregates, such as Alzheimer’s disease, Parkinson’s disease, and cataracts (Balch et al. 
2008; Douglas & Dillin 2010; Lopez-Otin et al. 2013). What are the underlying reasons 
leading to the disruption of proteome homeostasis in aged organisms? Theoretically, both 
increased production of damaged proteins and functional decline of the protein quality 
control system could lead to the collapse of proteostasis. However, for a long time, loss 
of proteostasis during aging was only attributed to increased protein damage by reactive 
oxygen species (ROS), as proposed by the free radical theory of aging (Harman 1956). 
The predominant effort for anti-aging therefore, has been placed on the prevention of 
oxidative damage with antioxidants. In recent years, there has been increased evidence 
indicating that the activity of the protein quality surveillance system is essential for 
organisms enjoying their full life span and enhanced activity of protein quality control 
system can successfully extend the life span of different model organisms. Together, 
these establish a strong linkage between the protein quality control system and longevity 
(Figure 1.7) (Munoz 2003; Koga et al. 2011; Denzel et al. 2014).     
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  Figure 1.7: Loss of proteostasis is a hallmark of aging 
 
Misfolded proteins may result from stress-induced unfolding of native proteins or from 
improperly folded newly synthesized proteins. Unfolded proteins are normally refolded 
by chaperones or targeted for proteasomal or lysosomal degradation. Failure to refold or 
degrade misfolded protein can lead to accumulation of protein aggregates and onset of 
some age-related diseases. Modified from Lopez-Otin et al. 2013. 
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Molecular chaperones in longevity and aging 
    The revelation that stress-stimulation of many heat shock proteins is impaired with 
aging has been shown in numerous studies. For example, stress-induced transcriptional 
up-regulation of HSP70 is decreased in many older organisms, including rats and 
monkeys (Fargnoli et al. 1990; Pahlavani et al. 1995). The reduced chaperone response 
can be restored by dietary restriction, successfully extending life span of various species, 
from yeast to human (Ehrenfried et al. 1996; Moore et al. 1998). Experimental induction 
of chaperones alone leads to an extended life span of most tested organisms, including 
both unicellular and multicellular organisms (Tatar et al. 1997). For instance, 
overexpression of heat shock factor (HSF), the transcriptional activator of chaperone 
proteins, successfully increased the longevity of C. elegans. Likewise, introducing extra 
copies of the HSP70 gene into flies and worms retarded their aging progress (Walker & 
Lithgow 2003). This phenomenon is not unique to cytosolic chaperones. Some organelle 
specific chaperones are also related to longevity, including ER specific chaperones, Bip, 
calnexin and PDI, and mitochondrial HSP70 (Kaul et al. 2003; Nuss et al. 2008). The 
molecular mechanism of the waning chaperone response during aging has been linked to 
the impaired ability of HSF to bind the heat shock element (HSE) on the promoters of 
chaperone genes (Heydari et al. 2000; Singh et al. 2006).    
UPS in longevity and aging 
    The UPS system can be separated into two independent systems: 1) the ubiquitin 
conjugation system, containing ubiquitin, E1 activating enzymes, E2 conjugating 
enzymes, E3 ligases and deubiquitinases; 2) the proteasome, containing the 20S core 
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particle and the 19S regulatory particle. The activity of the proteasome and several 
ubiquitin conjugation enzymes has been shown to decrease to a certain degree with aging 
(Carrard et al. 2003; Ruotolo et al. 2003; Ferrington et al. 2005). In some aged tissues, a 
decreased level of free ubiquitin has been reported (Jahngen et al. 1990). Many reasons 
have been proposed to contribute to the reduction of proteasome activity: 1) unbalanced 
expression of α and β catalytic subunits (Chondrogianni et al. 2003); 2) reduced 
expression of proteasomal subunits (Keller et al. 2000); 3) incorrect posttranslational 
modification of critical proteasomal subunits (Bulteau et al. 2001); 4) decreased levels of 
ATP in aged cells, impairing the assembly of proteasomes (Vernace et al. 2007); 5) an 
accumulation of protein aggregates that obstruct proteasomal function (Andersson et al. 
2013). The importance of the UPS in longevity has been further emphasized by the 
enhancement of proteasome activity, which can increase the life span of different model 
organisms (Kruegel et al. 2011).  
Autophagy/lysosome system in longevity and aging     
    There are three different forms of autophagy in mammalian cells: macroautophagy, 
microautophagy and chaperone-mediated autophagy. Longevity is linked predominantly 
to macroautophagy. Macroautophagy is negatively regulated by the mTOR (mammalian 
target of rapamycin) signaling pathway, which is the key regulator of longevity (Kamada 
et al. 2000). Inhibition of mTOR through its inhibitor, rapamycin, successfully increases 
the life span of many organisms, and rapamycin-induced activation of macroautophagy is 
required for maximum life span extension (Bjedov et al. 2010; Rubinsztein et al. 2011). 
In addition to rapamycin, the microautophagy specific inducer, spermidine, was also able 
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to promote longevity of yeast, flies and worms (Eisenberg et al. 2009). Dietary 
supplementation of omega-6 polyunsaturated fatty acids, the fatty acids normally found 
in fish oil, also increased the life span of worms via induction of autophagy (O'Rourke et 
al. 2013). Consistent with its important role against aging, decreased activity of 
macroautophagy with age has been reported in many mammalian tissues (Cuervo et al. 
2005; Cuervo 2008).          
Protein translation and longevity 
Most recently, the protein synthesis machinery has been proposed to be an important 
regulator of proteome homeostasis, as it functions in sensing the cellular folding 
environment, recruiting protein folding and translocation components, as well as 
adjusting elongation rate and pausing, which are essential for efficient de novo protein 
folding   (Pechmann et al. 2013). In the last decade, a strong connection has been 
established between protein translation and aging. A growing pool of evidence indicates 
that reduced mRNA translation can significantly promote longevity in both invertebrate 
and vertebrate model organisms, including yeast, worms, flies, and mice (Hansen et al. 
2007; Pan et al. 2007; Smith et al. 2008; Steffen et al. 2008; Selman et al. 2009; Zid et al. 
2009; Johnson et al. 2013). However, the exact mechanism by which the reduction of 
protein translation could increase life span is unclear. Two major explanations have been 
proposed. Firstly, one piece of evidence suggests that a subset of mRNAs encoding 
proteins that are beneficial for longevity and stress resistance are translated more 
efficiently when global translation is reduced (Steffen et al. 2008; Zid et al. 2009; Rogers 
et al. 2011). Secondly, a global reduction of protein synthesis is predicted to reduce the 
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production of both normal and damaged proteins, which may allow the cellular protein 
repair and degradation system to maintain toxic proteins at lower levels. This would 
result in an increase in proteome homeostasis (Kaeberlein & Kennedy 2007). The goal of 
Chapter 4 of my thesis is to uncover the underlying mechanism of the reduced translation 
induced life span extension.   
1.4 GOALS OF MY DOCTORAL WORK 
In our 2010 paper, we demonstrated that Herc5 could ISGylate a target protein only 
if the target was synthesized within the same window of time that the ISG15 conjugation 
system was active. In addition, we found that Herc5 co-fractionated with poly-ribosomes 
(polysomes), strongly suggesting that ISG15 conjugation was closely coupled with 
protein translation. Based on these observations, we proposed a co-translational model 
for ISG15 conjugation: Herc5 associates with 60S ribosome subunit, and transfers ISG15 
to the substrates when they are still being translated (Durfee et al. 2010). Although our 
previous data were consistent with this model, the direct evidence was still lacking. 
Therefore, the first part of my doctoral project was to rigorously test this co-translational 
model for ISG15 conjugation. Using two in vitro assays I developed (in vitro puromycin 
conjugation assay and run-off assay), I found that cells contain ISGylated ribosome-
associated nascent chains, demonstrating that ISG15 is conjugated to the substrates in a 
co-translational manner.     
Up to 30% of all newly synthesized proteins are rapidly degraded in eukaryotic cells 
in a proteasome-dependent manner. Consistent with this observation, it was recently 
reported that a large fraction of the total human ubiquitin-modified proteome is derived 
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from newly synthesized proteins. The second part of my thesis was to examine the 
relationship between protein translation, ubiquitination, and degradation. Using the 
approaches developed for studying co-translational ISGylation, I found that the pathway 
for degradation of newly synthesized proteins can be initiated while proteins are being 
actively translated, with cotranslational ubiquitination (CTU) of nascent polypeptides. 
This work defined CTU as a pathway for quality control of newly synthesized proteins. 
 Finally, a dramatic decrease of protein translation fidelity could lead to 
accumulation of misfolded proteins and hasten the aging process. As CTU is the pathway 
for quality control of newly synthesized proteins, the goal for the third part of my thesis 
was to explore whether CTU plays a protective role during the cellular aging process.       
 43 
Chapter 2: ISG15 is co-translationally conjugated to ribosome-
associated nascent polypeptides 
2.1 INTRODUCTION 
ISG15 is a 17 kD IFN-α/β-induced ubiquitin-like modifier consisting of two 
ubiquitin-like domains. ISG15 has anti-viral activity against several types of RNA and 
DNA viruses, including influenza, Sindbis, herpes, HIV, and Ebola virus(Lenschow et al. 
2005; Okumura et al. 2006; Okumura et al. 2008; Giannakopoulos et al. 2009; Hsiang et 
al. 2009; Lai et al. 2009). The E1, E2, and E3 enzymes that mediate ISG15 conjugation 
are also IFN-α/β-induced proteins, and these are Ube1L, UbcH8, and Herc5, 
respectively. Herc5 is a HECT domain ligase with N-terminal RCC1 repeats, and it is the 
only human HECT E3 known to conjugate a modifier other than ubiquitin (the mouse 
homolog, Herc6, is an IFN-induced HECT E3 that plays the equivalent role in mouse 
cells (Versteeg et al. 2010)). The biochemical effect of conjugation on target proteins 
remains unknown, although, like most other ubiquitin-like modifiers, it does not appear 
to specify proteasomal degradation. The utilization of a single E1 and E2 enzyme for 
ISG15 conjugation is consistent with other Ubl conjugation systems (e.g., Sumo, Nedd8), 
although it was surprising that a single E3 enzyme was responsible for nearly all ISG15 
conjugation activity, given that mass spectrometry-based target identification studies had 
identified approximately 300 high-confidence targets in human cells (Malakhov et al. 
2003; Giannakopoulos et al. 2005; Zhao et al. 2005; Takeuchi et al. 2006). siRNA 
depletion of Herc5 strongly suppressed overall conjugation, as well as conjugation to all 
individual target proteins analyzed (Dastur et al. 2006). Furthermore, co-expression of 
ISG15, Ube1L, UbcH8, and Herc5 in non-interferon-stimulated cells effectively 
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reconstituted total ISG15 conjugation, indicating that these proteins represent the core 
IFN-induced components of this conjugation system (Dastur et al. 2006). The cellular 
targets of ISG15 belong to many functional classes of proteins, and there were no 
apparent common characteristics of the target proteins (e.g., intracellular localization, 
potential recognition motifs). Therefore, a key question was how a single E3 enzyme was 
capable of recognizing such a large and diverse set of target proteins.  
      We previously demonstrated that Herc5 could ISGylate a target protein only if the 
target was synthesized in the same window of time that the ISG15 conjugation system 
was active. In addition, Herc5 was shown to co-fractionate with polysomes and free 60S 
ribosomal subunits, strongly suggesting that the processes of ISGylation and protein 
translation were closely coupled (Durfee et al. 2010). We proposed a model in which 
Herc5 stochastically modifies proteins, with very little substrate selectivity, as they are 
translated. In the context of an IFN-stimulated cell, this further suggested that newly 
translated viral proteins may be an important class of ISG15 targets, and that the inherent 
lack of substrate specificity of the system might be viewed as an attempt to target the 
widest possible range of viral proteins. Here, we test a critical aspect of the co-
translational model for conjugation of ISG15 by demonstrating that nascent polypeptides 
are ISGylated within active translation complexes.    
  
 45 
2.2 MATERIALS AND METHODS 
Plasmids and antibodies: Plasmids expressing Ube1L, Ube1L-ΔUFD, UbcH8, 
UbcH8-F62A, HA-Herc5, HA-Herc5-C994A, and 3XFLAG-ISG15 were described 
previously (Zhao et al. 2005; Dastur et al. 2006; Durfee et al. 2008). 3XFLAG-ISG15-
AA was made in this study by replacing the terminal glycine residues of ISG15 with 
alanines. Five methionine codons were introduced at the 3’ end of the ORFs encoding 
pcNTAP-IQA, -IQC, -p56, and FLAG-NS1A (Durfee et al. 2010). Anti-Ube1L and Anti-
FLAG M2 antibodies were purchased from Sigma Aldrich, anti-UbcH8 antibody was 
purchased from Abgent, anti-HA antibody was purchased from Covance, and anti-TAP 
antibody was purchased from Rockland Immunochemicals. Anti-puromycin antibody 
was a gift from Peter Walter (University of California, San Francisco) 
Cell culture, transfections, IFN-β treatment, and immunoblotting: HeLa and 
HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum. Plasmid DNA transfections were performed 
with cells at 60%-80% confluence by using Lipofectamine 2000 transfection reagent 
(Invitrogen). For the experiment shown in figure 2.3B, HeLa cells were transfected with 
either 3xFLAG-ISG15 or 3xFLAG-ISG15-AA as indicated. Twenty-four hours post-
transfection, ISG15 conjugation was induced by treating cells with 1000 units/ml IFN-β 
for another 24 hours. Cells were harvested and lysed in lysis buffer containing 1% NP-40, 
100 mM Tris, pH 7.9, 100 mM NaCl, 1 mM DTT, 100 µM phenylmethylsulfonyl 
fluoride (PMSF), 4 μM leupeptin, and 0.3 µM aprotinin.  
Protein expression and purification: Purified ISG15 was obtained by 
expression in E. coli as a GST fusion protein, with an added cAMP-dependent kinase 
recognition motif (RRASV). Cells were collected and resuspended in phosphate-buffer 
saline (PBS) containing 1% Triton X-100 (Sigma) and lysed by sonication. ISG15 was 
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purified from total cell lysate using GST-Bind Resin (Novagen) and resuspended in 50 µl 
of kinase buffer (40 mM Tris, pH 7.5, and 20 mM MgOAc). 32P labeling of ISG15 was 
performed by adding 2 µl of adenosine 5’-[γ-32P] triphosphate (PerkinElmer Life 
Sciences) and 2 µl of cAMP-dependent protein kinase (Promega). After 1h rotation at 
room temperature, unincorporated adenosine 5’-[γ-32P] triphosphate was removed by 
washing beads with kinase buffer. GST-ISG15 protein was then subjected to site-specific 
cleavage with PreScission protease (GE Healthcare) to release ISG15 from beads. The 
activity of purified ISG15 was tested in an E1-E2 thioester assay (Durfee et al. 2008), 
which was performed in the presence of 25 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM 
MgCl2, 0.1 mM DTT, 50 µg/ml of purified ISG15, 1.25 µg/ml of Ube1L (Boston 
Biochem), and 5 µg/ml UbcH8 (Boston Biochem).  
     Polysome preparation and in vitro run-off translation assays: A single 150-mm 
culture dish of either HeLa or 293T cells was harvested and lysed in 3 ml ice-cold lysis 
buffer containing 100 mM Tris (pH 7.4), 50 mM KCl, 25 mM MgCl2, 1 mM DTT, 100 
µM PMSF, 4 µM leupeptin, 0.3 µM aprotinin, 200 µg/ml heparin, and 40 U/ml 
RNaseOUT RNase inhibitor (Invitrogen). Lysates were clarified by centrifugation at 
16,300 x g for 10 min at 4°C, and the supernatants were loaded on top of a 2 ml 35% 
sucrose solution (10mM Tris, pH 7.4, 85mM KCl, 5mM MgCl2, 35% sucrose) and 
centrifuged for 90 min at 60,000 rpm in a Beckman NVT 65.2 rotor at 4°C. The 
polysome-containing pellets were resuspended in polysome buffer (10 mM Tris pH 7.4, 
10 mM NaCl, 3 mM MgCl2, and 0.2 mM DTT) at a concentration of 30 A260 unit/ml and 
stored at -80°C. 
In vitro run-off translations were performed as described previously (Vayda 
1995), with addition of 1 A260 units of polysomes, 25 µl rabbit reticulocyte lysate (RRL; 
Promega), 20 µM amino acid mixture (minus methionine), 10 mCi/ml 35S-methionine, 
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and 4 µl TNT reaction buffer to each 100 µl run-off reaction. Aurintricarboxylic acid 
(ATA; Sigma) was added to a final concentration of 0.1 mM to inhibit translation 
initiation (Stewart et al. 1971). After 1h incubation at 30 °C, one volume of RIPA buffer 
(50 mM Tris ,pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS) was added to terminate the 
reaction, and the mixtures were incubated with either Anti-FLAG M2 Affinity Gel 
(Sigma) or IgG-agarose (Sigma) overnight at 4 °C. The beads were washed four times 
with 0.1% NP-40 buffer (0.1% Nonidet P-40, 100 mM Tris, pH 7.9, 100 mM NaCl). 
Proteins were eluted from beads by adding SDS-PAGE loading buffer and boiling at 
90°C for 5 min, and the samples were analyzed by SDS-PAGE and autoradiography. For 
cycloheximide (CHX) treatment, CHX was added to the reaction at a final concentration 
of 200 µg/ml, and for the RNase treatment, RNase (Sigma) was added to polysome 
fractions at a final concentration of 10 µg/ml. The mixture was incubated at 4 °C for 5 
min before addition to the run-off translation reaction.   
    In vitro puromycin conjugation assays: Each 100 μl Bio-Puro conjugation assay 
contained the following components: 10 mM Tris, pH 7.4, 400 mM KCl, 3 mM MgCl2, 2 
A260 units of polysomes, and 2 μM biotin-linked puromycin (Jena 
Bioscience).  Puromycylation reactions were performed at 37°C for 90 min and post-
reaction, 5% of each sample was analyzed to determine the total nascent chains 
labeled.  For immunoprecipitation of FLAG-Ub modified nascent chains, two volumes 
of RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS) was added 
to equal amounts of total nascent chains, and the mixtures were incubated with anti-
FLAG M2 Affinity Gel (Sigma-Aldrich) overnight at 4°C. The beads were washed four 
times with 0.1% NP-40 buffer (0.1% NP-40,100 mM Tris, pH 7.9, 100 mM NaCl). 
Proteins were eluted from beads by adding SDS-PAGE loading buffer and boiling at 
90°C for 5 min, and the samples were analyzed by SDS-PAGE and probed with 
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fluorescently tagged streptavidin. For the experiment shown in Figure 2.2, polysomes 
were pretreated with either 200 μg/ml CHX (lane 5), 0.1 mg/ml RNase (lane 6), 10 μM 
unlabeled puromycin (lane 7), or 10 μg/ml biotin at 30°C for 15 min.   
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2.3 RESULTS 
2.3.1 Establishment of in vitro run-off translation and biotin-puromycin conjugation 
reactions. 
To determine whether nascent polypeptides were present in an ISGylated state 
within active translation complexes, we developed two in vitro assays to specifically 
probe ribosome-associated nascent chains: the in vitro run-off translation assay and the in 
vitro biotin-puromycin conjugation assay. In vitro run-off translation systems have been 
described previously, where polysomes are partially purified from cell extracts, and 
translation of the associated nascent chains is completed in vitro in the presence of 35S-
methionine, translational cofactors, and an inhibitor of translation initiation 
(aurintricarboxylic acid; ATA) (Stewart et al. 1971). The radiolabeled products of the 
reaction represent proteins that were initiated in vivo and completed in vitro.  
To first establish parameters and requirements for run-off translation, polysomes 
were collected from 293T cell extracts by centrifugation through 35% sucrose and added 
to reactions containing rabbit reticulocyte lysate (RRL), 35S-methionine, amino acids, and 
ATA. Figure 2.1A (lane 1) shows the complete spectrum of translation products from this 
reaction. Generation of the radiolabeled proteins was dependent on addition of polysomes 
and RRL, and all reaction products were eliminated when the polysome fraction was pre-
treated with RNase or cycloheximide (Figure 2.1A). Products were not significantly 
altered when the reaction was performed without addition of either exogenous amino 
acids (presumably due to a sufficient supply in the reticulocyte lysate) or ATA (Figure 
2.1A). As expected, since polysome-associated ribosomes direct translation of the run-off 
products, ribosome-depleted RRL supported run-off translation (Figure 2.1B), indicating 
that the required components contributed by the RRL were soluble translation factors and 
other small molecules (e.g., eEF1A, eEF2, aminoacyl-tRNAs, amino acids, GTP).  
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To determine whether individual proteins could be detected within total run-off 
reactions, polysomes were isolated from cells that had been transfected with a plasmid 
expressing either IQ-A or IQ-C (two previously described fragments of IQGAP1(Durfee 
et al. 2010)), both of which contained an N-terminal TAP tag and a C-terminal five-
methionine (5M) tag to increase incorporation of radiolabel. IgG sepharose beads were 
used to isolate the TAP-tagged proteins from the run-off reactions, and 35S-labeled 
products corresponding to the predicted size of both proteins were detected (Figure 2.1C). 
These results indicated that the assay was sensitive enough to detect a specific protein 
generated from a mixture of total polysome-associated nascent polypeptides.  
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Figure 2.1: In vitro run-off translation reactions.  
 
(A) Requirements for the in vitro run-off translation reaction. RRL: rabbit reticulocyte lysate; ATA: 
aurintricarboxylic acid; CHX: cycloheximide. (B) The ribosomes present in RRL are not required for 
the run-off reaction. Ribosomes were depleted from RRL by ultracentrifugation. The left panel shows an 
immunoblot for the L23a ribosomal protein in RRL (pre-spin), the supernatant from the spin (Sup), and 
the pellet fraction. Only a small amount of L23a was left in the supernatant, yet it supported run-off 
translation similarly to complete RRL (right panel). (C) Run-off translation, examining individual 
proteins. The total spectrum of 35S-labeled run-off products generated from 293T polysomes is shown in 
lane 1. Lanes 2-4 show IgG sepharose pull-downs of run-off products generated from polysomes isolated 
from untransfected cells (lane 2), cells transfected with TAP-tagged IQ-A-5M (80 kD predicted product; 
lane 3), or TAP-tagged IQ-C-5M (100 kD predicted product; lane 4). 
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      Puromycin is a structural analog of aminoacyl-tRNA that blocks translation by 
forming a covalent bond with the carboxyl-terminus of nascent polypeptides (Pestka 
1971). We utilized biotin-conjugated puromycin (Bio-Puro) to label polysome-associated 
nascent polypeptides in vitro. To establish reaction parameters, polysomes were collected 
from HEK293T cell extracts by centrifugation through 35% sucrose and incubated in 
vitro with Bio-Puro. Total reaction products were resolved by SDS-PAGE, blotted to 
nitrocellulose, and probed with fluorescent streptavidin. Figure 2.2 (lane 2) shows the 
complete spectrum of reaction products. Generation of the products was dependent on 
addition of Bio-Puro, as opposed to either free biotin (lane 3) or unlabeled puromycin 
(lane 4), and products were almost completely eliminated when polysomes were 
pretreated with RNase or unlabeled puromycin (Figure 2.2, lanes 6 and 7). The inhibitory 
effect of RNase on this reaction was likely due to cleavage of the peptidyl-tRNA ester 
linkage, which leads to release of nascent chains (Kelkar et al. 2012). The prior addition 
of cycloheximide to polysomes in vitro (CHX; lane 5) had no effect on the Bio-Puro 
reaction, consistent with the fact that CHX inhibits ribosome translocation without 
affecting peptidyl transferase activity (David et al. 2012).   
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  Figure 2.2: Validation of in vitro biotin-puromycin (Bio-Puro) conjugation reaction.  
 
Polysomes from HEK293T cells were used in all reactions. Reaction with Bio-Puro is shown 
in lane 2; Bio-Puro was deleted in lane 1, and replaced by free biotin (Bio) in lane 3 or by 
untagged puromycin (Puro) in lane 4. Polysomes were pretreated with cycloheximide (CHX), 
RNase, untagged puromycin or biotin in lane 5, 6, 7, and 8 respectively.  Bio-Puro was 
detected with fluorescently-labeled streptavidin. Background bands seen, for example, in lane 
1, represent endogenous biotin-conjugated proteins (e.g., arrow at 74 kD represents priopionyl-
CoA carboxylase). 
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2.3.2 Polysome-associated nascent chains are ISGylated 
The run-off translation assay was used to determine whether ISGylated nascent 
polypeptides were present within active translation complexes. As illustrated in Figure 
2.3A, the cotranslational model for ISGylation predicts that Herc5 transfers ISG15 to 
nascent chains on polysomes; if so, then the in vitro run-off products will contain proteins 
that are both ISGylated and labeled with 35S-methionine. In the first experiment, HeLa 
cells were transfected with a plasmid expressing 3XFLAG-ISG15 (3F-ISG15) or 3F-
ISG15-AA, a non-conjugatable form of ISG15 with the two terminal glycine residues 
converted to alanines; the cells were then either treated with IFN-β, or left untreated, for 
24 hours. Figure 2.3B (left) shows an anti-FLAG immunoblot of total cell extracts, 
demonstrating that in the presence of IFN-β treatment only 3F-ISG15, and not 3F-ISG15-
AA, was conjugated to cellular proteins. Polysomes from these extracts were then used in 
run-off translation reactions, and Figure 2.3B (center) shows that the distribution of total 
radiolabeled run-off products was similar in all reactions. Figure 2.3B (right) shows the 
anti-FLAG-ISG15 immunoprecipitation of the run-off products, demonstrating that 
FLAG-ISG15-containing radiolabeled run-off products could be immunoprecipitated 
from the reaction programmed with polysomes from IFN-treated cells, but not with 
polysomes from non-IFN-treated cells or cells that expressed 3F-ISG15-AA. These 
results indicate that ISG15 was conjugated to nascent chains in vivo in the context of 
fully competent translation complexes.  
A second experiment was performed using non-IFN-stimulated 293T cells 
expressing 3FISG15, Ube1L, UbcH8, and Herc5, or, as a control, 3F-ISG15 with inactive 
mutant forms of Ube1L (ΔUFD), UbcH8 (F62A), and Herc5 (C994A) (Durfee et al. 
2010). Consistent with the results above, radiolabeled 3F-ISG15 conjugates were 
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immunoprecipitated only from reactions programmed with polysomes from cells 
expressing the active conjugation enzymes (Figure 2.3C). 
 
      
 
  
Figure 2.3: Polysome-associated nascent chains are ISGylated.  
 
(A) Design of the run-off translation experiments. The co-translational model proposes that Herc5 modifies 
nascent chains on actively translating polysomes (left). The in vitro run-off translation products 
programmed with these polysomes should therefore contain proteins that were initiated and ISGylated in 
vivo, and translated to completion (in the presence of 35S-methionine; 35S-M) in vitro. (B) IFN-β-stimulated 
cells contain ISGylated nascent polypeptides. (C) Cells were transfected with plasmids expressing 3F-
ISG15, Ube1L, UbcH8, and Herc5 (WT), or 3F-ISG15 with inactive mutant forms (mut.) of Ube1L 
(ΔUFD), UbcH8 (F62A), and Herc5 (C994A). Left panel shows an anti-FLAG immunoblot of total cells 
extracts, and right panel shows 5% of the run-off reactions and the anti-FLAG immunoprecipitates of the 
run-off reactions.  
 56 
For the run-off experiments, it was important to demonstrate that the ISGylation 
of these radiolabeled proteins occurred in vivo, when they were nascent polypeptides, 
rather than in the in vitro run-off reaction. As shown in figure 2.4A, when 32P-labeled 
ISG15 was added to complete run-off reactions, it was not detectably activated or 
conjugated to any proteins, even when the polysomes were derived from cells expressing 
the wild-type conjugating enzymes (right panel; lane 4 compared to negative controls, 
lanes 2 and 5). Figure 2.4A (left panel) shows that the radiolabeled ISG15 used in this 
experiment was fully competent in forming thioester adducts with purified recombinant 
Ube1L and UbcH8. In addition, there was no detectable free ISG15, Ube1L, or UbcH8 
present in the polysome fractions derived from cells expressing the complete conjugation 
system (Figure 2.4B). Herc5, as expected, co-purified with polysomes (Figure 2.4B). We 
therefore conclude that the ISGylated run-off products, generated from polysomes from 
cells expressing ISG15, Ube1L, UbcH8, and Herc5 proteins, were ISGylated in vivo as 
nascent polypeptides.       
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  Figure 2.4: ISGylation does not occur in the run-off reaction.   
 
(A) 32P-labeled ISG15 was prepared and shown to be competent for conjugation in an in vitro Ube1L- 
and UbcH8-dependent thioester assay; Ube1L~ISG15 and UbcH8~ISG15 adducts are indicated in lane 
1, and these adducts are disrupted in the presence of DTT. 32P-labeled ISG15 was added to run-off 
translation assays programmed with polysomes from untransfected cells (lane 3), cells transfected with 
wild-type Ube1L, UbcH8, and Herc5 (lane 4), or cells transfected with inactive mutant versions of each 
enzyme (lane 5). The 32P-labeled ISG15 was not incorporated into conjugates in any case. (B) Ube1L, 
UbcH8, and free ISG15 were not present in polysome fractions from cells co-transfected with ISG15, 
Ube1L, UbcH8, and Herc5. Herc5, as expected, was the only component that co-fractionated with 
polysomes. Control immunoblots from untransfected cells are shown in the right two lanes. 
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We also utilized Bio-Puro, a translation terminator, in an alternative test of the co-
translational model. Puromycin terminates translation by being covalently incorporated 
into the C-terminus of nascent polypeptides. As above, polysomes were first isolated 
from cells in the absence or presence of active ISGylation components (3F-ISG15, 
Ube1L, UbcH8, Herc5). However, rather than adding rabbit reticulocyte lysate and other 
run-off reaction components, the polysomes were incubated only with puromycin, in the 
absence of any additional proteins, amino acids, or translation factors. As in the run-off 
reactions, the prediction was that if ISGylated nascent chains were present on polysomes, 
then these chains should subsequently incorporate Bio-Puro at their C-termini. Following 
incubation with Bio-Puro, 3F-ISG15 conjugates were immunoprecipitated with anti-
FLAG antibody and then probed with fluorescent streptavidin. As shown in Figure 2.5, 
Bio-Puro was robustly incorporated into ISG15-containing nascent polypeptides, 
confirming that nascent polypeptides are substrates for ISGylation. 
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  Figure 2.5: Incorporation of biotin-conjugated puromycin (Bio-Puro) into ISG15-
containing nascent chains.  
 
Cells were co-transfected with 3F-ISG15 and wild-type Ube1L, UbcH8, and Herc5 (ISGylation 
+) or mutant forms of the enzymes (ISGylation -), and polysomes were isolated and incubated 
with or without puromycin. 3F-ISG15 containing polypeptides were immunoprecipitated with 
anti-FLAG antibody and probed with fluorescent streptavidin (lanes 4 and 5). Lanes 1-3 
represent 5% of the total puromycin-containing reaction products before immunoprecipitation.    
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2.3.3 ISGylation of nascent polypeptides of individual target proteins 
I also examined ISGylation of individual target proteins by expressing, along with 
the conjugation components, target proteins with an N-terminal tag (TAP or FLAG) and a 
C-terminal 5M tag. Four target proteins were examined in this context: IQ-A, IQ-C, p56, 
and NS1A. As described above, IQ-A and C are two non-overlapping fragments of 
human IQGAP1, a previously identified ISG15 target protein (Zhao et al. 2005). p56 is a 
well-studied interferon-induced protein (Sen & Sarkar 2007) that was also identified as 
an ISG15 target (Zhao et al. 2005), and ISGylation of the influenza A NS1 protein 
(NS1A) has been shown to inhibit virus replication (Zhao et al. 2010). Typically, only 5-
20% of the total pool of a newly synthesized protein is ISGylated (Durfee et al. 2010), 
and that run-off products are predicted to contain both unmodified and ISGylated forms 
of the full-length target proteins, with the unmodified form predominating. Figure 2.6 
(left panels) shows Western blots of total cell extracts for the four different target proteins 
(TAP-IQ-A, TAP-IQ-C, TAP-p56, and FLAG-NS1A), demonstrating that all four 
proteins were ISGylated when co-expressed with ISG15, Ube1L, UbcH8, and Herc5. 
Figure 2.6 (right panels) shows the anti-TAP or anti-FLAG IPs of the corresponding run-
off translation products. In all cases, full-length unmodified and ISGylated forms of the 
target proteins were detected in reactions programmed with polysomes from cells 
expressing the complete conjugation system. The higher molecular weight conjugates of 
p56 were not detected in the run-off immunoprecipitation, which may be due to the 
position of the modification sites within the protein (i.e., the run-off assay has an inherent 
bias toward detecting more N-terminal ISGylation events). 
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  Figure 2.6: ISGylation of nascent polypeptides of individual target proteins.  
 
Four targets were examined: TAP-tagged IQ-A, IQ-C, and p56, and FLAG-tagged influenza NS1A. 
The targets were expressed by transfection, either by themselves or with plasmids expressing the 
E1, E2, and E3 enzymes, with or without ISG15. Left panels show immunoblots of total cell 
extracts (either anti-TAP or anti-FLAG). Right panels show autoradiograms of the run-off 
translation reaction products after IgG pulldown of the TAP-targets or anti-FLAG IP of NS1A. 
Arrows indicate the major ISGylated run-off products for each protein.  
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2.4 DISCUSSION 
The results presented here demonstrate that nascent ribosome-associated 
polypeptides are ISGylated while they are engaged in active translation complexes. This 
strongly supports the model that Herc5 is poised on the 60S ribosome to stochastically 
ISGylate a very broad spectrum of newly synthesized proteins, as they emerge from the 
ribosome. 
The efficiency of ISGylation, even when examining newly synthesized pools of 
proteins, is relatively low, with typical modification levels ranging from 5-20% of a 
given target protein. Although the basis of the apparent inefficiency of ISGylation is 
unknown, I speculate that the system is tuned to be efficient enough to elicit antiviral 
responses (e.g., through dominant-negative effects on viral structural proteins (Durfee et 
al. 2010)), yet inefficient enough to avoid extensive damage to newly translated cellular 
proteins. There are several possible factors that might influence ISGylation efficiency, 
including translation rates, co-translational folding rates, and primary or secondary 
structural elements that promote or interfere with ISGylation. Identifying the factors that 
influence the “code” for ISGylation will be important for understanding how Herc5 
recognizes lysine residues within nascent chains and may have implications for the 
evolution of viral protein sequences (i.e., have viral protein sequences been selected for 
evasion of ISGylation?).  
The use of run-off translation assays and the reaction of puromycin with partially 
purified polysomes allowed us to test the co-translational model in the absence of a 
completely reconstituted in vitro ISGylation system. It is now clear that complete in vitro 
reconstitution will require, at a minimum, the complete set of conjugating enzymes and 
an active translation system. Purified and biochemically active ISG15, Ube1L, and 
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UbcH8 are available (Durfee et al. 2008), and future efforts will be focused on the 
incorporation of biochemically active Herc5 into in vitro translation systems. 
Although Herc5 co-fractionates with 60S ribosomal subunits, the direct contact 
site(s) for Herc5 on this subunit are not yet known, but these could obviously be 
composed of rRNA and/or ribosomal proteins. Herc5 contains N-terminal RCC1 repeats, 
which, based on analogy to the yeast RCC1 protein, are likely to form a seven-bladed β-
propeller. The RCC1 repeats of Herc5 are required for ribosome co-fractionation (Durfee 
et al. 2010), and interestingly, yeast RCC1 is a chromatin-associated protein by 
interaction with both nucleic acid and protein within nucleosome complexes (Makde et 
al. 2010). An attractive model is that Herc5 is positioned near the polypeptide exit tunnel 
on the 60S subunit, modifying nascent chains as they emerge. Interestingly, ubiquitin- 
and proteasome-dependent degradation of newly synthesized misfolded or damaged 
proteins has been described in several contexts (Schubert et al. 2000; Turner & 
Varshavsky 2000; Bengtson & Joazeiro 2010), and it will be interesting to determine 
whether the ligases required for these processes are related to Herc5 with respect to 
enzyme mechanism, recognition of nascent chains, and their physical link to the 
translational machinery. 
 
 
 
 64 
Chapter 3: A co-translational ubiquitination pathway for quality 
control of newly synthesized proteins1 
3.1 INTRODUCTION 
      Newly synthesized proteins are prone to misfolding and aggregation (Ellis 2001), 
and this is compounded by errors in processes affecting transcription, mRNA processing, 
translation, and protein localization (Levine et al. 2005; Ogle & Ramakrishnan 2005; 
Pickrell et al. 2010). As a result, a significant fraction of newly synthesized proteins 
never attain their functional state. Timely and efficient clearance of misfolded proteins is 
crucial for maintaining cellular functions, and numerous human diseases are associated 
with a deficiency in eliminating aberrant proteins, including neurodegenerative diseases, 
type 2 diabetes, cystic fibrosis, peripheral amyloidosis, cancer, and cardiovascular disease 
(Hartl et al. ; Lenschow et al. 2005; Balch et al. 2008; Morimoto 2008; Hartl et al. 2011). 
Understanding the mechanisms of protein folding, quality control, and disposal of 
misfolded proteins is therefore crucial for therapeutic intervention in these disease states.  
      In eukaryotic cells, the ubiquitin-proteasome system (UPS) is the major pathway 
for elimination of misfolded proteins (Wolf & Hilt 2004; Qian et al. 2006). Substrates of 
the UPS are marked with ubiquitin via E1-E2-E3 enzyme cascades, and subsequently 
delivered to the 26S proteasome for degradation (Welchman et al. 2005). Surprisingly, 
between 6% and 30% of all eukaryotic newly synthesized proteins are very rapidly 
degraded by the UPS (Schubert et al. 2000; Qian et al. 2006), suggesting that the UPS 
plays an important role in quality control of newly synthesized proteins. The “DRiP” 
                                               
1 This chapter has been published in: “WANG, F., DURFEE, L.A. & HUIBREGTSE, J.M. A cotranslational 
ubiquitination pathway for quality control of misfolded proteins. 2013, Mol Cell 50: 368-78.”   
Author Contributions: F.W. and J.H. designed and interpreted all experiments; F.W. performed most of 
the experiments; L.D. performed the siRNA knockdown experiments; F.W., L.D. and J.H. wrote the paper. 
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(Defective Ribosomal Products) hypothesis proposed that these degradation products 
serve an important biological function as a source of MHC class I peptides (Yewdell et 
al. 1996; Reits et al. 2000). Although this hypothesis has been extensively debated 
(Yewdell & Nicchitta 2006), there is little doubt that, for many proteins, synthesis and 
degradation are closely coupled, in a seemingly energetically wasteful process.  
     Consistent with a role for ubiquitin in the process, it was recently reported that a 
large fraction of the total human ubiquitin-modified proteome is derived from newly 
synthesized proteins (Kim et al. 2011b). Importantly, the relationship between protein 
translation, ubiquitination, and degradation has not been established.  The simplest 
model is that newly translated proteins are targeted for ubiquitination after their release 
from the ribosome, perhaps after failing a quality control surveillance test or after 
unsuccessful attempts at chaperone-assisted folding (McClellan et al. 2005). 
Alternatively, certain protein chaperones engage nascent polypeptides as they emerge 
from the ribosome (Hartl et al. 2011; Preissler & Deuerling 2012), so it is conceivable 
that protein fate decisions might be made while translation is in progress. Consistent with 
this, Turner and Varshavsky showed that an engineered protein bearing an amino-
terminal (N-end) degradation signal could be degraded co-translationally in S. cerevisiae 
(Turner & Varshavsky 2000). Although this implied that the protein was ubiquitinated 
co-translationally, N-end rule ligases have not been shown to target their natural 
substrates co-translationally. The cystic fibrosis transmembrane conductance regulator 
(CFTR), which is a very large protein prone to misfolding, was shown to be subject to co-
translational ubiquitination in an in vitro rabbit reticulocyte lysate translation system 
(Sato et al. 1998), although this may have been related to the very slow translation rate in 
that system.   
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      An additional aspect of initial protein quality control is the recognition and 
disposal of translation products produced from defective mRNAs (Shoemaker & Green 
2012). For example, poly-lysine containing sequences generated from the poly-A tails of 
non-stop mRNAs trigger stalling of the nascent chain within the exit tunnel, and two 
ubiquitin ligases, Ltn1 and the CCR4/NOT complex, have been implicated in the 
ubiquitination and degradation of these protein products (Dimitrova et al. 2009; Bengtson 
& Joazeiro 2010; Brandman et al. 2012). In addition to nonstop decay (NSD), other 
mRNA surveillance mechanisms associated with translational stalling include no-go 
decay (NGD) and nonsense-mediated decay (NMD). The protein products of these stalled 
ribosomes, as well as those of ribosomes backed up behind stall sites, are likely to also be 
specifically targeted for degradation, but the mechanisms remain largely uncharacterized.     
      The Huibregtse lab previously demonstrated that ISG15, an interferon-induced 
ubiquitin-like modifier, is stochastically conjugated to newly synthesized proteins by 
Herc5, a ribosome-associated HECT domain ligase (Durfee et al., 2010). These results 
suggested that ISG15 is co-translationally conjugated to nascent polypeptides, and we 
proposed that this is an attempt to interfere with the function of newly synthesized viral 
proteins (Durfee et al. 2010; Skaug & Chen 2010). This observation, along with the 
reports on degradation of newly synthesized proteins, led us to address whether ubiquitin, 
perhaps similarly to ISG15, is co-translationally conjugated to ribosome-associated 
nascent polypeptides. I report that co-translational ubiquitination (CTU) is a surprisingly 
robust process in human cells and that CTU occurs in at least two contexts: within stalled 
complexes (CTUS) and within active translation complexes (CTUA). The latter is 
remarkable in that it implies that a protein can be marked for degradation before synthesis 
is completed. 
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3.2 MATERIALS AND METHODS 
      Cell culture, transfections, and antibodies: Saccharomyces cerevisiae strain 
BY4741 was grown at 30°C in rich medium (yeast extract peptone). HeLa, HEK293T, 
and NIH 3T3 cells (ATCC), and UBR1/2-/- and control MEFs (kindly provided by Yong 
Tae Kwon, University of Pittsburgh) were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum and 1% antibiotics mixture. 
Primary human keratinocytes (Lonza) were maintained in KGM-Gold™ Keratinocyte 
Growth Medium (Lonza). Plasmid DNA and siRNA transfections were performed with 
cells at 60%-80% confluence using Lipofectamine 2000 (Invitrogen). All plasmids, 
antibodies and siRNAs used in this study are listed in Table 3.1 and 3.2. IRDye 680RD 
Streptavidin was purchased from LI-COR Bioscience.  
      Polysome isolation: To isolate total polysomes, cells were lysed in high-salt 
polysome lysis buffer (100 mM Tris, pH 7.4, 50 mM KCl, 25 mM MgCl2,1 mM DTT, 
100 µM PMSF, 4µM leupeptin, 0.3 µM aprotinin, and 200 µg/ml heparin). Lysates were 
clarified by centrifugation at 16,300 x g for 10 min. at 4°C, and supernatant was loaded 
on a 2 ml 35% sucrose cushion (with 10 mM Tris pH 7.4, 85 mM KCl, 5 mM MgCl2) and 
centrifuged for 90 min. at 316,000 x g in a Beckman NVT 65.2 rotor at 4°C. Polysome-
containing pellets were resuspended in 200 µl polysome buffer (10 mM Tris, pH7.4, 10 
mM NaCl, 3 mM MgCl2, and 0.2 mM DTT) and stored at -80°C. For drug treatments 
prior to polysome isolation, cells were treated with 2 µM pactamycin (Sigma-Aldrich) for 
the indicated times (Figures 3.9-3.11) or cells were treated for 60 min. (Figure 3.10) with 
either 0.5 mg/ml AZC (Sigma-Aldrich), 20 μM VER155008 (Tocris Bioscience), 50 μM 
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Pifithrin-μ (Tocris Bioscience), 200 μg/ml hygromycin B (Cellgro), 1000 μg/ml geneticin 
(Gemini Bio Products), 20 µM Eeyarestatin 1 (Tocris Bioscience) or 20 nM 17-AAG 
(Selleck Chemicals). 
      Quantification of CTU level: Each 100 μl Puromycin conjugation assay 
contained the following components: 10 mM Tris, pH 7.4, 400 mM KCl, 3 mM MgCl2, 2 
A260 units of polysomes, and 2 μM fluorescent puromycin (2 μM 6-FAM-dc-Puro, Jena 
Bioscience).  Puromycylation reactions were performed at 37°C for 90 min and post-
reaction, two volumes of 0.1% NP40 buffer were added after the reaction, and the 
mixtures were spun through Microcon centrifugal filters (YM-3, Millipore) to remove 
unreacted 6-FAM-dc-Puro. Total reaction products (10%) were saved as input to estimate 
the amount of total nascent chains, and the rest was subjected to two rounds of Tandem 
Ubiquitin Binding Entity-Agarose (TUBE 2, LifeSensors) pull-downs to isolate ubiquitin 
conjugates. TUBE pull-down efficiency was evaluated by immunoblotting of pre- and 
post-down supernatants with anti-ubiquitin antibody. The fluorescent signal from the 
TUBE pull-down ubiquitin conjugates and from the input nascent polypeptides was 
measured with a SpectraMax-M3 Multi-mode plate reader, with the excitation 
wavelength at 485 nm.  
       Purification of CTU targets for LC-MS/MS:  HEK293T (twenty 150-mm 
culture dishes) were transfected with 5 μg per dish of plasmid expressing FLAG-Ub.  
Two days post-transfection, polysomes were isolated as described above and nascent 
polypeptides were labeled with Bio-Puro. Two volumes of RIPA buffer were added after 
the reaction, and the mixtures were incubated with anti-FLAG M2 Affinity Gel overnight 
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at 4°C to isolate FLAG-Ub conjugates. The beads were washed four times with 0.1% NP-
40 buffer, and proteins were eluted from beads by adding PBS containing 2% SDS and 
boiling at 90°C for 5 min. Eluted proteins were diluted with 0.1% NP40 buffer to 
decrease the final concentration of SDS to 0.2%, and then incubated with Avidin Agarose 
Resin (Thermo Scientific) overnight at 4°C to isolate FLAG-Ub conjugated nascent 
polypeptides. The beads were washed four times with RIPA buffer, and proteins were 
eluted from beads by adding SDS-PAGE loading buffer and boiling at 90°C for 5 min. 
The samples were analyzed by SDS-PAGE and stained with Coomassie Brilliant blue. 
Proteins greater than 30 kD were excised from the gel. LC-MS/MS was performed at the 
Taplin Mass Spectrometry Facility at Harvard Medical School. 
      Cytosolic and ER-associated polysome isolation: To isolate cytosolic and ER-
associated polysomes, a sequential detergent extraction method was used (Jagannathan et 
al. 2011). Cells in a 150-mm culture dish were washed once with 10 ml of PBS at room 
temperature, and then treated with 10 ml of ice-cold PBS containing 50 mg/ml CHX for 
10 min. on ice (to allow for microtubule depolymerization). Cells were then 
permeabilized with 2 ml of digitonin lysis buffer (110 mM KOAc, 25 mM K-HEPES, pH 
7.2, 2.5 mM Mg(OAc)2, 1 mM EGTA, 0.03% digitonin, 1 mM DTT, 50 mg/ml CHX, 
100 μM PMSF, 4 μM leupeptin, 0.3 μM aprotinin, 200 μg/ml heparin, 50 μM NEM, and 
40 U/ml RNaseOUT RNase inhibitor) for 5 min. on ice to release cytosolic polysomes. 
Permeabilized cells were washed once with the same buffer and then lysed in 3 ml ice-
cold high-salt polysome lysis buffer to solubilize ER-associated polysomes. Cytosolic 
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and ER-associated polysomes were then collected by pelleting through a 35% sucrose 
cushion as described in the Experimental Procedures.  
  
   
 PLASMIDS NOTES 
 FLAG-Ub Plasmids expressing FLAG-Ub and all  
 FLAG-UbΔGG mutant forms of Ub were made by  
 FLAG-Ub-K0 introducing the human ubiquitin ORF into  
 FLAG-Ub-K11/K48 the previously described pcDNA3XFlag  
 FLAG-Ub-R11/R48 vector (Zhao et al. 2005)using NotI and  
 FLAG-Ub-R11 XbaI. 
 FLAG-Ub-R48   
     
 ANTIBODIES NOTES 
 Anti-Bip BD Biosciences - 610978 
 Anti-BTF3 (FL-206) Santa Cruz Biotechnology - sc-28717 
 Anti-CHIP Sigma-Aldrich - C9243 
 Anti-CNOT4 Abcam - ab63028 
 Anti-CNOT4 (O-23) Santa Cruz Biotechnology - sc-130728 
 Anti-E6AP (Talis et al. 1998) 
 Anti-FLAG M2 Monoclonal Sigma-Aldrich - F3165 
 Anti-Ltn1 Sigma-Aldrich - HPA029143 
 Anti-RPL23a (3E11) Novus Biologicals- H00006147-M10 
 Anti-RPS6 (C-8) Santa Cruz Biotechnology - sc-74459 
 Anti-Tubulin EMD Millipore - CP06 
 Anti-UBE3C (N1N3) Genetex - GTX119102 
 Anti-Ubiquitin (VU-1) LifeSensors - VU101 
 
Table 3.1: Plasmids and antibodies used in chapter 3.  
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GENE siRNA NOTES 
BTF3 GGAUGAUGAUGAUGAAGUU (Kusumawidjaja et al. 2007)  
CHIP/STUB1 GGAGCAGGGCAAUCGUCUG (Wang et al. 2008) 
CNOT4 GUAGAUGGCAGAACACUUA Dharmacon: D-020323-01 
CNOT4 CCAAUUCUCUCAAUAGUAC Dharmacon: D-020323-02 
CNOT4 CGUCUUUGUUGUAGGUUUA Dharmacon: D-020323-03 
CNOT4 UAACCUAUAUCCGGUCAGA Dharmacon: D-020323-04 
E6AP CAACUCCUGCUCUGAGAUA (Kelley et al. 2005) 
LTN1 GAUACCUUCUCACUUGGAA Sigma-Aldrich: SASI_Hs01_00118676 
NACA CCAGUCAGUAAAGCAAAACTT (Hotokezaka et al. 2009) 
UBE3C (HUL5) GAGAGUAGAUGUUCAAGAA Dharmacon: D-007183-01 
UBE3C (HUL5) GAGAAUGCUUGAAGUAUUU Dharmacon: D-007183-02 
UBE3C (HUL5) GAAGAAAGGCGAAGGUUGA Dharmacon: D-007183-03 
UBE3C (HUL5) CGUUUUAACUGUUGGCGAA Dharmacon: D-007183-04 
Control Universal siRNA Negative Control #1 Sigma-Aldrich: SIC001 
 
 
Table 3.2: siRNAs used in chapter 3. 
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3.3 RESULTS 
3.3.1 CTU is a robust process in mammalian cells 
      I utilized the in vitro Bio-Puro conjugation assay, which was developed in 
Chapter 2, to determine whether nascent polypeptides were ubiquitinated on polysomes 
isolated from cells expressing FLAG-Ub. As illustrated in Figure 3.1A, if nascent 
polypeptides were ubiquitinated in cells, then the in vitro Bio-Puro reaction would 
generate polypeptides modified with both FLAG-Ub and Bio-Puro. In contrast, if 
ubiquitination of newly synthesized proteins was strictly post-translational (i.e., after 
release of peptides from ribosomes), then Bio-Puro-conjugated polypeptides would not 
contain FLAG-Ub. Polysomes were isolated from HEK293T cells expressing FLAG-Ub 
or FLAG-Ub-∆GG (a non-conjugatable form of ubiquitin) and nascent chains were 
labeled in vitro with Bio-Puro. Figure 3.1B (lanes 1 and 2) shows that the distribution of 
total biotin-labeled nascent polypeptides was similar in both reactions. An anti-FLAG 
immunoprecipitation (IP) was used to isolate ubiquitinated proteins, which were then 
analyzed by SDS-PAGE and immunoblotting with fluorescent streptavidin. Figure 3.1B 
(lanes 3 and 4) shows that the FLAG-Ub IP pulled down a broad distribution of proteins 
conjugated to Bio-Puro, while the FLAG-Ub-∆GG IP did not. This result indicated that 
polysome-associated nascent polypeptides were ubiquitinated in cells. Importantly, NEM 
was included in the cell lysis buffer to block any potential post-lysis ubiquitination 
activity, and control reactions confirmed that there was no ubiquitination activity in 
NEM-containing lysis buffer (Figure 3.1C).   
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Figure 3.1: Co-translational ubiquitination (CTU) in human cells.  
 
(A) Scheme for detection of CTU. If CTU occurs in vivo, polysomes should contain nascent 
polypeptides modified with both FLAG-ubiquitin and Bio-Puro. (B) Polysome-associated nascent 
polypeptides are conjugated to FLAG-Ub. Cells were transfected with plasmids expressing wild type 
FLAG-Ub (Ub) or FLAG-Ub-∆GG (∆GG). Nascent chains were labeled with Bio-Puro in vitro, then 
immunoprecipitated with anti-FLAG antibody, and blotted with fluorescent streptavidin. (C) No 
detectable ubiquitination occurs after cell lysis in the presence of NEM. Purified 32P-labeled ubiquitin 
was included in the high salt polysome lysis buffer to evaluate potential post-lysis ubiquitination. 
Cell lysates with or without NEM were incubated at either room temperature or 4℃ for 90 min, and 
then subjected to autoradiography analysis. Asterisk marks contaminating uncut GST-Ub.  
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       To eliminate the possibility that CTU was a result of overexpression of FLAG-
Ub, similar experiments were done with untransfected cells, examining conjugates to 
endogenous ubiquitin. Polysomes were collected from HEK293T cells and incubated in 
vitro with Bio-Puro (illustrated in Figure 3.2, left). Biotin-labeled nascent chains were 
isolated on neutravidin-agarose and immunoblotted with anti-ubiquitin antibody.  
Consistent with the results above, Figure 3.2 (middle) shows that a broad set of nascent 
polypeptides was modified with ubiquitin. Similar results were obtained using polysomes 
isolated from Saccharomyces cerevisiase cells expressing only endogenous ubiquitin 
(Figure 3.2, right).  
          
 
  Figure 3.2: Polysome-associated nascent polypeptides are conjugated to endogenous 
ubiquitin in human and yeast cells.  
 
Polysomes from untransfected HEK293T or S. cerevisiae cells were incubated with either Bio-
Puro or untagged Puro to label associated nascent chains. Biotin labeled polypeptides were 
isolated by neutravidin pull down and analyzed by anti-ubiquitin immunoblotting.  
 76 
   The percentage of nascent chains that were ubiquitinated in cells was estimated by 
using fluorescently labeled puromycin (6-FAM-dC-Puro; Figure 3.3A, left).  As above, 
polysomes were isolated from untransfected cells and total nascent polypeptides were 
labeled in vitro with 6-FAM-dC-Puro. Ubiquitinated polypeptides were then purified 
from the reaction on a ubiquitin-binding protein matrix (TUBE-Agarose, LifeSensors).  
The percentage of ubiquitinated nascent chains was determined by measuring the 
fluorescent signal of the TUBE pull-down compared to the fluorescent signal from the 
input nascent polypeptides (correcting for the efficiency of the TUBE pull-down, 
determined separately to be approximately 73%; Figure 3.3B). In HEK293T cells, 12-15% 
of the total nascent polypeptides were co-translationally ubiquitinated (Figure 3.3A, 
right).  Similar values were obtained in other human (HeLa) and mouse (NIH3T3) cell 
lines, as well as primary human foreskin keratinocytes (HFKs). These results indicate that 
CTU is a robust process across many mammalian cell types. The fraction of ubiquitinated 
nascent chains was reproducibly lower in budding yeast cells, with approximately 6% of 
total nascent chains being ubiquitinated (Figure 3.3A). 
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Figure 3.3: Quantitation of CTU in different cell types.  
 
(A) Quantitation of CTU in different cell types. Polysomes were isolated from the indicated cell 
types, and polysome-associated nascent chains were labeled with fluorescently-tagged 
puromycin (6-FAM-dC-Puro). Total reactions (10%) were used to estimate the amount of total 
nascent chains (input); the remainder was subject to TUBE pull down to isolate ubiquitinated 
proteins, and fluorescence intensity was measured. Error bars indicate standard error of the 
mean (SEM) of three independent experiments. (B) Evaluation of TUBE pull-down efficiency. 
The efficiency of binding of ubiquitinated proteins by TUBE beads was determined by 
immunoblotting of pre- and post pull-down supernatants with anti-ubiquitin antibody, followed 
by IRDye 680 anti-mouse Licor secondary antibody. Error bars indicate standard error of the 
mean (SEM) of three independent experiments.  
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3.3.2 CTU predominantly occurs on cytosolic rather than ER-associated polysomes  
      Secreted and membrane proteins comprise approximately 30% of the eukaryotic 
proteome (Stevens & Arkin 2000), and these are synthesized primarily on ER-associated 
polysomes. I determined the relative contribution of cytosolic and ER-associated 
polysomes to total CTU by fractionating the two types of polysomes by sequential 
detergent extraction (Figure 3.4A) (Jagannathan et al. 2011). Digitonin was used to 
selectively solubilize the plasma membrane and release cytosolic polysomes from FLAG-
Ub-transfected cells. The permeabilized cells were washed and ER-bound polysomes 
were then solubilized with Triton-X 100. The fractionation efficiency was validated via 
Western blot analysis with antibodies that recognize tubulin (a cytosolic protein) and 
BIP/GRP78 (an ER lumenal protein; Figure 3.4B). Immunoblotting of a ribosomal 
protein (RPS6) showed that polysomes were present in both cytosolic and ER fractions. 
The cytosolic and ER-derived polysomes were collected by centrifugation through 35% 
sucrose and used in in vitro Bio-Puro conjugation reactions (Figure 3.4C). Nascent 
polypeptides on cytosolic polysomes were heavily ubiquitinated, although the signal from 
ER-associated polysomes was approximately 5-fold less (normalized for total nascent 
chains). This indicated that CTU occurs predominantly, but not exclusively, on cytosolic 
polysomes (Figure 3.4C, right).   
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  Figure 3.4: CTU occurs predominantly on cytosolic rather than ER-associated polysomes.  
  
(A)  Scheme for fractionation of free and ER-associated polysomes. (B) Fractionation of 
cytosolic and ER-associated polysomes was validated by immunoblotting with antibodies that 
recognize tubulin (cytosolic protein), Bip (ER lumanal protein) and RPS6 (small ribosomal 
protein). (C) Cytosolic and ER-associated polysomes were isolated from HEK293T cells 
expressing FLAG-Ub. Polysome-associated nascent chains were labeled with Bio-Puro and 
then immunoprecipitated with anti-FLAG antibody. Left panel is 5% input of total Bio-Puro 
conjugation products, and the right panel represents immunoprecipitation of nascent proteins 
that were modified with both FLAG-Ub and Bio-Puro. 
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3.3.3 CTU targets are polyubiquitinated with K48 and K11 chains 
 To determine the ubiquitin chain topology on CTU target proteins, FLAG-Ub-
containing and Bio-Puro-labeled CTU products were incubated with the catalytic core of 
ubiquitin-specific protease 2 (USP2cc) to strip ubiquitin from target proteins. Addition of 
USP2cc to ubiquitinated nascent polypeptides led to a nearly complete loss of anti-
FLAG-Ub immunoreactivity (Figure 3.5A, left). When the same reaction products were 
probed with fluorescent streptavidin, the average molecular weight of the CTU products 
was significantly decreased (Figure 3.5A, right), suggesting that most puromycin-labeled 
CTU targets were modified with multiple ubiquitin molecules.   
       CTU products were purified and characterized by LC-MS/MS to determine 
chain type linkages and to identify a preliminary set of CTU targets. Figure 3.6A shows 
the Coomassie blue-stained SDS-PAGE gel of purified ubiquitinated nascent chains.  
Proteins greater than 30 kD were excised from the gel and tryptic peptides were identified 
by LC-MS/MS. The mass spectrometry analysis indicated the presence of K48- and K11-
linked polyubiquitin chains within the purified CTU products, with no evidence for other 
chain types. Both of these chain types can target proteins for proteasomal degradation 
(Xu et al. 2009; Behrends & Harper 2011). To confirm the chain topology observed by 
the LC-MS/MS analysis, a series of FLAG-Ub mutants (Figure 3.5B) were expressed in 
HEK293T cells. Polysomes were isolated, nascent chains were labeled with Bio-Puro, 
and FLAG-Ub-conjugates were immunoprecipitated and probed with fluorescent 
streptavidin. Expression of lysine-less ubiquitin (K0) led to a sharp decrease in the 
average apparent molecular weight distribution of CTU products (Figure 3.5C). 
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Expression of ubiquitin that retained only K11 and K48 (K11/K48) supported production 
of CTU products that appeared identical to those produced in the presence of wild-type 
FLAG-Ub. In contrast, expression of R11/R48 ubiquitin (with all other lysines intact) 
resulted in CTU products that appeared similar to those produced in the presence of K0 
ubiquitin. Expression of R48 ubiquitin had a similar effect as R48/R11 on the average 
length of CTU products, while R11 ubiquitin had no detectable effect on conjugates. 
These results suggest that K48-linked chains are the predominant type of chain formed on 
CTU products. In addition to the identification of K48- and K11-linked chains, the mass 
spectrometry analysis of CTU products identified approximately 130 putative CTU target 
proteins (Table 3.3), all of which were previously identified in a large-scale ubiquitin 
proteomics study that identified ~5000 ubiquitinated human proteins (Kim et al. 2011b).  
These proteins are distributed in diverse intracellular compartments, with nuclear and 
cytosolic proteins predominating (Figure 3.6C). Interestingly, large proteins are highly 
enriched in identified CTU targets, with average length of CTU targets longer than 1000 
amino acids (average length of all human proteins is around 500 amino acids) (Figure 
3.6B).  
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  Figure 3.5: CTU products contain primarily K48-linked polyubiquitin chains.   
 
(A) CTU target proteins are multi-ubiquitinated. Ubiquitinated nascent polypepetides were 
labeled with Bio-Puro, and immunoprecipitated with anti-FLAG antibody. The 
immunoprecipitated products were treated with the catalytic domain of ubiquitin-specific 
protease 2 (USP2cc) to strip ubiquitin (see schematic, left). Middle panel is the anti-FLAG-Ub 
blot analysis of samples before and after USP2cc treatment (HC is IgG heavy chain). Right 
panel shows the fluorescent-streptavidin blot of the FLAG IPs. The molecular weight change of 
CTU products after USP2cc treatment indicates that the majority of the CTU products 
contained multiple ubiquitin moieties. (B) Schematic diagram of mutant forms of FLAG-
ubiquitin expressed in HEK293T cells. (C) Polysomes were isolated from cells expressing the 
indicated form of ubiquitin. Nascent chains were labeled with Bio-Puro in vitro, and then 
immunoprecipitated with anti-FLAG antibody. The immunoprecipitated products were subject 
to SDS-PAGE, and detection was with fluorescent streptavidin.  
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Figure 3.6: Identification of CTU target proteins.   
 
(A) CTU products were double-affinity purified as described in the text, starting with polysomes 
from cells expressing with FLAG-Ub or FLAG-Ub-ΔGG. Purified proteins were subject to SDS-
PAGE and stained with Coomassie Blue. All proteins >30 kD were excised from the gel and tryptic 
peptides were identified by LC-MS/MS. See Table 3.3 for list of identified proteins. (B) Large 
proteins were enriched in identified CTU products. (C) Categorization of 130 CTU targets with 
respect to intracellular localization (localization according to Uniprot).  
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  To confirm that CTU products were subject to proteasomal degradation, cells 
were treated with cycloheximide prior to cell lysis for various periods of time to trap 
nascent polypeptides on polysomes. Polysomes were then isolated, nascent chains labeled 
with Bio-Puro, and FLAG-Ub-conjugates were immunoprecipitated and probed with 
fluorescent streptavidin. As shown in Figure 3.7 (top), the amount of ubiquitinated 
nascent chains increased after CHX treatment, reaching a peak between 5 and 10 minutes, 
then gradually decreased. A possible explanation for these observations was that CTU 
products transiently accumulated on cycloheximide-stalled polysomes and were then 
subject to proteasomal degradation over time. To test this, the experiment was repeated in 
the presence of both CHX and the proteasome inhibitor MG132. As shown in Figure 3.7 
(bottom), the amount of CTU products continued to increase beyond the 10 minute time 
point (Figure 3.7, bottom), indicating that ubiquitinated nascent chains are subject to 
proteasomal degradation. 
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  Figure 3.7: CTU products were subject to proteasomal degradation. 
 
HEK293T cells were transfected with plasmids expressing FLAG-Ub or FLAG-Ub-∆GG. 
Prior to lysis, cells were treated with CHX alone or simultaneously with CHX and MG132 for 
the indicated times. Polysomes were isolated from these cells and reacted with Bio-Puro.  
Nascent polypeptides were analyzed by anti-FLAG immunoprecipitation and detected with 
fluorescent streptavidin.    
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3.3.4 CTU occurs within both stalled and active translation complexes  
      In vitro run-off translation reactions developed in the last chapter were used to 
address whether CTU occurs within active or stalled translation complexes. Polysomes 
from cells transfected with FLAG-Ub or FLAG-Ub-∆GG were collected and used in run-
off translation reactions. As illustrated in Figure 3.8A, if CTU occurred in cells within 
translation-competent complexes, then 35S-labeled run-off products should also contain 
FLAG-Ub. In contrast, if CTU occurred post-translationally or if CTU products were 
derived exclusively from irreversibly stalled polysomes, then in vitro run-off translation 
products should not yield products that contained both 35S-Met and FLAG-Ub. Figure 
3.8B shows 35S-Met was robustly incorporated into FLAG-Ub-containing polypeptides, 
indicating that at least a portion of CTU products were generated within active, 
elongation-competent translation complexes.  
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Figure 3.8: CTU occurs within active translation complexes.  
 
(A) The CTU model predicts that if ubiquitin is conjugated to nascent chains on actively translating 
polysomes and translation can proceed following CTU, then in vitro run-off products will contain 
both ubiquitin and 35S-methionine. Green represents the portion of the polypeptide chain translated in 
vivo, and red represents the 35S-methionine-containing polypeptide translated in vitro. (B) Cells were 
transfected with plasmids expressing FLAG-Ub (WT) or FLAG-Ub-∆GG (∆GG), and polysomes 
from these cells were used in run-off reactions. Left panel shows an anti-FLAG immunoblot of total 
cell extracts, the center panel shows 10% of the run-off reactions, and the right panel shows the anti-
FLAG immunoprecipitates of the run-off reactions. 
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 I next sought to determine the relative proportion of total CTU products (CTUT) 
that were generated from active (CTUA) versus stalled (CTUS) translation complexes.  
Before addressing this, I first determined the proportion of total nascent chains that are in 
stalled translation complexes in cells, regardless of their ubiquitination state. A brief 
treatment of cells with pactamycin (5 or 10 minutes), an inhibitor of translation initiation, 
was used to allow run-off of all nascent chains present within active translation 
complexes. At an estimated translation rate of 5-9 amino acids per second (Orlowski & 
Ross 1981; Ross & Orlowski 1982), five minutes of pactamycin treatment is sufficient to 
allow completion of translation of all but the longest proteins. Figure 3.9A shows that a 5 
minute treatment of 293T cells with pactacmycin was sufficient to block any detectable 
incorporation of 35S-methionine into cellular proteins in a subsequent 5 minute metabolic 
pulse. Therefore nascent chains from untreated cells and from pactamycin treated cells (5 
or 10 minutes) were labeled with fluorescently-labeled puromycin and the total 
fluorescent signal was quantitated. The fluorescent-puromycin signal from pactamycin-
treated cells was approximately 27% and 22% of the untreated cells at the 5 and 10 
minute time points, respectively (Figure 3.9B), indicating that nearly a quarter of all 
nascent chains are in stalled complexes. The slight decrease in stalled nascent chains 
between the 5 and 10 minute time points is likely to represent the clearing of stalled 
complexes over time, either by degradation mechanisms or the resumption of transiently 
stalled complexes.   
     I next determined the fraction of total CTU products (CTUT) that were derived 
from stalled translation complexes (CTUS) by quantitating the amount of doubly-tagged 
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(ubiquitinated and puromycylated) nascent chains that remained on polysomes after 5 or 
10 minutes of pactamycin treatment. As shown in Figure 3.9C, CTUS was approximately 
36% of CTUT at the 5 minute time point, and slightly less (32%) at the 10 minute time 
point. Therefore, CTUS accounts for approximately a third of CTUT, and CTUA (the 
fraction of CTU products that ran-off during pactamycin treatment) accounts for the 
remaining two-thirds. Considering that ~25% of nascent chains are in stalled complexes, 
we infer that approximately 15-18% of stalled nascent chains are ubiquitinated, whereas 
11-14% of nascent chains in active translation complexes are ubiquitinated.  
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Figure 3.9: CTUA accounts for the majority of the total ubiquitination activity against nascent chains.  
 
(A) A brief treatment of cells with pactamycin was sufficient to allow run off of actively translating nascent 
chains. Cells were treated with pactamycin for the indicated times, followed by a 5 min. labeling with 35S-
methionine. In lane 3, pactamycin was added simultaneously with the 35S-Met. Coomassie Blue staining 
shows proteins were loaded equally in each lane. (B) A significant amount of nascent chains are in stalled 
ribosomes. Cells were either untreated or pretreated with pactamycin for 5 or 10 min. to run off of actively 
translating ribosomes. Polysomes were isolated from these cells and incubated with Bio-Puro in vitro to label 
associated nascent chains. (C) CTUS accounts for approximately one-third of CTUT. Cells expressing 
FLAG-Ub were treated with pactamycin for 10 min. and polysome-associated nascent chains were labeled 
with Bio-Puro in vitro and then immunoprecipitated with anti-FLAG antibody. The immunoprecipitated 
products were subject to SDS-PAGE analysis, and the fluorescent streptavidin signal was quantitated relative 
to cells that were not treated with pactamycin. Error bars represent SEM of three independent experiments.  
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3.3.5 CTU is enhanced under conditions that promote protein misfolding or 
translational errors 
  I next determined how CTUT was affected by agents that cause protein misfolding 
or translational stalling. Treatment with L-Azetidine-2-carboxylic acid (AZC), a proline 
analog that induces protein misfolding, enhanced CTUT by approximately 1.5-fold 
(Figure 3.10A). The role of Hsp70 family chaperones in CTU was tested using Hsp70 
inhibitors. VER155008 is an adenosine-derived inhibitor (Williamson et al. 2009) and 2-
Phenylethynesulfonamide (Pifithrin-μ) disrupts the association of Hsp70 with several co-
chaperones (e.g, Hsp40, BAG-1L/1M) and substrate proteins (Leu et al. 2009). Both 
inhibitors led to an approximately 1.7-fold increase in CTUT. Although Hsp70 is linked 
to co-translational protein folding, Hsp90 functions post-translationally (Hartl et al. 2011).  
Consistent with this, an inhibitor of Hsp90, 17-AGG, had no effect on CTUT.  
Aminoglycoside antibiotics, such as hygromycin B and G418, affect translational fidelity 
and read-through of stop codons (Brodersen et al. 2000), and both agents increased CTUT 
products to a similar degree (~1.4-fold). Eeyarestatin 1 (ES1), an inhibitor of Sec61-
dependent translocation that prevents translation into the ER (Cross et al. 2009; 
McKibbin et al. 2012), led to an approximately 1.4-fold increase in CTUT.  
     To discern whether the effects on CTUT were due to increased CTUS or CTUA, we 
pre-treated cells with pactamycin (10 minutes) to run-off active translation complexes. 
Both hygromycin B and ES1 led to a substantial increase in CTUS (approximately 42% 
and 37% of CTUT, respectively, compared to 31% for untreated cells; Figure 3.10B) and 
an increase in total stalled nascent chains (Figure 3.10C), consistent with a model where 
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translational stalling triggers CTUS. Cycloheximide, which results in nearly complete 
ribosome stalling, resulted in a 4-5-fold increase in stalled complexes and 3-fold increase 
in CTUS (i.e., nearly all CTU was CTUS; Figure 3.11). AZC and Hsp70 inhibition did not 
lead to increased CTUS and did not affect the fraction of stalled nascent chains, indicating 
that enhanced CTUA accounted for the increased CTUT induced by these agents. As the 
primary effects of AZC and Hsp70 are on protein folding, these results suggest that 
CTUA represents a quality control pathway that ubiquitinates nascent chains in response 
to folding errors. Consistent with this, siRNA knockdown of the BTF3 subunit of the 
NAC (Nascent Polypeptide-Associated Complex) (Preissler & Deuerling 2012) resulted 
in a 1.5-fold enhancement of CTUT (Figure 3.12) but did not affect accumulation of 
stalled ribosomes or CTUS (Figure 3.12). Together, these results indicate that CTUA is 
enhanced under conditions where folding of nascent polypeptides is impaired.  
  
 93 
                 
 
         
                  
 
  
Figure 3.10: CTU was enhanced under conditions that promoted translational errors or protein 
misfolding.  
 
(A) CTUT was analyzed after treating cells for 60 min. with either AZC, the Hsp70 chaperone 
inhibitors VER155008 (VER) or Pifithrin (Pfith), hygromycin B (Hygro), G418, eeyarestatin 1 (ES1) 
or the Hsp90 inhibitor 17-AGG (AAG). CTU products were quantified by measuring fluorescent-
streptavidin signal on blots, and relative signals were normalized in all panels to signal in the absence 
of inhibitor. Error bars indicate SEM of three independent experiments. (B) Cells expressing FLAG-
Ub were treated with the indicated agents for 60 min., and CTUS was quantitated as in Figure 3.10. 
Error bars indicate SEM of three independent experiments. (C) Cells were treated with the indicated 
agents for 60 min., and the stalled nascent chains were quantitated relative to total nascent chains. 
Error bars indicate SEM of three independent experiments.   
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  Figure 3.11: Cycloheximide triggers stalling and accumulation of ubiquitinated nascent chains.    
 
(A) Cells expressing FLAG-Ub were treated with or without cycloheximide (CHX) for 10 min. 
and then with or without pactamycin for 10 min. (top), and nascent chains were quantitated as in 
Figure 3.10 (bottom). Error bars indicate SEM of three independent experiments. (B) The 
nascent chains from Figure 3.12A were subjected to FLAG immunoprecipitation (top), and 
CTUS relative to CTUT was determined by the method shown in Figure 3.9. Error bars indicate 
SEM of three independent experiments.   
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Figure 3.12: Depletion of NAC activity enhances CTUT.  
 
(A) 293T cells were transfected with siRNAs targeting the mRNA for BTF3 (the β subunit of the NAC) 
or a control siRNA, and the FLAG-Ub plasmid DNA was transfected 15 hours later. Cells were 
harvested 48 hours post-siRNA transfection, and CTU products were analyzed by anti-FLAG 
immunoprecipitation followed by quantitation of Bio-Puro incorporation with fluorescent-streptavidin.  
Signal was normalized in all panels to that of the control siRNA.  Error bar indicates SEM of three 
independent experiments. (B) BTF3 siRNA knockdown was confirmed by immunoblotting, with tubulin 
probed as a loading control. (C) Total stalled nascent chains and CTUS was analyzed in BTF3 or control 
siRNA-treated cells, using a 10 min. pactamycin treatment (as in Figure 3.10). Error bars indicate SEM 
of three independent replicates.   
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3.4 DISCUSSION 
      I have shown here that co-translational ubiquitination is a robust process in human 
cells, with 12-15% of all nascent polypeptides being ubiquitinated in a variety of cell 
lines and primary cells. CTU occurs in two contexts: in stalled complexes (CTUS) and in 
active translation complexes (CTUA). CTUS has been described previously in the 
ubiquitination of stalled translation products arising from non-stop mRNAs (Dimitrova et 
al. 2009; Bengtson & Joazeiro 2010; Brandman et al. 2012). Stalling in this case is due to 
translation of the poly-A tail, generating a poly-lysine sequence that interacts strongly 
with the acidic ribosome exit tunnel. There are additional circumstances that CTUS is 
likely to be activated, such as in clearing of translation products at internal stop codons 
(associated with nonsense-mediated mRNA decay) or other types of damaged mRNAs 
(Shoemaker & Green 2012). While we found that ~22-27% of all ribosomes were in 
stalled complexes, only a fraction of these stalled complexes (~15-18%) contained 
ubiquitinated nascent chains, suggesting that there are multiple types of stalled complexes 
and possibly multiple responses to stalled complexes. It should also be noted that various 
forms of proteotoxic stress have recently been reported to trigger translational pausing 
(Liu et al. 2013; Shalgi et al. 2013), which might, in turn, also trigger CTUS.   
      CTUA couples synthesis to protein degradation, suggesting that protein fate 
decisions are made in the narrow window of time between emergence of the nascent 
polypeptide from the exit tunnel and the release of the full-length protein from the 
ribosome. CTUA was demonstrated in two ways. First, nascent chains that were 
ubiquitinated in vivo could be translated to completion in vitro when added to a 
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reticulocyte lysate system. Second, a short treatment with pactamycin was used to run-off 
active translation complexes in vivo, and this resulted in a loss of approximately two-
thirds of all ubiquitinated nascent chains from polysomes. A link between CTUA and 
protein folding quality control is suggested by the fact that Hsc/Hsp70 inhibitors, siRNA 
depletion of NAC subsunits, and AZC, led to an increase in CTUA. Both Hsc/Hsp70 and 
the NAC engage nascent polypeptides to initiate correct folding pathways before 
translation is complete (Hartl et al. 2011). In yeast, Hsp70 SSB associates with 
approximately 45% of nascent polypeptides (Willmund et al. 2013), consistent with the 
possibility that the relationship between nascent chain misfolding and ubiquitination may 
affect an incredibly broad range of cellular proteins.    
      The basis of recognition of nascent chains in both CTUS and CTUA remains 
unknown. I hypothesize that misfolding of the nascent chain is monitored and sensed by 
the CTUA system. In addition to off-pathway folding errors, the rate of amino acid mis-
incorporation during translation is relatively high, with amino acid substitutions 
estimated to occur between 1 in 103-104 codons translated (Drummond & Wilke 2009).  
It is conceivable that folding errors associated with mis-incorporations may account for a 
significant fraction of nascent chains that are subject to CTUA (roughly 8-10% of all 
nascent chains). In contrast to CTUA, CTUS appears to be directly associated with stalling 
of the translational machinery, as CTUS is induced by both drugs and polypeptide 
sequences (e.g., poly-lysine containing proteins) that promote stalling. It should also be 
noted that treatment of cells with cycloheximide leads to a transient accumulation of 
CTU products on polysomes. This effect should be considered in experimental designs 
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that include polysome isolation, as pre-treatment of cells with cycloheximide is a part of 
most polysome isolation protocols.   
 Two ubiquitin ligases have been implicated in ubiquitination of stalled nascent 
chains: Ltn1 and CCR4/Not complex (Dimitrova et al. 2009; Bengtson & Joazeiro 2010; 
Brandman et al. 2012). Additional factors - Tae2, Rqc1, and Cdc48 - have also recently 
been shown to function with Ltn1 in degradation of stalled nascent peptides (Bengtson & 
Joazeiro 2010; Brandman et al. 2012; Verma et al. 2013). As determined by siRNA 
knockdown, Ltn1 and CCR4/Not each accounted for less than 10% of total CTU activity 
in these assays (Figure 3.13A). The ligases for CTUA have not yet been identified, but 
several reasonable additional candidates have been ruled out. CHIP is an Hsp70-
associated RING E3 (Rosser et al. 2007), and the Ubr1 and Ubr2 ligases, have been 
shown to be involved in the co-translational degradation of artificial fusion proteins 
bearing destabilizing N-terminal residues (Turner & Varshavsky 2000). siRNA 
knockdown of CHIP had no effect on overall CTU, and Ubr1/Ubr2 double-knock out 
mouse embryo fibroblasts did not display diminished overall CTU (Figure 3.13B). Yeast 
Hul5 is a ubiquitin ligase that targets misfolded cytosolic proteins post-translationally 
(Fang et al. 2011), and siRNA knockdown of an apparent human ortholog (Ube3C) had 
no effect in our assays (Figure 3.13). Although the identity of the CTUA ligase(s) remains 
to be determined, I envision that these ligases may function in one of two basic ways: 
either as ribosome-associated ligase(s) that monitor nascent polypeptides as they emerge 
from the ribosome, or as free cytosolic ligase(s) that monitor exposed nascent chains, 
either with or without the cooperation of chaperones. The first model is akin to the 
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modification of newly translated proteins by the ubiquitin-like modifier ISG15, an 
interferon-induced Ubl (Durfee et al. 2010). In this case, a single E3 (Herc5) mediates 
ISG15 conjugation, and Herc5 co-fractionates with polysomes. Herc5 co-fractionates 
with the 80S ribosome upon RNase treatment and with 60S subunit upon disruption of 
polysomes with EDTA. In the second model, features of defective or misfolded nascent 
chains might be recognized by the E3, independent of interaction with the ribosome itself.  
               
 
 
 
     
 
Figure 3.13: Role of Specific E3 Ligases in CTUT.   
 
(A) 293T cells were initially transfected with siRNAs targeting the mRNAs for the indicated E3 ligases 
or a control siRNA, and then transfected with FLAG-Ub plasmid DNA fifteen hours later. Cells were 
harvested 48 hours post-siRNA transfection, and CTU products were analyzed. (B) CTUT was analyzed 
in wild-type and UBR1/2 double-knockout MEFs. CTU products were subjected to TUBE pulldown to 
isolate ubiquitinated nascent chains and CTU products were analyzed by quantitation of Bio-Puro 
incorporation with fluorescent-streptavidin. (C) The siRNA knockdowns were confirmed by 
immunoblotting with antibodies to the indicated ligases, with tubulin probed as a loading control. 
Asterisks mark background bands; arrows mark specific bands.  
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      Our analyses of CTU products indicated that they are modified primarily with 
K48-linked polyubiquitin chains, and proteasome inhibition led to the accumulation of 
ubiquitinated nascent chains on cycloheximide-stalled polysomes in cells. Whether the 
proteasome can begin degrading CTUA products before synthesis is complete (in the 
absence of cycloheximide-induced stalling) is not yet known. Our proteomic analysis 
preliminarily identified a set of ~130 CTU target proteins. These were mainly cytosolic 
or nuclear proteins, as opposed to membrane-associated proteins, consistent with our 
observation that less than 20% of CTU activity is associated with ribosomes at the ER.   
Further experimentation is required to distinguish between CTUS and CTUA targets in 
these analyses, and to determine whether subsets of CTU targets are ubiquitnated under 
different stress conditions.  
      Estimates of the fraction of newly synthesized proteins subject to rapid 
degradation in mammalian cells have varied from 6% to 30% (Wheatley et al. 1980; 
Schubert et al. 2000; Princiotta et al. 2003; Qian et al. 2005; Vabulas & Hartl 2005).  
Although this range illustrates the need for better techniques for assessing the turnover of 
newly synthesized proteins (Yewdell & Nicchitta 2006), these reports are generally 
consistent with our finding that CTU is a robust process in mammalian cells. Results 
presented here suggest that CTUA is a component of a protein folding quality control 
system. The characteristics and recognition of nascent polypeptides with CTUS and 
CTUA complexes clearly require further definition. Key questions to be addressed 
concern the identification of the enzymes and degrons involved in CTUS and CTUA, how 
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the enzymes are localized to the translational machinery or nascent peptides, and, in the 
case of CTUA, the basis for protein fate decisions being made in the course of translation. 
 
 
 
Gene 
Name 
Peptides Annotation Subcellular 
location 
ABCD3 (3)3 ATP-binding cassette sub-family D member 3 Membrane 
ACLY (2)2 ATP-citrate synthase Cytoplasm 
ALB (2)2 Putative uncharacterized protein ALB Unknown 
AP2B1 (2)3 AP-2 complex subunit beta Cytoskeleton-
associated 
AP2M1 (5)6  AP-2 complex subunit mu Cytoskeleton-
associated 
AP3D1 (1)1 AP-3 complex subunit delta-1 Cytoplasm 
ATP1A1 (3)5 Sodium pump subunit alpha-1 Membrane 
ATP1A2 (2)2 Sodium pump subunit alpha-2 Membrane 
ATP5A1 (6)7 ATP synthase subunit alpha Mitochondrial-
associated 
ATP6V0A1 (3)3 V-type proton ATPase 116 kDa subunit a 
isoform 1 
Mitochondrial-
associated 
BAT1 (1)1 Spliceosome RNA helicase DDX39B Nucleus 
CAD (20)25 CAD protein Cytoplasm 
CASP14 (1)1 CASP-14 Cytoplasm/Nucleus 
CCBL2 (3)3 Kynurenine aminotransferase III Mitochondrial-
associated 
CCT6A (4)5 T-complex protein 1 subunit zeta Cytoplasm 
CCT7 (2)2 T-complex protein 1 subunit eta Cytoplasm 
CCT8 (1)1 T-complex protein 1 subunit theta Cytoplasm 
CHD4 (2)2 Chromodomain-helicase-DNA-binding protein 
4 
Nucleus 
CLTC (25)49 Clathrin heavy chain 1 Cytoskeleton-
associated 
CLTCL1 (11)20 Clathrin heavy chain 2 Cytoskeleton-
associated 
COPA (21)31 Coatomer subunit alpha Cytoplasm 
CSDA (2)2 DNA-binding protein A Cytoplasm/Nucleus 
DARS (6)6 Aspartyl-tRNA synthetase Cytoplasm 
DDB2 (2)2 DNA damage-binding protein 2 Nucleus 
DDX20 (3)3 ATP-dependent RNA helicase DDX20 Cytoplasm 
DDX21 (8)12 Nucleolar RNA helicase 2 Nucleus  
DDX5 (1)1 Probable ATP-dependent RNA helicase DDX5 Nucleus  
Table 3.3 
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DHX30 (2)2 DEAH box protein 30 Mitochondrial-
associated 
DHX40 (1)1 Probable ATP-dependent RNA helicase 
DHX40 
Unkown 
DHX9 (13)22 ATP-dependent RNA helicase A Cytoplasm/Nucleus 
DYNC1H1 (8)9 Cytoplasmic dynein 1 heavy chain 1 Cytoskeleton-
associated 
EEF1A2 (3)3 Elongation factor 1-alpha 2 Ribosome-associated 
EEF2 (9)14 Elongation factor 2 Ribosome-associated 
EFTUD2 (9)14 Elongation factor Tu GTP-binding domain-
containing protein 2 
Nucleus 
EIF2AK2 (2)2 Interferon-inducible RNA-dependent protein 
kinase 
Cytoplasm 
EIF2S3 (2)2 Eukaryotic translation initiation factor 2 subunit 
3 
Ribosome-associated 
EIF3A (30)42 Eukaryotic translation initiation factor 3 subunit 
A 
Ribosome-associated 
EIF3G (3)3 Eukaryotic translation initiation factor 3 subunit 
G 
Ribosome-associated 
ENO1 (2)3 Alpha-enolase Cytoplasm 
EPRS (17)22 Bifunctional aminoacyl-tRNA synthetase Cytoplasm 
ERLIN1 (2)2 Endoplasmic reticulum lipid raft-associated 
protein 1 
ER-associated  
ERLIN2 (1)1 Erlin-2 ER-associated 
FAM115A (4)5 Protein FAM115A Unkown 
FASN (52)109 Fatty acid synthase Cytoplasm 
FLNA (3)4 Filamin-A Cytoskeleton-
associated 
FMR1 (2)3 Fragile X mental retardation protein 1 Cytoplasm 
GNB2L1 (4)4 Receptor for activated C kinase Ribosome-associated 
GTF3C1 (1)1 General transcription factor 3C polypeptide 1 Nucleus 
GTPBP4 (2)2 Nucleolar GTP-binding protein 1 Nucleus 
HECTD3 (1)1 E3 ubiquitin-protein ligase HECTD3 Cytoplasm 
HERC5 (2)2 E3 ISG15--protein ligase HERC5 Cytoplasm 
HIST1H1C (6)11 Histone H1d Nucleus 
HNRNPR (4)7 Heterogeneous nuclear ribonucleoprotein R Cytoplasm/Nucleus 
HNRNPU (20)43 Heterogeneous nuclear ribonucleoprotein U Cytoplasm/Nucleus 
HSPA1A (3)4 Heat shock 70 kDa protein 1A/1B Cytoplasm 
HSPA1L (2)2 Heat shock 70 kDa protein 1-like Cytoplasm 
HSPA8 (1)1 Heat shock 70 kDa protein 8 Cytoplasm 
HSPCB (4)5 Heat shock protein HSP 90-beta Cytoplasm 
HUWE1 (1)2 E3 ubiquitin-protein ligase HUWE1 Cytoplasm/Nucleus 
IARS (17)31 Isoleucyl-tRNA synthetase Cytoplasm 
IARS (3)4 Isoleucyl-tRNA synthetase Cytoplasm 
IGF2BP1 (4)5 Insulin-like growth factor 2 mRNA-binding 
protein 1 
Cytoplasm/Nucleus 
Table 3.3 (continued) 
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IGF2BP3 (1)1 Insulin-like growth factor 2 mRNA-binding 
protein 3 
Cytoplasm/Nucleus 
IRS4 (12)15 Insulin receptor substrate 4 Cytoplasm 
JAK1 (1)2 Tyrosine-protein kinase JAK1 Cytoplasm 
KATNAL2 (1)1 Katanin p60 ATPase-containing subunit A-like 
2 
Cytoskeleton-
associated 
KIDINS220 (3)3 Kinase D-interacting substrate of 220 kDa Cytoplasm 
KTN1 (2)2 Kinectin Cytoskeleton-
associated 
LARS (7)11 Leucyl-tRNA synthetase Cytoplasm 
LAS1L (1)2 Ribosomal biogenesis protein LAS1L Nucleus 
LBR (3)3 Lamin-B receptor Nucleus 
LRP1 (3)3 Apolipoprotein E receptor Cytoplasm 
MARS (6)8 Methionyl-tRNA synthetase Cytoplasm 
MCM5 (1)1 DNA replication licensing factor MCM5 Nucleus 
MOV10 (10)12 Putative helicase MOV-10 Cytoskeleton-
associated 
MSH6 (1)1 DNA mismatch repair protein Msh6 Nucleus 
MYCBP2 (7)9 Probable E3 ubiquitin-protein ligase MYCBP2 Nucleus 
MYH14 (1)1 Myosin-14 Cytoskeleton-
associated 
MYH9 (3)3 Myosin-9 Cytoskeleton-
associated 
MYO1B (2)2 Unconventional myosin-Ib Cytoskeleton-
associated 
MYO1C (1)2 Unconventional myosin-Ic Cytoskeleton-
associated 
MYO5B (3)3 Unconventional myosin-Vb Cytoskeleton-
associated 
MYO6 (2)3 Unconventional myosin-VI Cytoskeleton-
associated 
NCL (5)8 Nucleolin  Nucleus 
NCL3 (7)10 Calpain-5  Unkown 
NXF1 (3)4 Nuclear RNA export factor 1 Cytoplasm/Nucleus 
PA2G4 (3)4 Proliferation-associated protein 2G4 Cytoplasm/Nucleus 
PABPC1 (18)28 Polyadenylate-binding protein 1 Cytoplasm/Nucleus 
PABPC4 (7)10 Polyadenylate-binding protein 4 Cytoplasm 
PARP1 (10)13 Poly [ADP-ribose] polymerase 1 Nucleus 
PKM2 (2)2 Pyruvate kinase isozymes M1/M2 Cytoplasm 
PRKDC (11)14 DNA-dependent protein kinase catalytic 
subunit 
Nucleus 
PRPF8 (34)53 Pre-mRNA-processing-splicing factor 8  Nucleus 
PSMD2 (6)8 26S proteasome regulatory subunit S2 Cytoplasm 
PTPLAD1 (2)3 Protein tyrosine phosphatase-like protein 
PTPLAD1 
ER-associated 
RAD50 (2)2 DNA repair protein RAD50 Nucleus 
Table 3.3 (continued) 
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RBM39 (1)1 RNA-binding protein 39 Nucleus 
RBMXL2 (2)2 RNA-binding motif protein, X-linked-like-2 Nucleus 
RFC1 (3)5 Replication factor C subunit 1 Nucleus 
RPA1 (3)4 Replication protein A 70 kDa DNA-binding 
subunit 
Nucleus 
RPL6 (5)8 60S ribosomal protein L6 Ribosome-associated 
RPL7A (1)1 60S ribosomal protein L7a Ribosome-associated 
RPN2 (2)2 Ribophorin-2 ER-associated 
RPS2 (4)5 40S ribosomal protein S2 Ribosome-associated 
RPS3 (14)29 40S ribosomal protein S3 Ribosome-associated 
RPS7 (2)3 40S ribosomal protein S7 Ribosome-associated  
RPS8 (2)3 40S ribosomal protein S8 Ribosome-associated  
SF3B3 (2)2 Splicing factor 3B subunit 3 Nucleus 
SIN3A (3)5 Paired amphipathic helix protein Sin3a Nucleus 
SLC16A1 (1)1 Monocarboxylate transporter 1 Membrane 
SNRNP200 (9)11 U5 small nuclear ribonucleoprotein 200 kDa 
helicase 
Nucleus 
SSRP1 (2)2 FACT complex subunit SSRP1 Nucleus 
SUPT16H (6)7 FACT complex subunit SPT16 Nucleus 
SYNCRIP (1)1 Heterogeneous nuclear ribonucleoprotein Q Nucleus 
TARS (3)3 Threonine--tRNA ligase Cytoplasm 
TCP1_ (3)4 T-complex protein 1 subunit alpha Cytoplasm 
TFRC (1)2 Transferrin receptor protein 1 Membrane 
TOP2A (6)10 DNA topoisomerase 2-alpha Nucleus 
TOP2B (9)12 DNA topoisomerase 2-beta Cytoplasm/Nucleus 
TRIP12 (2)2 Probable E3 ubiquitin-protein ligase TRIP12 Cytoplasm 
TSR1 (1)1 Pre-rRNA-processing protein TSR1 homolog Nucleus 
TUBA1C (3)6 Tubulin alpha-1C chain Cytoskeleton-
associated 
TUBA4A (2)2 Tubulin alpha-4A chain Cytoskeleton-
associated 
USP9X (1)1 Ubiquitin-specific protease 9 Cytoplasm 
VCP (8)13 TER ATPase Cytoplasm 
WDR33 (4)6 pre-mRNA 3' end processing protein WDR33 Nucleus 
XRCC5 (2)3 DNA repair protein XRCC5 Nucleus 
XRCC6 (3)4 DNA repair protein XRCC6 Nucleus 
YBX1 (2)2 Nuclease-sensitive element-binding protein 1 Cytoplasm/Nucleus 
ZNF281 (2)4 Zinc finger protein 281 Nucleus 
 
 
Table 3.3 Identified CTU targets. 
 
CTU products identified by LC/MS/MS. "Peptides" refers to number of unique peptides 
identified and number of assigned spectra.    
 105 
Chapter 4: Potential role of CTU in against aging   
 
 
4.1 INTRODUCTION 
In the last decade, a strong connection has been established between protein 
translation and aging. Several findings indicate that reduced mRNA translation can 
significantly promote longevity of both invertebrate and vertebrate model organisms, 
including yeast, worms, flies, and mice (Hansen et al. 2007; Pan et al. 2007; Smith et al. 
2008; Steffen et al. 2008; Selman et al. 2009; Zid et al. 2009; Johnson et al. 2013). 
However, the mechanism of how reduced protein translation can increase life span is 
unclear. Two major explanations have been proposed: 1) a subset of mRNAs encoding 
proteins that are beneficial for longevity and stress resistance are translated more 
efficiently when global translation is reduced (Steffen et al. 2008; Zid et al. 2009; Rogers 
et al. 2011), and 2) global reduction of protein synthesis allows the cellular protein repair 
and degradation system to maintain toxic proteins at a lower level (Kaeberlein & 
Kennedy 2007).   
 Loss of proteome homeostasis can be considered a hallmark of aging (Lopez-Otin 
et al. 2013). Onset of many age-related diseases is connected to the accumulation of 
damaged proteins and/or protein aggregates, such as Alzheimer’s disease, Parkinson’s 
disease, and cataracts (Balch et al. 2008; Douglas & Dillin 2010; Lopez-Otin et al. 2013). 
Successful maintenance of protein homeostasis requires collaboration between the 
protein synthesis machinery, chaperone systems, and proteolytic systems (ubiquitin-
proteasome system (UPS) and autophage-lysosomal system). Disruption of protein 
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synthesis fidelity or chronic expression of misfolded proteins has been shown to induce 
accumulation of protein aggregates and development of some age-associated diseases 
(Lee et al. 2006; Powers et al. 2009). In contrast, up-regulation of some chaperones, 
components of UPS, or autophagy has been reported to delay aging in many organisms 
(Walker & Lithgow 2003; Min et al. 2008; Kruegel et al. 2011; Liu et al. 2011; 
Rubinsztein et al. 2011; Chiang et al. 2012).    
  Newly synthesized proteins are prone to misfolding and aggregation (Ellis 2001), 
and this is compounded by errors in processes affecting transcription, mRNA processing, 
translation, and protein localization (Levine et al. 2005; Ogle & Ramakrishnan 2005; 
Pickrell et al. 2010). As a result, a significant fraction of newly synthesized proteins 
never attain their functional state. Timely and efficient clearance of misfolded proteins is 
crucial for maintaining cellular functions. Surprisingly, 6% - 30% of all eukaryotic newly 
synthesized proteins are very rapidly degraded by the UPS (Schubert et al. 2000; Qian et 
al. 2006), suggesting that the UPS plays an important role in quality control of newly 
synthesized proteins. In addressing the relationship between protein translation, 
ubiquitination, and degradation, I found that co-translational ubiquitination (CTU) is a 
conserved and robust pathway from yeast to mammals, with 5-6% of total nascent 
polypeptides being ubiquitinated in S. cerevisiae, and 12-15% in human cells. In addition, 
I showed that CTU is enhanced under conditions that promote protein misfolding or 
translational errors, indicating CTU is a pathway for the quality control of newly 
synthesized proteins. Given the connection between the protein translation and longevity, 
and the role of CTU in quality control of newly synthesized proteins, I have tested the 
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hypothesis that CTU may play a preventative role in cellular aging. The findings 
presented here provide preliminary evidence supporting this hypothesis. 
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4.2 MATERIALS AND METHODS 
 Strains: All S. cerevisiae strains except for the Mother Enrichment Program 
(MEP) strains used in this study are derivatives of BY4741 (MATa; his3Δ1; leu2Δ; 
met15Δ; ura3Δ). The BY4741 is referred to here as “wild type” relative to mutant 
derivatives, and all deletion mutants were obtained from the YKO MATa Strain 
Collection (Thermo Scientific), with the gene of interest was replaced by the KanMX4 
cassette. MEP strains UCC5181 (MATα ade2::hisG his3 leu2 trp1Δ63 ura3Δ0 
met15Δ::ADE2 hoΔ::PSCW11-cre-EBD78-NATMX loxPUBC9-loxP-LEU2 loxP-
CDC20-Intron-loxP-HPHMX) and UCC5185 (MATa/MATα ade2::hisG/ade2::hisG 
his3/his3 leu2/leu2 LYS2/lys2 ura3Δ0/ura3Δ0 trp1Δ63/trp1Δ63 MET15/met15Δ::ADE2 
hoΔ::PSCW11-cre-EBD78-NATMX/hoΔ:: PSCW11-cre-EBD78-NATMX loxP-UBC9-
loxP-LEU2/loxP-UBC9-loxP-LEU2 loxP-CDC20-Intron-loxPHPHMX/loxP-CDC20-
Intron-loxP-HPHMX) were kindly provided by Daniel Gottschling (Fred Hutchinson 
Cancer Research) (Lindstrom & Gottschling 2009).  
Purification of Aged Cells (Magnetic Sorting Method): Mother enrichment 
program (MEP) cells were harvested from logarithmically growing YPD cultures 
(~OD600=1.2), washed twice in phosphate-buffer saline (PBS), and resuspended in PBS at 
1x108 cells/ml (1OD600≈1x107 cells/ml). Sulfa-NHS-LC-biotin (Pierce) was added at a 
final concentration of 1 mg/ml and incubated at room temperature, protected from light, 
for 30 min. Cells were washed with YPD media for three times, and inoculated to a 1 L 
YPD culture at 2x105 cells/ml. Cultures were incubated at 30℃ for 2 hours and then 
treated with estradiol at a final concentration of 1 µM. At each time point, 500 ml of the 
culture was harvested and cells were resuspended in 8ml PBS and distributed to eight 1.5 
ml microfuge tubes. Streptavidin-coated magnetic beads (Pierce) (100 µl) was added to 
each microfuge tube, and tubes were incubated for 30 min at room temperature. Cells 
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were then placed in a magnetic sorter (Promega), and after 15 min, the supernatants were 
carefully aspirated. Fresh YPD media (1 ml) was added to each tube, the mixtures were 
votexed and cells again placed in the sorter for 10 min, and the process was repeated 3 
times. Sorted cells were incubated in 25 ml pre-warmed YPD media for 20 min at 30℃, 
and then were pelleted and stored at -80 ℃.  
     Yeast bud scar staining with calcofluor: Cells were collected by centrifugation, 
washed once with distilled deionized water (ddH2O), resuspended in 1mg/ml calcofluor 
solution, and incubated at room temperature protected from light for 5 min. Cells were 
then washed 2-5 times with ddH2O, and directly observed by fluorescence microscopy.   
     Replicative life span analysis by micromanipulation: Mother enrichment 
program (MEP) cells from exponentially growing YPD liquid cultures were diluted with 
fresh YPD medium, and then applied to YPD plates containing 1 µM estradiol. Individual 
cells (50-100) were separated on the plates using dissecting microscope and a 
micromanipulator, and selected for life span analysis. Selected cells were incubated at 
30˚C for 4 days to form microcolonies. As only mother cells can divide in the presence of 
estradiol, the number of cells in a microcolony represents the number of times a mother 
cell divided (referred to as the replicative life span).  
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4.3 RESULTS 
4.3.1 Reduction of global protein translation leads to decreased CTU 
     CTU is a pathway for quality control of newly synthesized proteins, with the extent 
of CTU corresponding to the quality of ribosome-associated nascent chains (Duttler et al. 
2013; Wang et al. 2013). To examine the possible effect of reduced translation on the 
quality of newly synthesized proteins, I determined the CTU level under conditions of 
lower protein translation rate. The mammalian target of rapamycin (mTOR) is a 
serine/threonine protein kinase that regulates protein synthesis, and inhibition of mTOR 
with rapamycin has been found to decrease protein translation and increase life span in 
many organisms (Powers et al. 2006; Medvedik et al. 2007; Harrison et al. 2009; 
Thoreen et al. 2009; Bjedov et al. 2010). I therefore treated 293T cells with rapamycin or 
Torin 1 (more potent mTOR inhibitor) (Thoreen et al. 2009) for 2 hours and then isolated 
polysomes from cell extracts by centrifugation using a 35% sucrose cushion. Ribosome-
associated nascent chains were then labeled with biotinylated puromycin (Bio-Puro) in 
vitro. CTU products were isolated using TUBE-agarose beads and Bio-Puro-labeled 
nascent chains were detected with fluorescently tagged streptavidin. As shown in Figure 
4.1B, both rapamycin and Torin 1 treatments led to a ~20% and ~40% decrease, 
respectively, in CTU. Meanwhile, S35-Met-labeling showed that rapamycin and Torin1 
inhibited overall translation by ~15% and ~50%, respectively (Figure 4.1A), consistent 
with previous studies (Thoreen et al. 2009; Thoreen et al. 2012). This result suggests that 
a reduction in translational load can lead to an increase in the quality of nascent chains in 
human cells.        
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Figure 4.1: Rapamycin and Torin 1 treatments led to a decrease of global protein 
translation as well as CTU level in 293T cells. 
 
(A) 293T cells were treated with DMSO, 250 nM rapamycin or 250 nM torin1 for 2 hours 
and then labeled with 35S-methionine for 30 min. Cell lysates were analyzed by SDS-
PAGE and autoradiography. Anti-tubulin blot shows proteins were loaded equally in each 
lane. Error bars indicate SEM of three independent experiments. (B) Polysomes were 
isolated from DMSO, rapamycin and Torin 1 treated cells and used for in vitro Bio-Puro 
conjugation assay to determine CTU levels. Error bars indicate SEM of three independent 
experiments.   
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      CTU levels in yeast were also examined, using mutants that were predicted to 
decrease translational load. Several yeast deletion mutants were chosen, including Δtif1 
(Tif1 is a translation initiation factor), Δssf1 (Ssf1 is a 60S subunit maturation factor), 
Δtor1 (Tor 1 is a subunit of TORC1 kinase), Δrpl21b and Δrpl22a (Rpl21B and Rpl22A 
are two ribosomal proteins). All of these mutant strains have lower protein synthesis rates 
and extended replicative life spans (Steffen et al. 2008) (Figure 4.2A). Figure 4.2B shows 
that CTU level in all of these strains was 30%-50% lower than the wild-type strain, 
suggesting that reduction in protein synthesis increases the quality of translation products 
in yeast, as in human cells.        
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Figure 4.2: Yeast mutants with reduced protein synthesis rate show lower level of CTU. 
 
(A) Selected yeast mutant strains showed reduced protein translation rate. All strains were 
labeled with 35S-methionine for 30min, and then analyzed by SDS-PAGE and 
autoradiography. Error bars indicate SEM of three independent experiments. (B) CTU level 
was lower in mutant strains with reduced translation rate. The CTU level of all selected yeast 
strains was analyzed by polysome purification and in vitro Bio-Puro conjugation assays. 
Error bars indicate SEM of three independent experiments.   
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4.3.2 Newly synthesized proteins are a major source of proteasome substrates 
    A large fraction of newly synthesized proteins is rapidly degraded through a 
proteasome-dependent manner (Schubert et al. 2000). I therefore determined the fraction 
of total proteasome substrates that were derived from newly synthesized proteins. As 
expected, the total amount of ubiquitinated proteins in 293T cells increased about 60% 
after 2 hours of treatment with MG132, a proteasome inhibitor. Consistent with the 
findings of Kim et al. (Kim et al. 2011b), if cells were simultaneously treated with 
MG132 and cycloheximide (CHX), MG132 did not elicit a detectable increase of 
ubiquitinated proteins (Figure 4.3A). A similar result was observed when cells were co-
treated with MG132 and harringtonine (Figure 4.3A), a translation initiation inhibitor, 
consistent with the notion that nearly all of the ubiquitinated proteins that accumulate in 
the presence of MG132 are derived from newly translated proteins.  There was a slight 
decrease in total ubiquitination in samples only treated with CHX or harringtonine, 
representing the clearance of previously made newly synthesized proteins (Figure 4.3A). 
CHX also blocked the MG132-induced increase of ubiquitination in yeast cells (Figure 
4.3B). Combined, these data indicate that newly synthesized proteins are a major source 
of proteasome substrates under unstressed conditions in both human and yeast cells.  
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Figure 4.3: Newly synthesized proteins are the major source of proteasome substrates.  
 
(A) 293T cells were treated with drugs as indicated, with final concentrations of 2 µg/ml 
Harringtonine, 100 µg/ml CHX and 50 µM MG132, for 2 h. Cell lysates were analyzed by 
SDS-PAGE and blotting with anti-ubiquitin. Anti-tubulin blot shows proteins were loaded 
equally in each lane. Error bars indicate SEM of three independent experiments. (B) Yeast 
cells were inoculated into a synthetic medium (0.17% yeast nitrogenous base without 
ammonium sulfate, 0.1% proline, appropriate amino acids, and 2% glucose). The culture 
grown overnight at 30℃ was re-inoculated to a fresh media containing 0.003% SDS at 1:10 
ratio. The cells were grown for another 3 h at 30℃, and then were added with 50 µM MG132 
and/or 100 µg/ml CHX. After 2.5 h incubation, cells were harvested and lysates were analyzed 
by SDS-PAGE and blotting with ubiquitin specific antibodies. Anti-ADH blot shows that 
proteins were loaded equally in each lane. Error bars indicate SEM of three independent 
experiments.      
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4.3.3 Transient proteasome inhibition decreases replicative life span (RLS), and this 
is suppressed by inhibition of translation. 
     Considering that decreased translational load is correlated with both decreased 
CTU and increased life span, I hypothesized that a transient accumulation of rapidly 
degraded newly synthesized proteins, including CTU products, might have a deleterious 
effect on replicative life span (RLS) in yeast. This was tested by treating mother 
enrichment program (MEP) yeast cells with MG132 for 2.5 hours, in the absence or 
presence of cycloheximide, followed by determination of replicative life span of 15 
individual cells through micromanipulation. As shown in Figure 4.4, MG132 treatment 
led to around 25% decrease in RLS, with the median RLS decreased from 34 to 25 
generations. Surprisingly, if the MG132-treated cells were simultaneously treated with 
CHX, the median RLS was restored back to 37 generations. These data indicate that 
accumulation of ubiquitinated newly synthesized proteins over a short period of time has 
long-term adverse effects of the yeast RLS. Given that the major source of proteasome 
substrates under unstressed conditions are newly synthesized proteins, this suggests that 
quality control of newly synthesized proteins might be an important determinant of aging 
under physiological conditions.           
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Figure 4.4: MG132 treatment led to a decrease of yeast RLS whereas co-treatment 
with CHX can restore it. 
 
Yeast cells were inoculated into synthetic media as described in Figure 4.3B. The overnight 
culture was re-inoculated into the fresh synthetic media plus 0.003% SDS and grown for 3 
more hours prior to addition of 50 µM MG132 plus or minus of 100 µg/ml CHX. Cells were 
incubated 2.5 h at 30 ℃, and then washed 3 times with YPD media. The RLS of cells were 
then analyzed by micromanipulation.   
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4.3.4 CTU is increased in aged yeast 
     Aging is a process accompanied with the loss of proteasome homeostasis 
(proteostasis) (Lopez-Otin et al. 2013). One possible reason for loss of proteostasis is that 
production of misfolded/damaged proteins exceeds the capacity of proteolytic systems. 
With this in mind, I examined the CTU level in aged yeast cells. Aged yeast cells were 
enriched and isolated through a previously described magnetic sorting method (Smeal et 
al. 1996), as illustrated in Figure 4.5A. Briefly, the cell walls of exponentially growing 
yeast cells were first labeled with biotin (Sulfa-NHS0LC-biotin) in PBS, unincorporated 
biotin was washed away, and cells were returned to growth media for 24 hours. As the 
cell walls of daughter cells consist of only newly synthesized components, biotin-labeled 
molecules are only found on cell walls of mother cells. After 24 hours, mother cells were 
isolated from the total cell populations using streptavidin-coated magnetic beads. The 
average age of the mother cell population was estimated based on bud scars, as visualized 
by calcofluor white staining.  
     As shown in Figure 4.5B, the “aged” mother cells had greater than 10 bud scars. To 
enrich for “young” cells, the same procedure was followed, but cells were returned to 
growth media after biotin labeling for only 1 hour before collecting the biotin labeled 
cells. Importantly, although these were, by definition, mother cells, they were 
nevertheless “young” cells since an exponentially growing culture of yeast cells, as was 
used for the biotin labeling, consists primarily of daughter cells. This was confirmed 
again by calcofluor white staining, which showed that this “young” cell population had, 
on average, less than 2 bud scars. Polysomes were purified from both young and aged 
cells and the extent of CTU was determined using the in vitro Bio-Puromycin 
conjugation and TUBE pull-down approach. Figure 4.5C shows that CTU level of aged 
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cells was over 60% higher than the level of young cells, suggesting that the quality of 
newly synthesized proteins is lower in aged cells. 
 
                 
               
                 
Figure 4.5 The CTU level is increased in old cells. 
 
(A) Strategy for isolating old mother cells from total yeast populations. (B) Bud scar staining 
with calcofluor. Isolated cells were stained with calcofluor to determine the number of bud 
scars, which represent the age of the cell. (C) CTU level is increased with cell aging. 
Polysomes were isolated from both young and old cells, and used for the in vitro Bio-Puro 
conjugation assay to determine CTU level. Error bars indicate SEM of three independent 
experiments.      
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4.3.5 Deletion of Ltn1, the major E3 ligase for CTUS, decreases RLS. 
The results described above show that 1) decreased translational load decreases 
CTU and increases RLS, 2) transient accumulation of CTU products (via proteasome 
inhibition) has a deleterious effect on RLS, and 3) that CTU is higher in aged cells than in 
young cells. CTU is a combination of CTUS and CTUA (Wang et al. 2013). Although we 
do not know the ubiquitin ligases or other components involved in CTUA, the majority of 
CTUS is mediated by the Ltn1 ligase (Bengtson & Joazeiro 2010; Brandman et al. 2012; 
Shao et al. 2013).  
To begin to evaluate the effect of Ltn1 on RLS, I first determined the contribution 
of Ltn1 to total CTU levels in yeast, which had not previously been reported. Polysomes 
were isolated from both wild type and Δltn1 strains and incubated with Bio-Puro in test 
tubes to label nascent chains. CTU products were isolated with TUBE-beads and detected 
with fluorescent streptavidin. As shown in Figure 4.6A, deletion of Ltn1 led to over 50% 
decrease of CTUT level, and the nearly complete elimination of CTUS.  Thus, Ltn1 is the 
major CTUS ligase in yeast, and CTUS accounts for approximately half of all CTU in 
yeast.  
To evaluate the importance of CTUS in RLS, the ltn1∆ mutation was created in 
the MEP yeast strain background. Figure 4.6B shows that deletion of Ltn1 caused a 
reduction of median RLS from 38 to 29 generations, suggesting that blocking the CTUS 
pathway has an adverse effect on yeast RLS.  
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   Figure 4.6: Deletion of Ltn1 gene led to a decrease of RLS.  
(A) Deletion of Ltn1 led to ~50% decrease of CTUT and ~90% decrease of CTUS. Polysomes 
were purified from both wild type and Δltn1 strains, and then used for in vitro Bio-Puro 
conjugation assay to determine the level of CTU. For CTUS analysis, prior to polysome 
purification, cells were switched to YP media (YPD without glucose) and incubated at 30℃ for 
10 min to run-off active translation complexes (Ashe et al. 2000). Error bars indicate SEM of 
three independent experiments. (B) Deletion of Ltn1 shortens the RLS of yeast. The RLS of both 
wild type and Δltn1 strains were measured through micromanipulation as described in Materials 
and Methods. RLS of 50 individual cells were examined for each strain, with median RLS of 
wild type strain is 38 generations and median RLS of Δltn1 strain is 29 generations.   
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4.4 DISCUSSION 
     The proteasome is the primary site for protein degradation, responsible for 80-90% 
of total intracellular protein turnover (Herrmann et al. 2010). In this study, I found that 
newly synthesized proteins are a major source of proteasome substrates in both yeast and 
human cells under physiological conditions, consistent with the previous finding that a 
very significant fraction of the ubiquitinated proteome represents the modification of 
newly synthesized proteins (Kim et al. 2011b). To test for a link between the degradation 
of newly synthesized proteins and longevity, I blocked the proteasome function to 
accumulate rapidly degraded newly made proteins (most are presumed to be due to 
folding failure) in yeast. Surprisingly, only two and half hours of proteasome inhibition 
by MG132 treatment shortened the RLS of yeast by 25%, with the median RLS 
decreased from 34 to 25 generations. Interestingly, if the MG132-treated cells were co-
treated with CHX, their RLS was restored. These data indicate that accumulation of 
ubiquitinated newly synthesized proteins over a short period of time has long-term 
adverse effects of the yeast RLS. Given that the major source of proteasome substrates 
under unstressed conditions are newly synthesized proteins, this suggests that quality 
control of newly synthesized proteins might be an important determinant of aging under 
physiological conditions.           
 Reduced mRNA translation is believed to be beneficial for maintenance of 
proteome homeostasis, as the production of both normal and damaged proteins are 
reduced (Kaeberlein & Kennedy 2007). I have shown here that reduced translation can 
also increase the quality of newly synthesized proteins. For example, rapamycin 
treatment of 293T cells led to ~15% decrease of total protein translation and ~20% 
decrease of CTU (Figure 4.1). Therefore, if all CTU products represent 
misfolded/damaged proteins, the rapamycin treatment will result in ~35% reduction of 
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aberrant protein production from mRNA translation. A similar effect was also observed 
in yeast mutants with lower protein synthesis rates. As shown in Figure 4.2, all tested 
yeast mutants showed 5%-40% less protein translation, and meanwhile exhibited 30%-
50% lower CTU levels, indicating that they only produce 30%-60% of misfolded proteins 
normally made from translation in wild-type yeast. Given that the major source of 
proteasome substrates under unstressed conditions are newly synthesized proteins (Figure 
4.3), slight reductions of mRNA translation can significantly relieve the burden of the 
proteasome.            
     Levels of damaged/misfolded proteins and protein aggregates increase with age of 
various organisms, ranging from yeast to humans (Stadtman et al. 1992; Koga et al. 
2011; Baraibar & Friguet 2012). Once these toxic proteins reach a critical level, a 
negative feedback loop is believed to further accelerate aging by exacerbating 
proteostatic decline (Andersson et al. 2013). Either increased production of damaged 
proteins or decreased capacity of protein quality control system can disrupt the protein 
homeostatic balance and lead to accumulation of toxic proteins. Indeed, the activity of the 
proteasome has been shown to decline during aging in many model organisms (Friguet et 
al. 2000; Shringarpure & Davies 2002; Baraibar & Friguet 2012). However, a recent 
study reported that the level and potential capacity of the proteasome is actually 
maintained in aged yeast, and proteasomes that cannot function properly are 
predominantly due to age-associated protein aggregates obstructing their function 
(Andersson et al. 2013). This observation raises an interesting question: Is the declined 
activity of proteasome a reason or a result of the accumulated damaged proteins in aged 
cells? In this study, I showed that the CTU level in aged cells (>10 generations) is ~70% 
higher than the level in young cells, supporting the hypothesis that increased production 
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of damaged proteins with age is a reason for disruption of the protein homeostatic 
balance.       
     CTU is a pathway for quality control of newly synthesized proteins (Duttler et al. 
2013; Wang et al. 2013). Ltn1 has been confirmed as the major E3 ligase of CTUS 
pathway in yeast in this study, since deletion of Ltn1 nearly eliminates all CTUS 
products. In addition, I showed that deletion of Ltn1 resulted in ~25% decrease of yeast 
RLS. A previous study has reported that Ltn1 knockout mice exhibit extremely short life 
span, with ~90% death within 100 days (no wild-type mice died in this period of time). 
Moreover, the Ltn1-/- mice showed profound early-onset and aged-dependent progressive 
neurological and motor dysfunction (Chu et al. 2009). Taken together, these data suggest 
that the CTU pathway plays a protective role during the aging process.  
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Chapter 5: Conclusion and future directions 
 
 
5.1 CHARACTERIZATION OF THE CTU PATHWAY 
     In Chapter 3, I showed that CTU is a conserved and robust pathway from yeast to 
humans, with 5-6% of total nascent polypeptides being ubiquitinated in S. cerevisiae, and 
12-15% in human cells. A preliminary set of CTU targets (~130) have been identified 
through my study. Several interesting findings were among this first set of targets. First, 
the mass spectrometry results showed strong evidence for K11 and K48 polyubiquitin 
chains on CTU targets, with no evidence of any other chain types. This result was 
confirmed by the experiment in which expression of R11/R48 ubiquitin led to a sharp 
decrease of the average molecular weight distribution of CTU products (Figure 3.5C). 
Second, most of the identified CTU targets are high molecular weight proteins, with the 
average length over 1000 amino acids, which is as twice long as the average length of 
total human proteins (~485 amino acids). Given the lower folding and higher aggregation 
propensity of the longer proteins (Ivankov et al. 2003; Wong et al. 2005; Kiraga et al. 
2007; Ouyang & Liang 2008), this observation is consistent with the model that CTU is a 
quality control pathway for newly synthesized proteins. Although another group reported 
a similar finding in yeast (Duttler et al. 2013), we cannot rule out the possibility that this 
observation is a result of experimental bias. Since longer proteins normally contain more 
ubiquitination sites and are more likely to be highly ubiquitinated, the anti-ubiquitin pull 
down step in the purification of CTU products may tend to enrich those highly 
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ubiquitinated large proteins. Therefore, an unbiased strategy is required to isolate CTU 
targets for LC-MS/MS identification.  
    A recently developed technique by using an antibody that specifically recognizes the 
GG dipeptide “remnant” left on ubiquitinated lysine side chains after tryptic digestion 
would be a good choice to isolate CTU products in an unbiased manner (Xu et al. 2010). 
This approach has been successfully used by the Harper and Gygi labs to globally map 
ubiquitination sites (Kim et al. 2011b). Therefore, this approach is also able to identify 
the sites of CTU on the modified nascent polypeptides. This information could be 
important for at least two major reasons. Firstly, many proteins in our preliminary 
proteomic analysis were known in the Harper/Gygi study to contain many ubiquitination 
sites, in one case as many as 94 (PRKDC). I will be interesting if all of these sites, or 
only a subset, represent sites of co-translational ubiquitination, with another subset 
representing sites critical for post-translational ubiquitination. Secondly, the modification 
site results could be used to determine if there is a “code” for co-translational 
ubiquitination in terms of consensus recognition sites. Combining this technique with the 
approaches for separating stalled and active translation complexes, the targets of CTUA 
and CTUS, separately, can potentially be identified.  
      Although nascent chains have been previously shown to be ubiquitinated within 
stalled and defective translation complexes (referred to as CTUS) (Bengtson & Joazeiro 
2010; Brandman et al. 2012; Shao et al. 2013; Verma et al. 2013), I showed that nascent 
chain ubiquitination also occurred within active translation complexes (CTUA). CTUA 
accounted for approximately two-thirds of total CTU (CTUT) in human cells and 
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approximately half of CTUT in yeast cells. CTUA and CTUS may reflect two different 
mechanisms for recognition of defective proteins.  
     Translational stalling is thought to be the key determinant for substrate recognition 
in the CTUS pathway (Bengtson & Joazeiro 2010). Since much of the ribosome stalling is 
due to translation of damaged/truncated mRNA, CTUS is often coupled with mRNA 
quality control pathways: such as nonsense-mediated decay (NMD), no-go decay (NGD) 
and nonstop decay (NSD) (Shoemaker & Green 2012). By using a brief pactamycin 
treatment to run-off the nascent chains on active translation complexes, I found that 
approximately 20% of ribosomes are stalled or transiently paused complexes. 
Interestingly, only a fraction of these stalled/paused complexes (~15%-18%) contain 
ubiquitinated nascent chains. This is consistent with the model that a portion of 
translation stalling/pausing may provide a regulatory role of protein synthesis at a post-
translation initiation level (those do not trigger ubiquitination) (Shalgi et al. 2013). This 
observation raised an important question: how does a cell distinguish ‘unnaturally’ stalled 
nascent chains needing to be disposed, from transient translation pausing with regulatory 
function? Although the exact mechanism of this discrimination remains unknown, a 
proposed model theorizes that the length of stalling time might be critical (Shoemaker & 
Green 2012).              
     Treatments that induced protein misfolding led to increased level of CTUA (Figure 
3.11), suggesting that misfolded nascent chains are the targets of CTUA. The protein 
quality control system recognizes misfolded proteins based on their unique properties, 
such as exposure of long stretches of hydrophobic residues. However, since nascent 
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chains share the same properties with misfolded proteins, how the quality control system 
is able to discriminate misfolded nascent chains from normal nascent chains is an 
interesting question that needs to be addressed. Polypeptides normally cannot complete 
folding until they are fully synthesized and released from the ribosome, whereas protein 
domains are relatively independent folding units and usually can form stable and compact 
three-dimensional structures. A promising model is that polypeptides are undergoing a 
“domain-wise” co-translational quality surveillance, which corresponds to the “domain-
wise” co-translational folding. In other words, a protein domain, but not the full length 
protein, is the minimal quality control unit. In this model, the nascent polypeptide 
containing at least one full length misfolded domain is the preferred target of the co-
translational quality control pathway. Consistent with this hypothesis, large proteins with 
multiple domains are highly enriched among identified CTU targets; meanwhile proteins 
shorter than 300 amino acids are largely excluded (the length of a domain is between 50-
300 amino acids) (Duttler et al. 2013).  
     Although the CTU pathway functions in quality control of newly synthesized 
proteins, whether the high basal level of CTU products all represents aberrant proteins 
requires further investigation. Besides misfolded nascent chains, short-lived regulatory 
proteins are a possible group of CTU targets. Many regulatory proteins are degraded very 
rapidly, with a half-life less than 10 min. For example, the protein HIF-1α (hypoxia-
inducible factor-1 alpha), which is a transcription factor that senses the availability of 
oxygen in the cellular environment and promotes the formation of blood vessels in 
hypoxic environments, is normally degraded with a half-life of 10 min (Salceda & Caro 
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1997). Rapid elimination of short-lived regulatory proteins is critical for the regulation of 
transcription, metabolism and growth. However, regulatory proteins are normally low 
abundance proteins, so deeper proteomic identification with high substrate coverage is 
required to identify this possible type of CTU targets.   
     The E3 ligase(s) that are responsible for CTUA and CTUS pathways remain to be 
identified. The ribosome-associated E3 ligase, Ltn1, has been reported to be involved in 
the CTUS pathway (Bengtson & Joazeiro 2010; Brandman et al. 2012). I showed here 
that deletion of Ltn1 in yeast eliminated nearly all CTUS products and led to ~50% 
decrease of CTUT. However, knocking down Ltn1 in human cells by siRNA showed only 
a minor decrease of CTUT level (~10% decrease). These data indicate that Ltn1 is the 
major E3 ligase of CTUS pathway in yeast, but how important is Ltn1 in mammalian 
CTUS pathway requires further evaluation. The issue with the siRNA experiment in 
mammalian cells is that it cannot knock down Ltn1 completely, so the more accurate way 
to test the role of Ltn1 in mammalian cells is by using the Ltn1-/- mouse cell line which 
is available (Chu et al. 2009).  
     Hel2 is another ribosome-associated E3 ligase that has been proposed to function 
upstream of Ltn1 for clearance of stalled nascent chains (Brandman et al. 2012). My 
result revealed that deletion of Hel2 only caused a moderate decrease of CTUS level (~15% 
decrease), suggesting that Hel2 is not a prerequisite of Ltn1-mediated degradation of 
stalled nascent chains. The exact function of Hel2 in the CTUS pathway needs further 
evaluation. Little is known about what E3 ligase(s) are involved in the CTUA process. 
Several E3 ligases, which are known to function in protein quality control, have been 
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tested, but none of them seems to play a major role in the CTUA pathway (Duttler et al. 
2013; Wang et al. 2013). One possible model is that there are multiple E3 ligases 
functioning in the CTUA pathway, with each of them recognizing a subset of CTUA 
substrates.      
 
5.2 PROTEIN TRANSLATION AND CTU IN LONGEVITY AND AGING       
Newly synthesized proteins contribute a consistent stream of misfolded proteins to 
the cellular quality control system. In Chapter 4, I showed that newly synthesized 
proteins are the major source of proteasome substrates under non-stressed conditions 
(Figure. 4.3), consistent with a previous finding that a very significant fraction of the 
ubiquitinated proteasome is represented by newly synthesized proteins (Kim et al. 2011b). 
It is interesting to consider the impact of rapidly degraded newly made proteins, 
including CTU products, on overall cellular homeostasis. Since the number of ribosomes 
is several fold higher than the number of proteasomes in eukaryotic cells, and a large 
fraction of newly made proteins need to be disposed rapidly, the damaged/misfolded 
newly synthesized proteins should represent a substantial burden for the proteasome 
pathway. Now the questions are: what percentage of proteasome capacity is occupied by 
rapidly degraded newly synthesized proteins under non-stressed conditions, and more 
importantly, what capacity of the proteasome system is left for possible stress-induced 
misfolded proteins?  
The capacity of the proteasome can be represented as the degradation rate of a given 
substrate. The load of proteasome substrates can be depleted by inhibition of protein 
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translation (as newly synthesized proteins are the major sources of proteasome substrates). 
Therefore, the full capacity of the proteasome system can be represented as the time 
required for degradation of a certain amount of a given substrate in cells, when 
endogenous proteasome substrates are pre-cleared by inhibition of translation. Likewise, 
the un-occupied proteasome capacity can be estimated when endogenous proteasome 
substrates are not pre-cleared.  
 Reduced protein translation has been shown to increase the life span of various 
organisms. One possible reason is that it is a benefit for maintenance of proteome 
homeostasis, because the production of both normal and aberrant proteins is reduced, 
leading to less influx of misfolded proteins to the quality control system. I showed that 
reduction of protein translation is actually more beneficial to proteostasis than had been 
previously thought. I found that reduced protein translation leads to a lower level of CTU. 
As the extent of CTU corresponds to the quality of nascent polypeptides (Figure 3.11), it 
suggests that reduced protein translation can increase the quality of newly synthesized 
proteins, possibly by relieving the burden of chaperone systems. Further evidence is 
required to verify this hypothesis. Increased quality of newly synthesized proteins should 
be accompanied with reduced production of aberrant proteins by translation. Therefore, it 
is important to measure the fraction of rapidly degraded newly synthesized proteins, 
under conditions with a lower protein translation rate. Furthermore, it is also important to 
test whether reduction of protein translation retards the accumulation of protein 
aggregates in aged cells. Protein aggregates can be detected by expression of the GFP-
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fused HSP104 chaperone, which normally co-localizes with protein aggregates in vivo 
(Erjavec et al. 2007).  
 It is interesting to note that aged yeast cells contain higher level of CTU. This 
might be a consequence of accumulated cellular damage that occurs with age, which can 
impair the accuracy of protein synthesis. This is consistent with the findings that aged 
cells have accumulated DNA damage and show less RNA-processing fidelity, both of 
which could decrease the accuracy of protein synthesis (Moskalev et al. 2013).     
    The potential role of CTU in aging was also tested in Chapter 4. Deletion of Ltn1, 
the major E3 ligase of CTUS pathway, led to an approximate 25% decrease of yeast RLS. 
To further confirm the role of Ltn1 in aging, it will be important to test whether loss of 
Ltn1 accelerates the disruption of proteome homeostasis, a hallmark of aging. A previous 
study has reported that Ltn1 knockout mice exhibit an extremely short life span, with 
~90% of them dying within 100 days, and moreover, the mutant mice showed profound 
early-onset and aged-dependent progressive neurological and motor dysfunction (Chu et 
al. 2009). These data support the idea that the CTU pathway, at least CTUS pathway, has 
a potential role in retarding aging. However, the role of the CTUA pathway in aging 
remains unknown. A method that can specifically block the CTUA pathway is required 
for testing the role of CTUA in aging progression.  
 
     
 
 
  
 133 
References 
 
AGASHE, V.R., GUHA, S., CHANG, H.C., GENEVAUX, P., HAYER-HARTL, M., STEMP, M., 
GEORGOPOULOS, C., HARTL, F.U. & BARRAL, J.M. 2004. Function of trigger 
factor and DnaK in multidomain protein folding: increase in yield at the expense 
of folding speed. Cell 117: 199-209. 
AGUILANIU, H., GUSTAFSSON, L., RIGOULET, M. & NYSTROM, T. 2003. Asymmetric 
inheritance of oxidatively damaged proteins during cytokinesis. Science 299: 
1751-3. 
AKERFELT, M., MORIMOTO, R.I. & SISTONEN, L. 2010. Heat shock factors: integrators of 
cell stress, development and lifespan. Nat Rev Mol Cell Biol 11: 545-55. 
ALBANESE, V., YAM, A.Y., BAUGHMAN, J., PARNOT, C. & FRYDMAN, J. 2006. Systems 
analyses reveal two chaperone networks with distinct functions in eukaryotic 
cells. Cell 124: 75-88. 
ANAN, T., NAGATA, Y., KOGA, H., HONDA, Y., YABUKI, N., MIYAMOTO, C., KUWANO, 
A., MATSUDA, I., ENDO, F., SAYA, H. & NAKAO, M. 1998. Human ubiquitin-
protein ligase Nedd4: expression, subcellular localization and selective interaction 
with ubiquitin-conjugating enzymes. Genes Cells 3: 751-63. 
ANDERSSON, V., HANZEN, S., LIU, B., MOLIN, M. & NYSTROM, T. 2013. Enhancing 
protein disaggregation restores proteasome activity in aged cells. Aging (Albany 
NY) 5: 802-12. 
ANFINSEN, C.B. 1973. Principles that govern the folding of protein chains. Science 181: 
223-30. 
ARIAS, E. & CUERVO, A.M. 2011. Chaperone-mediated autophagy in protein quality 
control. Curr Opin Cell Biol 23: 184-9. 
ARNDT, V., ROGON, C. & HOHFELD, J. 2007. To be, or not to be--molecular chaperones in 
protein degradation. Cell Mol Life Sci 64: 2525-41. 
ASHE, M.P., DE LONG, S.K. & SACHS, A.B. 2000. Glucose depletion rapidly inhibits 
translation initiation in yeast. Mol Biol Cell 11: 833-48. 
ASHERIE, N. 2004. Protein crystallization and phase diagrams. Methods 34: 266-72. 
BAILLY, V., LAUDER, S., PRAKASH, S. & PRAKASH, L. 1997. Yeast DNA repair proteins 
Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA 
binding, and ATP hydrolytic activities. J Biol Chem 272: 23360-5. 
BALCH, W.E., MORIMOTO, R.I., DILLIN, A. & KELLY, J.W. 2008. Adapting proteostasis 
for disease intervention. Science 319: 916-9. 
BARAIBAR, M.A. & FRIGUET, B. 2012. Changes of the proteasomal system during the 
aging process. Prog Mol Biol Transl Sci 109: 249-75. 
BECK, F., UNVERDORBEN, P., BOHN, S., SCHWEITZER, A., PFEIFER, G., SAKATA, E., 
NICKELL, S., PLITZKO, J.M., VILLA, E., BAUMEISTER, W. & FORSTER, F. 2012. 
Near-atomic resolution structural model of the yeast 26S proteasome. Proc Natl 
Acad Sci U S A 109: 14870-5. 
 134 
BEHRENDS, C. & HARPER, J.W. 2011. Constructing and decoding unconventional 
ubiquitin chains. Nat Struct Mol Biol 18: 520-8. 
BENAROUDJ, N., ZWICKL, P., SEEMULLER, E., BAUMEISTER, W. & GOLDBERG, A.L. 2003. 
ATP hydrolysis by the proteasome regulatory complex PAN serves multiple 
functions in protein degradation. Mol Cell 11: 69-78. 
BENCSATH, K.P., PODGORSKI, M.S., PAGALA, V.R., SLAUGHTER, C.A. & SCHULMAN, 
B.A. 2002. Identification of a multifunctional binding site on Ubc9p required for 
Smt3p conjugation. J Biol Chem 277: 47938-45. 
BENGTSON, M.H. & JOAZEIRO, C.A. 2010. Role of a ribosome-associated E3 ubiquitin 
ligase in protein quality control. Nature 467: 470-3. 
BENNETT, E.J. & HARPER, J.W. 2008. DNA damage: ubiquitin marks the spot. Nat Struct 
Mol Biol 15: 20-2. 
BJEDOV, I., TOIVONEN, J.M., KERR, F., SLACK, C., JACOBSON, J., FOLEY, A. & 
PARTRIDGE, L. 2010. Mechanisms of life span extension by rapamycin in the fruit 
fly Drosophila melanogaster. Cell Metab 11: 35-46. 
BOGUNOVIC, D., BYUN, M., DURFEE, L.A., ABHYANKAR, A., SANAL, O., MANSOURI, D., 
SALEM, S., RADOVANOVIC, I., GRANT, A.V., ADIMI, P., MANSOURI, N., OKADA, 
S., BRYANT, V.L., KONG, X.F., KREINS, A., VELEZ, M.M., BOISSON, B., 
KHALILZADEH, S., OZCELIK, U., DARAZAM, I.A., SCHOGGINS, J.W., RICE, C.M., 
AL-MUHSEN, S., BEHR, M., VOGT, G., PUEL, A., BUSTAMANTE, J., GROS, P., 
HUIBREGTSE, J.M., ABEL, L., BOISSON-DUPUIS, S. & CASANOVA, J.L. 2012. 
Mycobacterial disease and impaired IFN-gamma immunity in humans with 
inherited ISG15 deficiency. Science 337: 1684-8. 
BRADLEY, M.O., HAYFLICK, L. & SCHIMKE, R.T. 1976. Protein degradation in human 
fibroblasts (WI-38). Effects of aging, viral transformation, and amino acid 
analogs. J Biol Chem 251: 3521-9. 
BRANDMAN, O., STEWART-ORNSTEIN, J., WONG, D., LARSON, A., WILLIAMS, C.C., LI, 
G.W., ZHOU, S., KING, D., SHEN, P.S., WEIBEZAHN, J., DUNN, J.G., ROUSKIN, S., 
INADA, T., FROST, A. & WEISSMAN, J.S. 2012. A ribosome-bound quality control 
complex triggers degradation of nascent peptides and signals translation stress. 
Cell 151: 1042-54. 
BRANDT, F., ETCHELLS, S.A., ORTIZ, J.O., ELCOCK, A.H., HARTL, F.U. & BAUMEISTER, 
W. 2009. The native 3D organization of bacterial polysomes. Cell 136: 261-71. 
BRODERSEN, D.E., CLEMONS, W.M., JR., CARTER, A.P., MORGAN-WARREN, R.J., 
WIMBERLY, B.T. & RAMAKRISHNAN, V. 2000. The structural basis for the action 
of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S 
ribosomal subunit. Cell 103: 1143-54. 
BULTEAU, A.L., LUNDBERG, K.C., HUMPHRIES, K.M., SADEK, H.A., SZWEDA, P.A., 
FRIGUET, B. & SZWEDA, L.I. 2001. Oxidative modification and inactivation of the 
proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057-63. 
CABRITA, L.D., HSU, S.T., LAUNAY, H., DOBSON, C.M. & CHRISTODOULOU, J. 2009. 
Probing ribosome-nascent chain complexes produced in vivo by NMR 
spectroscopy. Proc Natl Acad Sci U S A 106: 22239-44. 
 135 
CARRARD, G., DIEU, M., RAES, M., TOUSSAINT, O. & FRIGUET, B. 2003. Impact of ageing 
on proteasome structure and function in human lymphocytes. Int J Biochem Cell 
Biol 35: 728-39. 
CHAN, H.S. & DILL, K.A. 1998. Protein folding in the landscape perspective: chevron 
plots and non-Arrhenius kinetics. Proteins 30: 2-33. 
CHASTAGNER, P., ISRAEL, A. & BROU, C. 2006. Itch/AIP4 mediates Deltex degradation 
through the formation of K29-linked polyubiquitin chains. EMBO Rep 7: 1147-
53. 
CHEN, B., RETZLAFF, M., ROOS, T. & FRYDMAN, J. 2011. Cellular strategies of protein 
quality control. Cold Spring Harb Perspect Biol 3: a004374. 
CHIANG, W.C., CHING, T.T., LEE, H.C., MOUSIGIAN, C. & HSU, A.L. 2012. HSF-1 
regulators DDL-1/2 link insulin-like signaling to heat-shock responses and 
modulation of longevity. Cell 148: 322-34. 
CHONDROGIANNI, N., STRATFORD, F.L., TROUGAKOS, I.P., FRIGUET, B., RIVETT, A.J. & 
GONOS, E.S. 2003. Central role of the proteasome in senescence and survival of 
human fibroblasts: induction of a senescence-like phenotype upon its inhibition 
and resistance to stress upon its activation. J Biol Chem 278: 28026-37. 
CHU, J., HONG, N.A., MASUDA, C.A., JENKINS, B.V., NELMS, K.A., GOODNOW, C.C., 
GLYNNE, R.J., WU, H., MASLIAH, E., JOAZEIRO, C.A. & KAY, S.A. 2009. A mouse 
forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved 
in neurodegeneration. Proc Natl Acad Sci U S A 106: 2097-103. 
CIECHANOVER, A., HELLER, H., ELIAS, S., HAAS, A.L. & HERSHKO, A. 1980. ATP-
dependent conjugation of reticulocyte proteins with the polypeptide required for 
protein degradation. Proc Natl Acad Sci U S A 77: 1365-8. 
CIECHANOVER, A., HELLER, H., KATZ-ETZION, R. & HERSHKO, A. 1981. Activation of the 
heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad 
Sci U S A 78: 761-5. 
CIEHANOVER, A., HOD, Y. & HERSHKO, A. 1978. A heat-stable polypeptide component of 
an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res 
Commun 81: 1100-5. 
CLEMENTZ, M.A., CHEN, Z., BANACH, B.S., WANG, Y., SUN, L., RATIA, K., BAEZ-
SANTOS, Y.M., WANG, J., TAKAYAMA, J., GHOSH, A.K., LI, K., MESECAR, A.D. & 
BAKER, S.C. 2010. Deubiquitinating and interferon antagonism activities of 
coronavirus papain-like proteases. J Virol 84: 4619-29. 
CROSS, B.C., MCKIBBIN, C., CALLAN, A.C., ROBOTI, P., PIACENTI, M., RABU, C., 
WILSON, C.M., WHITEHEAD, R., FLITSCH, S.L., POOL, M.R., HIGH, S. & 
SWANTON, E. 2009. Eeyarestatin I inhibits Sec61-mediated protein translocation 
at the endoplasmic reticulum. J Cell Sci 122: 4393-400. 
CUERVO, A.M., BERGAMINI, E., BRUNK, U.T., DROGE, W., FFRENCH, M. & TERMAN, A. 
2005. Autophagy and aging: the importance of maintaining "clean" cells. 
Autophagy 1: 131-40. 
CUERVO, A.M. 2008. Autophagy and aging: keeping that old broom working. Trends 
Genet 24: 604-12. 
 136 
DA FONSECA, P.C., HE, J. & MORRIS, E.P. 2012. Molecular model of the human 26S 
proteasome. Mol Cell 46: 54-66. 
DASTUR, A., BEAUDENON, S., KELLEY, M., KRUG, R.M. & HUIBREGTSE, J.M. 2006. 
Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of 
ISG15 in human cells. J Biol Chem 281: 4334-8. 
DAVID, A., DOLAN, B.P., HICKMAN, H.D., KNOWLTON, J.J., CLAVARINO, G., PIERRE, P., 
BENNINK, J.R. & YEWDELL, J.W. 2012. Nuclear translation visualized by 
ribosome-bound nascent chain puromycylation. J Cell Biol 197: 45-57. 
DENZEL, M.S., STORM, N.J., GUTSCHMIDT, A., BADDI, R., HINZE, Y., JAROSCH, E., 
SOMMER, T., HOPPE, T. & ANTEBI, A. 2014. Hexosamine pathway metabolites 
enhance protein quality control and prolong life. Cell 156: 1167-78. 
DEPRISTO, M.A., WEINREICH, D.M. & HARTL, D.L. 2005. Missense meanderings in 
sequence space: a biophysical view of protein evolution. Nat Rev Genet 6: 678-
87. 
DESHAIES, R.J. & JOAZEIRO, C.A. 2009. RING domain E3 ubiquitin ligases. Annu Rev 
Biochem 78: 399-434. 
DIMITROVA, L.N., KUROHA, K., TATEMATSU, T. & INADA, T. 2009. Nascent peptide-
dependent translation arrest leads to Not4p-mediated protein degradation by the 
proteasome. J Biol Chem 284: 10343-52. 
DOUGLAS, P.M. & DILLIN, A. 2010. Protein homeostasis and aging in neurodegeneration. 
J Cell Biol 190: 719-29. 
DRUMMOND, D.A. & WILKE, C.O. 2009. The evolutionary consequences of erroneous 
protein synthesis. Nat Rev Genet 10: 715-24. 
DUNKER, A.K., SILMAN, I., UVERSKY, V.N. & SUSSMAN, J.L. 2008. Function and 
structure of inherently disordered proteins. Curr Opin Struct Biol 18: 756-64. 
DURFEE, L.A., LYON, N., SEO, K. & HUIBREGTSE, J.M. The ISG15 conjugation system 
broadly targets newly synthesized proteins: implications for the antiviral function 
of ISG15. Mol Cell 38: 722-32. 
DURFEE, L.A., KELLEY, M.L. & HUIBREGTSE, J.M. 2008. The basis for selective E1-E2 
interactions in the ISG15 conjugation system. J Biol Chem 283: 23895-902. 
DURFEE, L.A. 2010. The Enzymology and Substrate Selectivity of the ISG15 Conjugation 
System. PhD Dissertation. 
DURFEE, L.A., LYON, N., SEO, K. & HUIBREGTSE, J.M. 2010. The ISG15 conjugation 
system broadly targets newly synthesized proteins: implications for the antiviral 
function of ISG15. Mol Cell 38: 722-32. 
DUTTLER, S., PECHMANN, S. & FRYDMAN, J. 2013. Principles of cotranslational 
ubiquitination and quality control at the ribosome. Mol Cell 50: 379-93. 
EHRENFRIED, J.A., EVERS, B.M., CHU, K.U., TOWNSEND, C.M., JR. & THOMPSON, J.C. 
1996. Caloric restriction increases the expression of heat shock protein in the gut. 
Ann Surg 223: 592-7; discussion 597-9. 
EICHMANN, C., PREISSLER, S., RIEK, R. & DEUERLING, E. 2010. Cotranslational structure 
acquisition of nascent polypeptides monitored by NMR spectroscopy. Proc Natl 
Acad Sci U S A 107: 9111-6. 
 137 
EISENBERG, T., KNAUER, H., SCHAUER, A., BUTTNER, S., RUCKENSTUHL, C., CARMONA-
GUTIERREZ, D., RING, J., SCHROEDER, S., MAGNES, C., ANTONACCI, L., FUSSI, H., 
DESZCZ, L., HARTL, R., SCHRAML, E., CRIOLLO, A., MEGALOU, E., WEISKOPF, D., 
LAUN, P., HEEREN, G., BREITENBACH, M., GRUBECK-LOEBENSTEIN, B., HERKER, 
E., FAHRENKROG, B., FROHLICH, K.U., SINNER, F., TAVERNARAKIS, N., MINOIS, 
N., KROEMER, G. & MADEO, F. 2009. Induction of autophagy by spermidine 
promotes longevity. Nat Cell Biol 11: 1305-14. 
ELETR, Z.M., HUANG, D.T., DUDA, D.M., SCHULMAN, B.A. & KUHLMAN, B. 2005. E2 
conjugating enzymes must disengage from their E1 enzymes before E3-dependent 
ubiquitin and ubiquitin-like transfer. Nat Struct Mol Biol 12: 933-4. 
ELETR, Z.M. & KUHLMAN, B. 2007. Sequence determinants of E2-E6AP binding affinity 
and specificity. J Mol Biol 369: 419-28. 
ELLIS, R.J. 2001. Macromolecular crowding: obvious but underappreciated. Trends 
Biochem Sci 26: 597-604. 
ELLIS, R.J. & MINTON, A.P. 2006. Protein aggregation in crowded environments. Biol 
Chem 387: 485-97. 
ERJAVEC, N., LARSSON, L., GRANTHAM, J. & NYSTROM, T. 2007. Accelerated aging and 
failure to segregate damaged proteins in Sir2 mutants can be suppressed by 
overproducing the protein aggregation-remodeling factor Hsp104p. Genes Dev 
21: 2410-21. 
ESCUSA-TORET, S., VONK, W.I. & FRYDMAN, J. 2013. Spatial sequestration of misfolded 
proteins by a dynamic chaperone pathway enhances cellular fitness during stress. 
Nat Cell Biol 15: 1231-43. 
ETLINGER, J.D. & GOLDBERG, A.L. 1977. A soluble ATP-dependent proteolytic system 
responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl 
Acad Sci U S A 74: 54-8. 
FANG, N.N., NG, A.H., MEASDAY, V. & MAYOR, T. 2011. Hul5 HECT ubiquitin ligase 
plays a major role in the ubiquitylation and turnover of cytosolic misfolded 
proteins. Nat Cell Biol 13: 1344-52. 
FARGNOLI, J., KUNISADA, T., FORNACE, A.J., JR., SCHNEIDER, E.L. & HOLBROOK, N.J. 
1990. Decreased expression of heat shock protein 70 mRNA and protein after 
heat treatment in cells of aged rats. Proc Natl Acad Sci U S A 87: 846-50. 
FARRELL, P.J., BROEZE, R.J. & LENGYEL, P. 1979. Accumulation of an mRNA and 
protein in interferon-treated Ehrlich ascites tumour cells. Nature 279: 523-5. 
FERRINGTON, D.A., HUSOM, A.D. & THOMPSON, L.V. 2005. Altered proteasome 
structure, function, and oxidation in aged muscle. FASEB J 19: 644-6. 
FINLEY, D., BARTEL, B. & VARSHAVSKY, A. 1989. The tails of ubiquitin precursors are 
ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. 
Nature 338: 394-401. 
FINLEY, D., ULRICH, H.D., SOMMER, T. & KAISER, P. 2012. The ubiquitin-proteasome 
system of Saccharomyces cerevisiae. Genetics 192: 319-60. 
FRIAS-STAHELI, N., GIANNAKOPOULOS, N.V., KIKKERT, M., TAYLOR, S.L., BRIDGEN, A., 
PARAGAS, J., RICHT, J.A., ROWLAND, R.R., SCHMALJOHN, C.S., LENSCHOW, D.J., 
 138 
SNIJDER, E.J., GARCIA-SASTRE, A. & VIRGIN, H.W.T. 2007. Ovarian tumor 
domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate 
immune responses. Cell Host Microbe 2: 404-16. 
FRIGUET, B., BULTEAU, A.L., CHONDROGIANNI, N., CONCONI, M. & PETROPOULOS, I. 
2000. Protein degradation by the proteasome and its implications in aging. Ann N 
Y Acad Sci 908: 143-54. 
FRYDMAN, J., ERDJUMENT-BROMAGE, H., TEMPST, P. & HARTL, F.U. 1999. Co-
translational domain folding as the structural basis for the rapid de novo folding 
of firefly luciferase. Nat Struct Biol 6: 697-705. 
FUJIWARA, K., ISHIHAMA, Y., NAKAHIGASHI, K., SOGA, T. & TAGUCHI, H. 2010. A 
systematic survey of in vivo obligate chaperonin-dependent substrates. EMBO J 
29: 1552-64. 
GIANNAKOPOULOS, N.V., LUO, J.K., PAPOV, V., ZOU, W., LENSCHOW, D.J., JACOBS, B.S., 
BORDEN, E.C., LI, J., VIRGIN, H.W. & ZHANG, D.E. 2005. Proteomic 
identification of proteins conjugated to ISG15 in mouse and human cells. 
Biochem Biophys Res Commun 336: 496-506. 
GIANNAKOPOULOS, N.V., ARUTYUNOVA, E., LAI, C., LENSCHOW, D.J., HAAS, A.L. & 
VIRGIN, H.W. 2009. ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L 
are important for innate immune control of Sindbis virus. J Virol 83: 1602-10. 
GOLDBERG, A.L. & ST JOHN, A.C. 1976. Intracellular protein degradation in mammalian 
and bacterial cells: Part 2. Annu Rev Biochem 45: 747-803. 
GOLDKNOPF, I.L. & BUSCH, H. 1977. Isopeptide linkage between nonhistone and histone 
2A polypeptides of chromosomal conjugate-protein A24. Proc Natl Acad Sci U S 
A 74: 864-8. 
GOLDSTEIN, G., SCHEID, M., HAMMERLING, U., SCHLESINGER, D.H., NIALL, H.D. & 
BOYSE, E.A. 1975. Isolation of a polypeptide that has lymphocyte-differentiating 
properties and is probably represented universally in living cells. Proc Natl Acad 
Sci U S A 72: 11-5. 
GOLL, D.E., NETI, G., MARES, S.W. & THOMPSON, V.F. 2008. Myofibrillar protein 
turnover: the proteasome and the calpains. J Anim Sci 86: E19-35. 
GROLL, M., DITZEL, L., LOWE, J., STOCK, D., BOCHTLER, M., BARTUNIK, H.D. & HUBER, 
R. 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386: 
463-71. 
GUERRA, S., CACERES, A., KNOBELOCH, K.P., HORAK, I. & ESTEBAN, M. 2008. Vaccinia 
virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4: 
e1000096. 
HAAS, A.L., WARMS, J.V., HERSHKO, A. & ROSE, I.A. 1982. Ubiquitin-activating 
enzyme. Mechanism and role in protein-ubiquitin conjugation. J Biol Chem 257: 
2543-8. 
HAAS, A.L. & WILKINSON, K.D. 2008. DeTEKting ubiquitination of APC/C substrates. 
Cell 133: 570-2. 
HALLER, O., STAEHELI, P. & KOCHS, G. 2007. Interferon-induced Mx proteins in antiviral 
host defense. Biochimie 89: 812-8. 
 139 
HANSEN, M., TAUBERT, S., CRAWFORD, D., LIBINA, N., LEE, S.J. & KENYON, C. 2007. 
Lifespan extension by conditions that inhibit translation in Caenorhabditis 
elegans. Aging Cell 6: 95-110. 
HANSON, P.I. & WHITEHEART, S.W. 2005. AAA+ proteins: have engine, will work. Nat 
Rev Mol Cell Biol 6: 519-29. 
HARMAN, D. 1956. Aging: a theory based on free radical and radiation chemistry. J 
Gerontol 11: 298-300. 
HARRISON, D.E., STRONG, R., SHARP, Z.D., NELSON, J.F., ASTLE, C.M., FLURKEY, K., 
NADON, N.L., WILKINSON, J.E., FRENKEL, K., CARTER, C.S., PAHOR, M., JAVORS, 
M.A., FERNANDEZ, E. & MILLER, R.A. 2009. Rapamycin fed late in life extends 
lifespan in genetically heterogeneous mice. Nature 460: 392-5. 
HARTL, F.U., BRACHER, A. & HAYER-HARTL, M. Molecular chaperones in protein 
folding and proteostasis. Nature 475: 324-32. 
HARTL, F.U. & HAYER-HARTL, M. 2009. Converging concepts of protein folding in vitro 
and in vivo. Nat Struct Mol Biol 16: 574-81. 
HARTL, F.U., BRACHER, A. & HAYER-HARTL, M. 2011. Molecular chaperones in protein 
folding and proteostasis. Nature 475: 324-32. 
HAYDEN, M.S. & GHOSH, S. 2008. Shared principles in NF-kappaB signaling. Cell 132: 
344-62. 
HERRMANN, J., LERMAN, L.O. & LERMAN, A. 2010. On to the road to degradation: 
atherosclerosis and the proteasome. Cardiovasc Res 85: 291-302. 
HERSHKO, A., CIECHANOVER, A., HELLER, H., HAAS, A.L. & ROSE, I.A. 1980. Proposed 
role of ATP in protein breakdown: conjugation of protein with multiple chains of 
the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A 77: 
1783-6. 
HERSHKO, A., CIECHANOVER, A. & ROSE, I.A. 1981. Identification of the active amino 
acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol 
Chem 256: 1525-8. 
HERSHKO, A., HELLER, H., ELIAS, S. & CIECHANOVER, A. 1983. Components of 
ubiquitin-protein ligase system. Resolution, affinity purification, and role in 
protein breakdown. J Biol Chem 258: 8206-14. 
HERSHKO, A., LESHINSKY, E., GANOTH, D. & HELLER, H. 1984. ATP-dependent 
degradation of ubiquitin-protein conjugates. Proc Natl Acad Sci U S A 81: 1619-
23. 
HEYDARI, A.R., YOU, S., TAKAHASHI, R., GUTSMANN-CONRAD, A., SARGE, K.D. & 
RICHARDSON, A. 2000. Age-related alterations in the activation of heat shock 
transcription factor 1 in rat hepatocytes. Exp Cell Res 256: 83-93. 
HIPP, M.S., KALVERAM, B., RAASI, S., GROETTRUP, M. & SCHMIDTKE, G. 2005. FAT10, a 
ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 25: 
3483-91. 
HIRSCH, C., GAUSS, R., HORN, S.C., NEUBER, O. & SOMMER, T. 2009. The ubiquitylation 
machinery of the endoplasmic reticulum. Nature 458: 453-60. 
 140 
HOLCIK, M. & SONENBERG, N. 2005. Translational control in stress and apoptosis. Nat 
Rev Mol Cell Biol 6: 318-27. 
HORWICH, A.L. & FENTON, W.A. 2009. Chaperonin-mediated protein folding: using a 
central cavity to kinetically assist polypeptide chain folding. Q Rev Biophys 42: 
83-116. 
HOTOKEZAKA, Y., VAN LEYEN, K., LO, E.H., BEATRIX, B., KATAYAMA, I., JIN, G. & 
NAKAMURA, T. 2009. alphaNAC depletion as an initiator of ER stress-induced 
apoptosis in hypoxia. Cell Death Differ 16: 1505-14. 
HOUGH, R., PRATT, G. & RECHSTEINER, M. 1987. Purification of two high molecular 
weight proteases from rabbit reticulocyte lysate. J Biol Chem 262: 8303-13. 
HSIANG, T.Y., ZHAO, C. & KRUG, R.M. 2009. Interferon-induced ISG15 conjugation 
inhibits influenza A virus gene expression and replication in human cells. J Virol 
83: 5971-7. 
HUANG, D.T., PAYDAR, A., ZHUANG, M., WADDELL, M.B., HOLTON, J.M. & SCHULMAN, 
B.A. 2005. Structural basis for recruitment of Ubc12 by an E2 binding domain in 
NEDD8's E1. Mol Cell 17: 341-50. 
HUANG, L., KINNUCAN, E., WANG, G., BEAUDENON, S., HOWLEY, P.M., HUIBREGTSE, 
J.M. & PAVLETICH, N.P. 1999. Structure of an E6AP-UbcH7 complex: insights 
into ubiquitination by the E2-E3 enzyme cascade. Science 286: 1321-6. 
HUIBREGTSE, J.M., SCHEFFNER, M. & HOWLEY, P.M. 1991. A cellular protein mediates 
association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 
18. EMBO J 10: 4129-35. 
HUIBREGTSE, J.M., SCHEFFNER, M., BEAUDENON, S. & HOWLEY, P.M. 1995. A family of 
proteins structurally and functionally related to the E6-AP ubiquitin-protein 
ligase. Proc Natl Acad Sci U S A 92: 5249. 
IVANKOV, D.N., GARBUZYNSKIY, S.O., ALM, E., PLAXCO, K.W., BAKER, D. & 
FINKELSTEIN, A.V. 2003. Contact order revisited: influence of protein size on the 
folding rate. Protein Sci 12: 2057-62. 
IWAI, K. & TOKUNAGA, F. 2009. Linear polyubiquitination: a new regulator of NF-
kappaB activation. EMBO Rep 10: 706-13. 
JAGANNATHAN, S., NWOSU, C. & NICCHITTA, C.V. 2011. Analyzing mRNA localization 
to the endoplasmic reticulum via cell fractionation. Methods Mol Biol 714: 301-
21. 
JAHNGEN, J.H., LIPMAN, R.D., EISENHAUER, D.A., JAHNGEN, E.G., JR. & TAYLOR, A. 
1990. Aging and cellular maturation cause changes in ubiquitin-eye lens protein 
conjugates. Arch Biochem Biophys 276: 32-7. 
JAISWAL, H., CONZ, C., OTTO, H., WOLFLE, T., FITZKE, E., MAYER, M.P. & ROSPERT, S. 
2011. The chaperone network connected to human ribosome-associated complex. 
Mol Cell Biol 31: 1160-73. 
JENTSCH, S. & RUMPF, S. 2007. Cdc48 (p97): a "molecular gearbox" in the ubiquitin 
pathway? Trends Biochem Sci 32: 6-11. 
JIN, J., LI, X., GYGI, S.P. & HARPER, J.W. 2007. Dual E1 activation systems for ubiquitin 
differentially regulate E2 enzyme charging. Nature 447: 1135-8. 
 141 
JIN, L., WILLIAMSON, A., BANERJEE, S., PHILIPP, I. & RAPE, M. 2008. Mechanism of 
ubiquitin-chain formation by the human anaphase-promoting complex. Cell 133: 
653-65. 
JOAZEIRO, C.A., WING, S.S., HUANG, H., LEVERSON, J.D., HUNTER, T. & LIU, Y.C. 1999. 
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent 
ubiquitin-protein ligase. Science 286: 309-12. 
JOHNSON, S.C., RABINOVITCH, P.S. & KAEBERLEIN, M. 2013. mTOR is a key modulator 
of ageing and age-related disease. Nature 493: 338-45. 
KAEBERLEIN, M. & KENNEDY, B.K. 2007. Protein translation, 2007. Aging Cell 6: 731-4. 
KAGANOVICH, D., KOPITO, R. & FRYDMAN, J. 2008. Misfolded proteins partition between 
two distinct quality control compartments. Nature 454: 1088-95. 
KAMADA, Y., FUNAKOSHI, T., SHINTANI, T., NAGANO, K., OHSUMI, M. & OHSUMI, Y. 
2000. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. 
J Cell Biol 150: 1507-13. 
KAMPINGA, H.H. & CRAIG, E.A. 2010. The HSP70 chaperone machinery: J proteins as 
drivers of functional specificity. Nat Rev Mol Cell Biol 11: 579-92. 
KAUL, S.C., YAGUCHI, T., TAIRA, K., REDDEL, R.R. & WADHWA, R. 2003. Overexpressed 
mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro 
lifespan of human fibroblasts. Exp Cell Res 286: 96-101. 
KELKAR, D.A., KHUSHOO, A., YANG, Z. & SKACH, W.R. 2012. Kinetic analysis of 
ribosome-bound fluorescent proteins reveals an early, stable, cotranslational 
folding intermediate. J Biol Chem 287: 2568-78. 
KELLER, J.N., HUANG, F.F. & MARKESBERY, W.R. 2000. Decreased levels of proteasome 
activity and proteasome expression in aging spinal cord. Neuroscience 98: 149-
56. 
KELLEY, M.L., KEIGER, K.E., LEE, C.J. & HUIBREGTSE, J.M. 2005. The global 
transcriptional effects of the human papillomavirus E6 protein in cervical 
carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 79: 3737-
47. 
KERNER, M.J., NAYLOR, D.J., ISHIHAMA, Y., MAIER, T., CHANG, H.C., STINES, A.P., 
GEORGOPOULOS, C., FRISHMAN, D., HAYER-HARTL, M., MANN, M. & HARTL, 
F.U. 2005. Proteome-wide analysis of chaperonin-dependent protein folding in 
Escherichia coli. Cell 122: 209-20. 
KETSCHER, L., BASTERS, A., PRINZ, M. & KNOBELOCH, K.P. 2012. mHERC6 is the 
essential ISG15 E3 ligase in the murine system. Biochem Biophys Res Commun 
417: 135-40. 
KIM, H.C. & HUIBREGTSE, J.M. 2009. Polyubiquitination by HECT E3s and the 
determinants of chain type specificity. Mol Cell Biol 29: 3307-18. 
KIM, H.C., STEFFEN, A.M., OLDHAM, M.L., CHEN, J. & HUIBREGTSE, J.M. 2011a. 
Structure and function of a HECT domain ubiquitin-binding site. EMBO Rep 12: 
334-41. 
KIM, W., BENNETT, E.J., HUTTLIN, E.L., GUO, A., LI, J., POSSEMATO, A., SOWA, M.E., 
RAD, R., RUSH, J., COMB, M.J., HARPER, J.W. & GYGI, S.P. 2011b. Systematic 
 142 
and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44: 
325-40. 
KIM, Y.E., HIPP, M.S., BRACHER, A., HAYER-HARTL, M. & HARTL, F.U. 2013. Molecular 
chaperone functions in protein folding and proteostasis. Annu Rev Biochem 82: 
323-55. 
KIMURA, Y. & TANAKA, K. 2010. Regulatory mechanisms involved in the control of 
ubiquitin homeostasis. J Biochem 147: 793-8. 
KIRAGA, J., MACKIEWICZ, P., MACKIEWICZ, D., KOWALCZUK, M., BIECEK, P., POLAK, N., 
SMOLARCZYK, K., DUDEK, M.R. & CEBRAT, S. 2007. The relationships between 
the isoelectric point and: length of proteins, taxonomy and ecology of organisms. 
BMC Genomics 8: 163. 
KISSELEV, A.F., AKOPIAN, T.N., WOO, K.M. & GOLDBERG, A.L. 1999. The sizes of 
peptides generated from protein by mammalian 26 and 20 S proteasomes. 
Implications for understanding the degradative mechanism and antigen 
presentation. J Biol Chem 274: 3363-71. 
KLASS, M.R. 1983. A method for the isolation of longevity mutants in the nematode 
Caenorhabditis elegans and initial results. Mech Ageing Dev 22: 279-86. 
KLIONSKY, D.J., BAEHRECKE, E.H., BRUMELL, J.H., CHU, C.T., CODOGNO, P., CUERVO, 
A.M., DEBNATH, J., DERETIC, V., ELAZAR, Z., ESKELINEN, E.L., FINKBEINER, S., 
FUEYO-MARGARETO, J., GEWIRTZ, D., JAATTELA, M., KROEMER, G., LEVINE, B., 
MELIA, T.J., MIZUSHIMA, N., RUBINSZTEIN, D.C., SIMONSEN, A., THORBURN, A., 
THUMM, M. & TOOZE, S.A. 2011. A comprehensive glossary of autophagy-related 
molecules and processes (2nd edition). Autophagy 7: 1273-94. 
KNOBELOCH, K.P., UTERMOHLEN, O., KISSER, A., PRINZ, M. & HORAK, I. 2005. 
Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of 
UBP43-deficient mice. Mol Cell Biol 25: 11030-4. 
KNOWLES, S.E. & BALLARD, F.J. 1976. Selective control of the degradation of normal 
and aberrant proteins in Reuber H35 hepatoma cells. Biochem J 156: 609-17. 
KOGA, H., KAUSHIK, S. & CUERVO, A.M. 2011. Protein homeostasis and aging: The 
importance of exquisite quality control. Ageing Res Rev 10: 205-15. 
KOMANDER, D., CLAGUE, M.J. & URBE, S. 2009. Breaking the chains: structure and 
function of the deubiquitinases. Nat Rev Mol Cell Biol 10: 550-63. 
KOMATSU, M., WAGURI, S., UENO, T., IWATA, J., MURATA, S., TANIDA, I., EZAKI, J., 
MIZUSHIMA, N., OHSUMI, Y., UCHIYAMA, Y., KOMINAMI, E., TANAKA, K. & 
CHIBA, T. 2005. Impairment of starvation-induced and constitutive autophagy in 
Atg7-deficient mice. J Cell Biol 169: 425-34. 
KRUEGEL, U., ROBISON, B., DANGE, T., KAHLERT, G., DELANEY, J.R., KOTIREDDY, S., 
TSUCHIYA, M., TSUCHIYAMA, S., MURAKAMI, C.J., SCHLEIT, J., SUTPHIN, G., 
CARR, D., TAR, K., DITTMAR, G., KAEBERLEIN, M., KENNEDY, B.K. & SCHMIDT, 
M. 2011. Elevated proteasome capacity extends replicative lifespan in 
Saccharomyces cerevisiae. PLoS Genet 7: e1002253. 
KUSUMAWIDJAJA, G., KAYED, H., GIESE, N., BAUER, A., ERKAN, M., GIESE, T., HOHEISE, 
J.D., FRIESS, H. & KLEEFF, J. 2007. Basic transcription factor 3 (BTF3) regulates 
 143 
transcription of tumor-associated genes in pancreatic cancer cells. Cancer Biol 
Ther 6: 367-76. 
LAI, C., STRUCKHOFF, J.J., SCHNEIDER, J., MARTINEZ-SOBRIDO, L., WOLFF, T., GARCIA-
SASTRE, A., ZHANG, D.E. & LENSCHOW, D.J. 2009. Mice lacking the ISG15 E1 
enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and 
non-mouse-adapted influenza B virus infection. J Virol 83: 1147-51. 
LAKE, M.W., WUEBBENS, M.M., RAJAGOPALAN, K.V. & SCHINDELIN, H. 2001. 
Mechanism of ubiquitin activation revealed by the structure of a bacterial MoeB-
MoaD complex. Nature 414: 325-9. 
LANDER, G.C., ESTRIN, E., MATYSKIELA, M.E., BASHORE, C., NOGALES, E. & MARTIN, 
A. 2012. Complete subunit architecture of the proteasome regulatory particle. 
Nature 482: 186-91. 
LEE, J., GIORDANO, S. & ZHANG, J. 2012. Autophagy, mitochondria and oxidative stress: 
cross-talk and redox signalling. Biochem J 441: 523-40. 
LEE, J.W., BEEBE, K., NANGLE, L.A., JANG, J., LONGO-GUESS, C.M., COOK, S.A., 
DAVISSON, M.T., SUNDBERG, J.P., SCHIMMEL, P. & ACKERMAN, S.L. 2006. 
Editing-defective tRNA synthetase causes protein misfolding and 
neurodegeneration. Nature 443: 50-5. 
LEIDEL, S., PEDRIOLI, P.G., BUCHER, T., BROST, R., COSTANZO, M., SCHMIDT, A., 
AEBERSOLD, R., BOONE, C., HOFMANN, K. & PETER, M. 2009. Ubiquitin-related 
modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. 
Nature 458: 228-32. 
LEIMKUHLER, S., WUEBBENS, M.M. & RAJAGOPALAN, K.V. 2001. Characterization of 
Escherichia coli MoeB and its involvement in the activation of molybdopterin 
synthase for the biosynthesis of the molybdenum cofactor. J Biol Chem 276: 
34695-701. 
LENSCHOW, D.J., GIANNAKOPOULOS, N.V., GUNN, L.J., JOHNSTON, C., O'GUIN, A.K., 
SCHMIDT, R.E., LEVINE, B. & VIRGIN, H.W.T. 2005. Identification of interferon-
stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. 
J Virol 79: 13974-83. 
LEU, J.I., PIMKINA, J., FRANK, A., MURPHY, M.E. & GEORGE, D.L. 2009. A small 
molecule inhibitor of inducible heat shock protein 70. Mol Cell 36: 15-27. 
LEVINE, C.G., MITRA, D., SHARMA, A., SMITH, C.L. & HEGDE, R.S. 2005. The efficiency 
of protein compartmentalization into the secretory pathway. Mol Biol Cell 16: 
279-91. 
LINDNER, H.A., LYTVYN, V., QI, H., LACHANCE, P., ZIOMEK, E. & MENARD, R. 2007. 
Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-
like protease. Arch Biochem Biophys 466: 8-14. 
LINDSTROM, D.L. & GOTTSCHLING, D.E. 2009. The mother enrichment program: a 
genetic system for facile replicative life span analysis in Saccharomyces 
cerevisiae. Genetics 183: 413-22, 1SI-13SI. 
LIU, B., HAN, Y. & QIAN, S.B. 2013. Cotranslational response to proteotoxic stress by 
elongation pausing of ribosomes. Mol Cell 49: 453-63. 
 144 
LIU, G., ROGERS, J., MURPHY, C.T. & RONGO, C. 2011. EGF signalling activates the 
ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J 30: 2990-
3003. 
LOPEZ-OTIN, C., BLASCO, M.A., PARTRIDGE, L., SERRANO, M. & KROEMER, G. 2013. The 
hallmarks of aging. Cell 153: 1194-217. 
LOWE, J., STOCK, D., JAP, B., ZWICKL, P., BAUMEISTER, W. & HUBER, R. 1995. Crystal 
structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A 
resolution. Science 268: 533-9. 
LU, G., REINERT, J.T., PITHA-ROWE, I., OKUMURA, A., KELLUM, M., KNOBELOCH, K.P., 
HASSEL, B. & PITHA, P.M. 2006. ISG15 enhances the innate antiviral response by 
inhibition of IRF-3 degradation. Cell Mol Biol (Noisy-le-grand) 52: 29-41. 
MAKDE, R.D., ENGLAND, J.R., YENNAWAR, H.P. & TAN, S. 2010. Structure of RCC1 
chromatin factor bound to the nucleosome core particle. Nature 467: 562-6. 
MALAKHOV, M.P., MALAKHOVA, O.A., KIM, K.I., RITCHIE, K.J. & ZHANG, D.E. 2002. 
UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol 
Chem 277: 9976-81. 
MALAKHOV, M.P., KIM, K.I., MALAKHOVA, O.A., JACOBS, B.S., BORDEN, E.C. & ZHANG, 
D.E. 2003. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 
modifies key regulators of signal transduction. J Biol Chem 278: 16608-13. 
MALAKHOVA, O.A., KIM, K.I., LUO, J.K., ZOU, W., KUMAR, K.G., FUCHS, S.Y., SHUAI, 
K. & ZHANG, D.E. 2006. UBP43 is a novel regulator of interferon signaling 
independent of its ISG15 isopeptidase activity. EMBO J 25: 2358-67. 
MCCLELLAN, A.J., TAM, S., KAGANOVICH, D. & FRYDMAN, J. 2005. Protein quality 
control: chaperones culling corrupt conformations. Nat Cell Biol 7: 736-41. 
MCKIBBIN, C., MARES, A., PIACENTI, M., WILLIAMS, H., ROBOTI, P., PUUMALAINEN, M., 
CALLAN, A.C., LESIAK-MIECZKOWSKA, K., LINDER, S., HARANT, H., HIGH, S., 
FLITSCH, S.L., WHITEHEAD, R.C. & SWANTON, E. 2012. Inhibition of protein 
translocation at the endoplasmic reticulum promotes activation of the unfolded 
protein response. Biochem J 442: 639-48. 
MEDVEDIK, O., LAMMING, D.W., KIM, K.D. & SINCLAIR, D.A. 2007. MSN2 and MSN4 
link calorie restriction and TOR to sirtuin-mediated lifespan extension in 
Saccharomyces cerevisiae. PLoS Biol 5: e261. 
MIN, J.N., WHALEY, R.A., SHARPLESS, N.E., LOCKYER, P., PORTBURY, A.L. & 
PATTERSON, C. 2008. CHIP deficiency decreases longevity, with accelerated 
aging phenotypes accompanied by altered protein quality control. Mol Cell Biol 
28: 4018-25. 
MOGENSEN, T.H. 2009. Pathogen recognition and inflammatory signaling in innate 
immune defenses. Clin Microbiol Rev 22: 240-73, Table of Contents. 
MOORE, S.A., LOPEZ, A., RICHARDSON, A. & PAHLAVANI, M.A. 1998. Effect of age and 
dietary restriction on expression of heat shock protein 70 in rat alveolar 
macrophages. Mech Ageing Dev 104: 59-73. 
MORETT, E. & BORK, P. 1999. A novel transactivation domain in parkin. Trends Biochem 
Sci 24: 229-31. 
 145 
MORIMOTO, R.I. 2008. Proteotoxic stress and inducible chaperone networks in 
neurodegenerative disease and aging. Genes Dev 22: 1427-38. 
MOSKALEV, A.A., SHAPOSHNIKOV, M.V., PLYUSNINA, E.N., ZHAVORONKOV, A., 
BUDOVSKY, A., YANAI, H. & FRAIFELD, V.E. 2013. The role of DNA damage and 
repair in aging through the prism of Koch-like criteria. Ageing Res Rev 12: 661-
84. 
MUNOZ, M.J. 2003. Longevity and heat stress regulation in Caenorhabditis elegans. Mech 
Ageing Dev 124: 43-8. 
MURROW, L. & DEBNATH, J. 2013. Autophagy as a stress-response and quality-control 
mechanism: implications for cell injury and human disease. Annu Rev Pathol 8: 
105-37. 
NAKASATO, N., IKEDA, K., URANO, T., HORIE-INOUE, K., TAKEDA, S. & INOUE, S. 2006. 
A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with 
ISG15. Biochem Biophys Res Commun 351: 540-6. 
NARASIMHAN, J., WANG, M., FU, Z., KLEIN, J.M., HAAS, A.L. & KIM, J.J. 2005. Crystal 
structure of the interferon-induced ubiquitin-like protein ISG15. J Biol Chem 280: 
27356-65. 
NEFF, N.T., DEMARTINO, G.N. & GOLDBERG, A.L. 1979. The effect of protease inhibitors 
and decreased temperature on the degradation of different classes of proteins in 
cultured hepatocytes. J Cell Physiol 101: 439-57. 
NETZER, W.J. & HARTL, F.U. 1997. Recombination of protein domains facilitated by co-
translational folding in eukaryotes. Nature 388: 343-9. 
NOMA, A., SAKAGUCHI, Y. & SUZUKI, T. 2009. Mechanistic characterization of the 
sulfur-relay system for eukaryotic 2-thiouridine biogenesis at tRNA wobble 
positions. Nucleic Acids Res 37: 1335-52. 
NUSS, J.E., CHOKSI, K.B., DEFORD, J.H. & PAPACONSTANTINOU, J. 2008. Decreased 
enzyme activities of chaperones PDI and BiP in aged mouse livers. Biochem 
Biophys Res Commun 365: 355-61. 
NUSSBAUM, A.K., DICK, T.P., KEILHOLZ, W., SCHIRLE, M., STEVANOVIC, S., DIETZ, K., 
HEINEMEYER, W., GROLL, M., WOLF, D.H., HUBER, R., RAMMENSEE, H.G. & 
SCHILD, H. 1998. Cleavage motifs of the yeast 20S proteasome beta subunits 
deduced from digests of enolase 1. Proc Natl Acad Sci U S A 95: 12504-9. 
O'ROURKE, E.J., KUBALLA, P., XAVIER, R. & RUVKUN, G. 2013. omega-6 
Polyunsaturated fatty acids extend life span through the activation of autophagy. 
Genes Dev 27: 429-40. 
OGLE, J.M. & RAMAKRISHNAN, V. 2005. Structural insights into translational fidelity. 
Annu Rev Biochem 74: 129-77. 
OKUMURA, A., LU, G., PITHA-ROWE, I. & PITHA, P.M. 2006. Innate antiviral response 
targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl 
Acad Sci U S A 103: 1440-5. 
OKUMURA, A., PITHA, P.M. & HARTY, R.N. 2008. ISG15 inhibits Ebola VP40 VLP 
budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. 
Proc Natl Acad Sci U S A 105: 3974-9. 
 146 
OLZSCHA, H., SCHERMANN, S.M., WOERNER, A.C., PINKERT, S., HECHT, M.H., 
TARTAGLIA, G.G., VENDRUSCOLO, M., HAYER-HARTL, M., HARTL, F.U. & 
VABULAS, R.M. 2011. Amyloid-like aggregates sequester numerous metastable 
proteins with essential cellular functions. Cell 144: 67-78. 
ORLOWSKI, M. & ROSS, J.F. 1981. Relationship of internal cyclic AMP levels, rates of 
protein synthesis and mucor dimorphism. Arch Microbiol 129: 353-6. 
OUDSHOORN, D., VAN BOHEEMEN, S., SANCHEZ-APARICIO, M.T., RAJSBAUM, R., GARCIA-
SASTRE, A. & VERSTEEG, G.A. 2012. HERC6 is the main E3 ligase for global 
ISG15 conjugation in mouse cells. PLoS One 7: e29870. 
OUELLET, J. & BARRAL, Y. 2012. Organelle segregation during mitosis: lessons from 
asymmetrically dividing cells. J Cell Biol 196: 305-13. 
OUYANG, Z. & LIANG, J. 2008. Predicting protein folding rates from geometric contact 
and amino acid sequence. Protein Sci 17: 1256-63. 
PAHLAVANI, M.A., HARRIS, M.D., MOORE, S.A., WEINDRUCH, R. & RICHARDSON, A. 
1995. The expression of heat shock protein 70 decreases with age in lymphocytes 
from rats and rhesus monkeys. Exp Cell Res 218: 310-8. 
PAN, K.Z., PALTER, J.E., ROGERS, A.N., OLSEN, A., CHEN, D., LITHGOW, G.J. & KAPAHI, 
P. 2007. Inhibition of mRNA translation extends lifespan in Caenorhabditis 
elegans. Aging Cell 6: 111-9. 
PANDEY, U.B., NIE, Z., BATLEVI, Y., MCCRAY, B.A., RITSON, G.P., NEDELSKY, N.B., 
SCHWARTZ, S.L., DIPROSPERO, N.A., KNIGHT, M.A., SCHULDINER, O., 
PADMANABHAN, R., HILD, M., BERRY, D.L., GARZA, D., HUBBERT, C.C., YAO, 
T.P., BAEHRECKE, E.H. & TAYLOR, J.P. 2007. HDAC6 rescues neurodegeneration 
and provides an essential link between autophagy and the UPS. Nature 447: 859-
63. 
PASSMORE, L.A. & BARFORD, D. 2004. Getting into position: the catalytic mechanisms of 
protein ubiquitylation. Biochem J 379: 513-25. 
PECHMANN, S., WILLMUND, F. & FRYDMAN, J. 2013. The ribosome as a hub for protein 
quality control. Mol Cell 49: 411-21. 
PESTKA, S. 1971. Inhibitors of ribosome functions. Annu Rev Microbiol 25: 487-562. 
PETROSKI, M.D. & DESHAIES, R.J. 2005. Function and regulation of cullin-RING 
ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20. 
PICKART, C.M. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 
503-33. 
PICKRELL, J.K., PAI, A.A., GILAD, Y. & PRITCHARD, J.K. 2010. Noisy splicing drives 
mRNA isoform diversity in human cells. PLoS Genet 6: e1001236. 
POOLE, B. & WIBO, M. 1973. Protein degradation in cultured cells. The effect of fresh 
medium, fluoride, and iodoacetate on the digestion of cellular protein of rat 
fibroblasts. J Biol Chem 248: 6221-6. 
POOLE, B., OHKUMA, S. & WARBURTON, M.J. 1977. The accumulation of weakly basic 
substances in lysosomes and the inhibition of intracellular protein degradation. 
Acta Biol Med Ger 36: 1777-88. 
 147 
POTU, H., SGORBISSA, A. & BRANCOLINI, C. 2010. Identification of USP18 as an 
important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. 
Cancer Res 70: 655-65. 
POWERS, E.T., MORIMOTO, R.I., DILLIN, A., KELLY, J.W. & BALCH, W.E. 2009. 
Biological and chemical approaches to diseases of proteostasis deficiency. Annu 
Rev Biochem 78: 959-91. 
POWERS, R.W., 3RD, KAEBERLEIN, M., CALDWELL, S.D., KENNEDY, B.K. & FIELDS, S. 
2006. Extension of chronological life span in yeast by decreased TOR pathway 
signaling. Genes Dev 20: 174-84. 
PREISSLER, S. & DEUERLING, E. 2012. Ribosome-associated chaperones as key players in 
proteostasis. Trends Biochem Sci 37: 274-83. 
PRINCIOTTA, M.F., FINZI, D., QIAN, S.B., GIBBS, J., SCHUCHMANN, S., BUTTGEREIT, F., 
BENNINK, J.R. & YEWDELL, J.W. 2003. Quantitating protein synthesis, 
degradation, and endogenous antigen processing. Immunity 18: 343-54. 
QIAN, S.B., BENNINK, J.R. & YEWDELL, J.W. 2005. Quantitating defective ribosome 
products. Methods Mol Biol 301: 271-81. 
QIAN, S.B., PRINCIOTTA, M.F., BENNINK, J.R. & YEWDELL, J.W. 2006. Characterization 
of rapidly degraded polypeptides in mammalian cells reveals a novel layer of 
nascent protein quality control. J Biol Chem 281: 392-400. 
RANI, N., AICHEM, A., SCHMIDTKE, G., KREFT, S.G. & GROETTRUP, M. 2012. FAT10 and 
NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-
mediated proteolysis. Nat Commun 3: 749. 
RAPE, M. 2009. Ubiquitin, infinitely seductive: symposium on the many faces of 
ubiquitin. EMBO Rep 10: 558-62. 
REITS, E.A., VOS, J.C., GROMME, M. & NEEFJES, J. 2000. The major substrates for TAP 
in vivo are derived from newly synthesized proteins. Nature 404: 774-8. 
ROGERS, A.N., CHEN, D., MCCOLL, G., CZERWIENIEC, G., FELKEY, K., GIBSON, B.W., 
HUBBARD, A., MELOV, S., LITHGOW, G.J. & KAPAHI, P. 2011. Life span extension 
via eIF4G inhibition is mediated by posttranscriptional remodeling of stress 
response gene expression in C. elegans. Cell Metab 14: 55-66. 
ROSPERT, S., DUBAQUIE, Y. & GAUTSCHI, M. 2002. Nascent-polypeptide-associated 
complex. Cell Mol Life Sci 59: 1632-9. 
ROSS, J.F. & ORLOWSKI, M. 1982. Growth-rate-dependent adjustment of ribosome 
function in chemostat-grown cells of the fungus Mucor racemosus. J Bacteriol 
149: 650-3. 
ROSSER, M.F., WASHBURN, E., MUCHOWSKI, P.J., PATTERSON, C. & CYR, D.M. 2007. 
Chaperone functions of the E3 ubiquitin ligase CHIP. J Biol Chem 282: 22267-
77. 
RUBINSZTEIN, D.C., MARINO, G. & KROEMER, G. 2011. Autophagy and aging. Cell 146: 
682-95. 
RUOTOLO, R., GRASSI, F., PERCUDANI, R., RIVETTI, C., MARTORANA, D., MARAINI, G. & 
OTTONELLO, S. 2003. Gene expression profiling in human age-related nuclear 
cataract. Mol Vis 9: 538-48. 
 148 
SALCEDA, S. & CARO, J. 1997. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is 
rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. 
Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 
22642-7. 
SATO, S., WARD, C.L. & KOPITO, R.R. 1998. Cotranslational ubiquitination of cystic 
fibrosis transmembrane conductance regulator in vitro. J Biol Chem 273: 7189-
92. 
SAUER, R.T. & BAKER, T.A. 2011. AAA+ proteases: ATP-fueled machines of protein 
destruction. Annu Rev Biochem 80: 587-612. 
SCHEFFNER, M., HUIBREGTSE, J.M., VIERSTRA, R.D. & HOWLEY, P.M. 1993. The HPV-16 
E6 and E6-AP complex functions as a ubiquitin-protein ligase in the 
ubiquitination of p53. Cell 75: 495-505. 
SCHEFFNER, M., NUBER, U. & HUIBREGTSE, J.M. 1995. Protein ubiquitination involving 
an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373: 81-3. 
SCHEFFNER, M. & KUMAR, S. 2014. Mammalian HECT ubiquitin-protein ligases: 
biological and pathophysiological aspects. Biochim Biophys Acta 1843: 61-74. 
SCHMIDTKE, G., KALVERAM, B. & GROETTRUP, M. 2009. Degradation of FAT10 by the 
26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 
583: 591-4. 
SCHOGGINS, J.W. & RICE, C.M. 2011. Interferon-stimulated genes and their antiviral 
effector functions. Curr Opin Virol 1: 519-25. 
SCHUBERT, U., ANTON, L.C., GIBBS, J., NORBURY, C.C., YEWDELL, J.W. & BENNINK, J.R. 
2000. Rapid degradation of a large fraction of newly synthesized proteins by 
proteasomes. Nature 404: 770-4. 
SCHULMAN, B.A. & HARPER, J.W. 2009. Ubiquitin-like protein activation by E1 
enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 
10: 319-31. 
SEBASTIAN, S. & LUBAN, J. 2005. TRIM5alpha selectively binds a restriction-sensitive 
retroviral capsid. Retrovirology 2: 40. 
SELMAN, C., TULLET, J.M., WIESER, D., IRVINE, E., LINGARD, S.J., CHOUDHURY, A.I., 
CLARET, M., AL-QASSAB, H., CARMIGNAC, D., RAMADANI, F., WOODS, A., 
ROBINSON, I.C., SCHUSTER, E., BATTERHAM, R.L., KOZMA, S.C., THOMAS, G., 
CARLING, D., OKKENHAUG, K., THORNTON, J.M., PARTRIDGE, L., GEMS, D. & 
WITHERS, D.J. 2009. Ribosomal protein S6 kinase 1 signaling regulates 
mammalian life span. Science 326: 140-4. 
SEN, G.C. & SARKAR, S.N. 2007. The interferon-stimulated genes: targets of direct 
signaling by interferons, double-stranded RNA, and viruses. Curr Top Microbiol 
Immunol 316: 233-50. 
SHA, Z., BRILL, L.M., CABRERA, R., KLEIFELD, O., SCHELIGA, J.S., GLICKMAN, M.H., 
CHANG, E.C. & WOLF, D.A. 2009. The eIF3 interactome reveals the translasome, 
a supercomplex linking protein synthesis and degradation machineries. Mol Cell 
36: 141-52. 
 149 
SHALGI, R., HURT, J.A., KRYKBAEVA, I., TAIPALE, M., LINDQUIST, S. & BURGE, C.B. 
2013. Widespread regulation of translation by elongation pausing in heat shock. 
Mol Cell 49: 439-52. 
SHAO, S., VON DER MALSBURG, K. & HEGDE, R.S. 2013. Listerin-dependent nascent 
protein ubiquitination relies on ribosome subunit dissociation. Mol Cell 50: 637-
48. 
SHOEMAKER, C.J. & GREEN, R. 2012. Translation drives mRNA quality control. Nat 
Struct Mol Biol 19: 594-601. 
SHRINGARPURE, R. & DAVIES, K.J. 2002. Protein turnover by the proteasome in aging and 
disease. Free Radic Biol Med 32: 1084-9. 
SINGH, R., KOLVRAA, S., BROSS, P., JENSEN, U.B., GREGERSEN, N., TAN, Q., KNUDSEN, 
C. & RATTAN, S.I. 2006. Reduced heat shock response in human mononuclear 
cells during aging and its association with polymorphisms in HSP70 genes. Cell 
Stress Chaperones 11: 208-15. 
SKAUG, B. & CHEN, Z.J. 2010. Emerging role of ISG15 in antiviral immunity. Cell 143: 
187-90. 
SMEAL, T., CLAUS, J., KENNEDY, B., COLE, F. & GUARENTE, L. 1996. Loss of 
transcriptional silencing causes sterility in old mother cells of S. cerevisiae. Cell 
84: 633-42. 
SMIT, J.J. & SIXMA, T.K. 2014. RBR E3-ligases at work. EMBO Rep 15: 142-54. 
SMITH, E.D., TSUCHIYA, M., FOX, L.A., DANG, N., HU, D., KERR, E.O., JOHNSTON, E.D., 
TCHAO, B.N., PAK, D.N., WELTON, K.L., PROMISLOW, D.E., THOMAS, J.H., 
KAEBERLEIN, M. & KENNEDY, B.K. 2008. Quantitative evidence for conserved 
longevity pathways between divergent eukaryotic species. Genome Res 18: 564-
70. 
SONTAG, E.M., VONK, W.I. & FRYDMAN, J. 2014. Sorting out the trash: the spatial nature 
of eukaryotic protein quality control. Curr Opin Cell Biol 26: 139-46. 
SPRIGGS, K.A., BUSHELL, M. & WILLIS, A.E. 2010. Translational regulation of gene 
expression during conditions of cell stress. Mol Cell 40: 228-37. 
STADTMAN, E.R., STARKE-REED, P.E., OLIVER, C.N., CARNEY, J.M. & FLOYD, R.A. 1992. 
Protein modification in aging. EXS 62: 64-72. 
STEFFEN, K.K., MACKAY, V.L., KERR, E.O., TSUCHIYA, M., HU, D., FOX, L.A., DANG, 
N., JOHNSTON, E.D., OAKES, J.A., TCHAO, B.N., PAK, D.N., FIELDS, S., KENNEDY, 
B.K. & KAEBERLEIN, M. 2008. Yeast life span extension by depletion of 60s 
ribosomal subunits is mediated by Gcn4. Cell 133: 292-302. 
STEVENS, T.J. & ARKIN, I.T. 2000. Do more complex organisms have a greater 
proportion of membrane proteins in their genomes? Proteins 39: 417-20. 
STEWART, M.L., GROLLMAN, A.P. & HUANG, M.T. 1971. Aurintricarboxylic acid: 
inhibitor of initiation of protein synthesis. Proc Natl Acad Sci U S A 68: 97-101. 
STREMLAU, M., OWENS, C.M., PERRON, M.J., KIESSLING, M., AUTISSIER, P. & SODROSKI, 
J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection 
in Old World monkeys. Nature 427: 848-53. 
 150 
STREMLAU, M., PERRON, M., LEE, M., LI, Y., SONG, B., JAVANBAKHT, H., DIAZ-
GRIFFERO, F., ANDERSON, D.J., SUNDQUIST, W.I. & SODROSKI, J. 2006. Specific 
recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha 
restriction factor. Proc Natl Acad Sci U S A 103: 5514-9. 
TAKEUCHI, T., INOUE, S. & YOKOSAWA, H. 2006. Identification and Herc5-mediated 
ISGylation of novel target proteins. Biochem Biophys Res Commun 348: 473-7. 
TALIS, A.L., HUIBREGTSE, J.M. & HOWLEY, P.M. 1998. The role of E6AP in the 
regulation of p53 protein levels in human papillomavirus (HPV)-positive and 
HPV-negative cells. J Biol Chem 273: 6439-45. 
TANAKA, K., WAXMAN, L. & GOLDBERG, A.L. 1983. ATP serves two distinct roles in 
protein degradation in reticulocytes, one requiring and one independent of 
ubiquitin. J Cell Biol 96: 1580-5. 
TATAR, M., KHAZAELI, A.A. & CURTSINGER, J.W. 1997. Chaperoning extended life. 
Nature 390: 30. 
TAYLOR, S.V., KELLEHER, N.L., KINSLAND, C., CHIU, H.J., COSTELLO, C.A., 
BACKSTROM, A.D., MCLAFFERTY, F.W. & BEGLEY, T.P. 1998. Thiamin 
biosynthesis in Escherichia coli. Identification of ThiS thiocarboxylate as the 
immediate sulfur donor in the thiazole formation. J Biol Chem 273: 16555-60. 
THOREEN, C.C., KANG, S.A., CHANG, J.W., LIU, Q., ZHANG, J., GAO, Y., REICHLING, L.J., 
SIM, T., SABATINI, D.M. & GRAY, N.S. 2009. An ATP-competitive mammalian 
target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J 
Biol Chem 284: 8023-32. 
THOREEN, C.C., CHANTRANUPONG, L., KEYS, H.R., WANG, T., GRAY, N.S. & SABATINI, 
D.M. 2012. A unifying model for mTORC1-mediated regulation of mRNA 
translation. Nature 485: 109-13. 
TURNER, G.C. & VARSHAVSKY, A. 2000. Detecting and measuring cotranslational protein 
degradation in vivo. Science 289: 2117-20. 
VABULAS, R.M. & HARTL, F.U. 2005. Protein synthesis upon acute nutrient restriction 
relies on proteasome function. Science 310: 1960-3. 
VAN DER REIJDEN, B.A., ERPELINCK-VERSCHUEREN, C.A., LOWENBERG, B. & JANSEN, 
J.H. 1999. TRIADs: a new class of proteins with a novel cysteine-rich signature. 
Protein Sci 8: 1557-61. 
VAN DER VEEN, A.G. & PLOEGH, H.L. 2012. Ubiquitin-like proteins. Annu Rev Biochem 
81: 323-57. 
VAN WIJK, S.J. & TIMMERS, H.T. 2010. The family of ubiquitin-conjugating enzymes 
(E2s): deciding between life and death of proteins. FASEB J 24: 981-93. 
VAYDA, M.E. 1995. Assessment of translational regulation by run-off translation of 
polysomes in vitro. Methods Cell Biol 50: 349-59. 
VERMA, R., ARAVIND, L., OANIA, R., MCDONALD, W.H., YATES, J.R., 3RD, KOONIN, E.V. 
& DESHAIES, R.J. 2002. Role of Rpn11 metalloprotease in deubiquitination and 
degradation by the 26S proteasome. Science 298: 611-5. 
 151 
VERMA, R., OANIA, R.S., KOLAWA, N.J. & DESHAIES, R.J. 2013. Cdc48/p97 promotes 
degradation of aberrant nascent polypeptides bound to the ribosome. Elife 2: 
e00308. 
VERNACE, V.A., ARNAUD, L., SCHMIDT-GLENEWINKEL, T. & FIGUEIREDO-PEREIRA, M.E. 
2007. Aging perturbs 26S proteasome assembly in Drosophila melanogaster. 
FASEB J 21: 2672-82. 
VERSTEEG, G.A., HALE, B.G., VAN BOHEEMEN, S., WOLFF, T., LENSCHOW, D.J. & 
GARCIA-SASTRE, A. 2010. Species-specific antagonism of host ISGylation by the 
influenza B virus NS1 protein. J Virol 84: 5423-30. 
VOISINE, C., PEDERSEN, J.S. & MORIMOTO, R.I. 2010. Chaperone networks: tipping the 
balance in protein folding diseases. Neurobiol Dis 40: 12-20. 
WALKER, G.A. & LITHGOW, G.J. 2003. Lifespan extension in C. elegans by a molecular 
chaperone dependent upon insulin-like signals. Aging Cell 2: 131-9. 
WANG, F., DURFEE, L.A. & HUIBREGTSE, J.M. 2013. A cotranslational ubiquitination 
pathway for quality control of misfolded proteins. Mol Cell 50: 368-78. 
WANG, L., DONG, H., SOROKA, C.J., WEI, N., BOYER, J.L. & HOCHSTRASSER, M. 2008. 
Degradation of the bile salt export pump at endoplasmic reticulum in progressive 
familial intrahepatic cholestasis type II. Hepatology 48: 1558-69. 
WAXMAN, L., FAGAN, J.M. & GOLDBERG, A.L. 1987. Demonstration of two distinct high 
molecular weight proteases in rabbit reticulocytes, one of which degrades 
ubiquitin conjugates. J Biol Chem 262: 2451-7. 
WELCHMAN, R.L., GORDON, C. & MAYER, R.J. 2005. Ubiquitin and ubiquitin-like 
proteins as multifunctional signals. Nat Rev Mol Cell Biol 6: 599-609. 
WENZEL, D.M., LISSOUNOV, A., BRZOVIC, P.S. & KLEVIT, R.E. 2011. UBCH7 reactivity 
profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 474: 105-8. 
WERNEKE, S.W., SCHILTE, C., ROHATGI, A., MONTE, K.J., MICHAULT, A., ARENZANA-
SEISDEDOS, F., VANLANDINGHAM, D.L., HIGGS, S., FONTANET, A., ALBERT, M.L. 
& LENSCHOW, D.J. 2011. ISG15 is critical in the control of Chikungunya virus 
infection independent of UbE1L mediated conjugation. PLoS Pathog 7: 
e1002322. 
WHEATLEY, D.N., GIDDINGS, M.R. & INGLIS, M.S. 1980. Kinetics of degradation of 
"short-" and "long-lived" proteins in cultured mammalian cells. Cell Biol Int Rep 
4: 1081-90. 
WILLIAMSON, D.S., BORGOGNONI, J., CLAY, A., DANIELS, Z., DOKURNO, P., DRYSDALE, 
M.J., FOLOPPE, N., FRANCIS, G.L., GRAHAM, C.J., HOWES, R., MACIAS, A.T., 
MURRAY, J.B., PARSONS, R., SHAW, T., SURGENOR, A.E., TERRY, L., WANG, Y., 
WOOD, M. & MASSEY, A.J. 2009. Novel adenosine-derived inhibitors of 70 kDa 
heat shock protein, discovered through structure-based design. J Med Chem 52: 
1510-3. 
WILLMUND, F., DEL ALAMO, M., PECHMANN, S., CHEN, T., ALBANESE, V., DAMMER, 
E.B., PENG, J. & FRYDMAN, J. 2013. The cotranslational function of ribosome-
associated hsp70 in eukaryotic protein homeostasis. Cell 152: 196-209. 
 152 
WOLF, D.H. & HILT, W. 2004. The proteasome: a proteolytic nanomachine of cell 
regulation and waste disposal. Biochim Biophys Acta 1695: 19-31. 
WOLFF, S., WEISSMAN, J.S. & DILLIN, A. 2014. Differential scales of protein quality 
control. Cell 157: 52-64. 
WONG, P., FRITZ, A. & FRISHMAN, D. 2005. Designability, aggregation propensity and 
duplication of disease-associated proteins. Protein Eng Des Sel 18: 503-8. 
XU, G., PAIGE, J.S. & JAFFREY, S.R. 2010. Global analysis of lysine ubiquitination by 
ubiquitin remnant immunoaffinity profiling. Nat Biotechnol 28: 868-73. 
XU, P., DUONG, D.M., SEYFRIED, N.T., CHENG, D., XIE, Y., ROBERT, J., RUSH, J., 
HOCHSTRASSER, M., FINLEY, D. & PENG, J. 2009. Quantitative proteomics reveals 
the function of unconventional ubiquitin chains in proteasomal degradation. Cell 
137: 133-45. 
YAO, T. & COHEN, R.E. 2002. A cryptic protease couples deubiquitination and 
degradation by the proteasome. Nature 419: 403-7. 
YE, Y. 2006. Diverse functions with a common regulator: ubiquitin takes command of an 
AAA ATPase. J Struct Biol 156: 29-40. 
YE, Y. & RAPE, M. 2009. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol 
Cell Biol 10: 755-64. 
YEWDELL, J.W., ANTON, L.C. & BENNINK, J.R. 1996. Defective ribosomal products 
(DRiPs): a major source of antigenic peptides for MHC class I molecules? J 
Immunol 157: 1823-6. 
YEWDELL, J.W. & NICCHITTA, C.V. 2006. The DRiP hypothesis decennial: support, 
controversy, refinement and extension. Trends Immunol 27: 368-73. 
YUAN, W. & KRUG, R.M. 2001. Influenza B virus NS1 protein inhibits conjugation of the 
interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 20: 362-71. 
ZENG, W., SUN, L., JIANG, X., CHEN, X., HOU, F., ADHIKARI, A., XU, M. & CHEN, Z.J. 
2010. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored 
polyubiquitin chains in innate immunity. Cell 141: 315-30. 
ZHANG, G. & IGNATOVA, Z. 2009. Generic algorithm to predict the speed of translational 
elongation: implications for protein biogenesis. PLoS One 4: e5036. 
ZHAO, C., BEAUDENON, S.L., KELLEY, M.L., WADDELL, M.B., YUAN, W., SCHULMAN, 
B.A., HUIBREGTSE, J.M. & KRUG, R.M. 2004. The UbcH8 ubiquitin E2 enzyme is 
also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. 
Proc Natl Acad Sci U S A 101: 7578-82. 
ZHAO, C., DENISON, C., HUIBREGTSE, J.M., GYGI, S. & KRUG, R.M. 2005. Human ISG15 
conjugation targets both IFN-induced and constitutively expressed proteins 
functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 102: 10200-5. 
ZHAO, C., HSIANG, T.Y., KUO, R.L. & KRUG, R.M. 2010. ISG15 conjugation system 
targets the viral NS1 protein in influenza A virus-infected cells. Proc Natl Acad 
Sci U S A 107: 2253-8. 
ZHAO, C., COLLINS, M.N., HSIANG, T.Y. & KRUG, R.M. 2013. Interferon-induced ISG15 
pathway: an ongoing virus-host battle. Trends Microbiol 21: 181-6. 
 153 
ZHENG, N., WANG, P., JEFFREY, P.D. & PAVLETICH, N.P. 2000. Structure of a c-Cbl-
UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102: 
533-9. 
ZHOU, M., FISHER, E.A. & GINSBERG, H.N. 1998. Regulated Co-translational 
ubiquitination of apolipoprotein B100. A new paradigm for proteasomal 
degradation of a secretory protein. J Biol Chem 273: 24649-53. 
ZID, B.M., ROGERS, A.N., KATEWA, S.D., VARGAS, M.A., KOLIPINSKI, M.C., LU, T.A., 
BENZER, S. & KAPAHI, P. 2009. 4E-BP extends lifespan upon dietary restriction 
by enhancing mitochondrial activity in Drosophila. Cell 139: 149-60. 
ZOU, W. & ZHANG, D.E. 2006. The interferon-inducible ubiquitin-protein isopeptide 
ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 281: 3989-94. 
 
 
  
 154 
Vita 
 
     Feng Wang was born in Guilin, People’s Republic of China. He is the son of 
Fuqiang Wang and Jinyu Bai. In Jun. 2005, he graduated from Xiamen University, China, 
with a Bachelor of Science degree in Biology. He received his Master of Science degree 
in 2008 in Dr. Xiang Xiao’s lab at the same university. In 2008, he came to U.S for his 
graduate education in Microbiology program in the University of Texas at Austin. In 
2009, he joined Dr. Jon Huibregtse’s lab for his doctoral studies.   
 
 
Permanent email: fengwang@utexas.edu  
 
This dissertation was typed by Feng Wang. 
